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The major and minor nitroreductase enzymes of Escherichia coli, NfsA and NfsB, 
have both been identified as potential prodrug activating enzymes in Gene-Directed 
Enzyme Prodrug Therapy (GDEPT) of cancer with 5-(aziridin-1-yl)-2,4-
dinitrobenzamide (CB1954). NfsB mutants have been selected for their ability to 
sensitize cells to successively lower concentrations of CB1954. In this study the 
crystal structures of most improved double (T41L/N71S), triple (T41Q/N71S/F124T) 
and quadruple (T41Q/N71S/F124T/M127V) mutants have been determined using X-
ray crystallography. The structures help explain the improvements seen with the 
mutants, in particular, the structure of the triple mutant reveals a hydrogen bond 
between Gln41 and Thr124, explaining why this mutation has greater activity than 
expected from the single mutants. Crystal structures of NfsB mutants where Phe124 is 
replaced with either of the unnatural amino acids para-nitrophenylalanine or para-
aminophenylalanine show a shift in the side chain rotamer allowing these polar groups 
to interact with substrates, suggesting this leads to their increased activity. For the first 
time, the crystal structure of NfsA is presented bound to a series of ligands, including 
the inhibitors succinate and fumarate, and the substrate nitrofurantoin. Another 
structure bound to a second FMN shows how the flexible loop may move to form a 
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GDEPT Gene-Directed Enzyme Prodrug Therapy 
Gln Glutamine 
HIV Human Immunodeficiency Virus 
HPLC High Performance (or Pressure) Liquid Chromatography 
IC50 Deffine!!!!!! 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
kcat The Catalytic Rate Constant of an enzyme catalysed reaction 
Km The Michaelis Constant of an enzyme catalysed reaction 
Kmapp The apparent Michaelis Constant 
LB Luria broth 
Lys Lysine 
MDEPT Macromolecule-Directed Enzyme Prodrug Therapy 
mRNA Messenger RNA 
NAD Nicotinamide adenine dinucleotide 
NAD(P)H Reduced form of NAD(P) 






NAT2 Human N-Acetyltransferase II 
NFN Nitrofurantoin 
NfsA Major oxygen-insensitive nitroreductase from Escherichia coli 
NfsB Minor oxygen-insensitive nitroreductase from Escherichia coli  
NFZ Nitrofurazone 
NMP N-Methylpyrrolidone 
NMR Nuclear Magnetic Resonance 
NOX NADH oxidase from Thermus thermophilus 
NR Nitroreductase from Enterobacter cloacae 
NRH Dihydronicotinamide Riboside 
NTR Minor oxygen-insensitive nitroreductase from Escherichia coli (NfsB) 
NQO1 NAD(P)H:quinone oxidoreductase 1or DT-Diaphorase 
NQO2 NRH:quinone oxidoreductase 2 
PAE Prodrug-activating enzyme 
pAF Para-aminophenylalanine 
PCR Polymerase Chain Reaction 
PDEPT Polymer-Directed Enzyme Prodrug Therapy 




PSA Prostate-Specific Antigen 
Quinol Hydroquinone or Benzene 1,4-diol 
Quinone 1,4-Benzoquinone 
rEK Recombinant Enterokinase 
RNA Ribonucleic Acid 
S. typhimurium Salmonella typhimurium 
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
SER Surface Entropy Reduction 
SKOV-3 Human ovarian carcinoma cell line 
STE Salt Tris EDTA buffer 
Thr Threonine 
TNT Trinitrotoluene 
tRNA Transfer RNA 
Tyr Tyrosine 
Val Valine 
VDEPT Virus-Directed Enzyme Prodrug Therapy 
WT Wild-Type 
YfkO Nitroreductase from Bacillus licheniformis 







1.1 Enzymes as Biological catalysts 
1.1.1 The Nature of Catalysis 
Many chemical reactions would not be likely to occur without catalysts. The rate of 
any chemical reaction is limited by the free-energy of activation (Ea), and catalysts 
work by lowering this (Figure 1-1). Catalysts provide a different transition state with a 
lower Ea (as shown in red in Figure 1-1) and thereby allow reactions that would 
normally be unlikely to occur because some kinetic or energetic barrier. However it 
does not change the energy difference between the starting reactants and the final 
products, called the Gibbs free energy or ∆G. This lower Ea allows reactions to occur 
at a faster rate than would be possible without a catalyst at the same temperature, as 
more reactants will have the required energy to react. The Ea is related the the rate 
constant (k) for a chemical reaction through the Arrhenius equation (equation 1.1). 
Where T is temperature in Kelvin, R is the universal gas constant and A is the pre-
exponential factor. It is the nature of catalysts that they are not themselves altered at 
the end of the reaction and do not alter its extent or equilibrium. They can be altered 




Figure 1-1: The Thermodynamic effect of catalysis on 
give Z (with a Gibb’s free energy, 
shown, with the effect of the catalyst on the 
reaction is opened up





Enzymes are the catalysts of the biological world, and make up the majority of 
proteins found in bacterial and mammalian cells. The term enzyme was first coined by 
Wilhelm Kühne in 1878 and comes from the 
the discovery that the catalytic activity of cells came from within not the whole 
microrganism. At this point humanity had been utilizing enzymes for centuries 
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without knowing it in processes such as fermentation and cheese-making. Eduard 
Buchnar in 1897 showed for the first time isolated enzymatic activity in the absence of 
whole cells, in discovering that yeast extracts alone could still catalyze fermentation, 
he received the Nobel Prize for his work in 1907 (Buchner, 1897). In 1894 Emil 
Fischer proposed the ‘lock and key’ hypothesis of enzyme specificity (Figure 1-2) 
based upon experiments performed with carbohydrate metabolising enzymes, where 
the enzyme’s specificity for its substrate was shown (Fischer, 1894).  
 
Figure 1-2: The lock and key hypothesis of enzyme action. The substrate (green) and 
enzyme (orange) are shaped such that the substrate has to be approximately the right 
shape for the enzyme. 
 
The chemical makeup of enzymes was unknown until 1926 when Sumner crystallized 
urease, which catalyses the hydrolysis of urea to carbon dioxide and water, and it was 
shown that it was made up entirely of amino acids linked through amide bonds, i.e. 
protein (Sumner, 1926). This chemical nature of catalysis may have been missed if 
Sumner’s techniques had been more sensitive, as they would have revealed a small 





ultracentrifuge (also in the 1920’s, for which he won the Nobel Prize in 1927), 
allowed wide-ranging isolation of enzymes and showed (along with the earlier 
crystallization) that they were individually isolatable molecules of specific masses 
(generally with Mr’s ranging from 10
4 to 107 Da), instead of colloidal suspensions. 
This suggested that enzymes were not random polymers but organised structures 
whose chemical action could be deduced, and this was confirmed in the 1960’s, firstly 
with the determination of the amino acid sequence of ribonuclease (Hirs et al., 1960), 
and secondly with the determination of the three-dimensional structure of lysozyme by 
X-ray crystallography (Blake et al., 1965). Today, the structures of many thousands of 
enzymes (and other proteins) have been determined. 
 
Studies in the 1950’s and 1960’s suggested that enzymes showed greater flexibility 
than was implied by the ‘lock and key’ hypothesis, and in 1958 the induced fit model 
(Figure 1-3) was proposed by Koshland to account for the catalytic power and 
specificity of enzymes (Koshland, 1958). It became obvious that enzyme activity 
could be controlled by chemical conditions in the cell and the ‘allosteric model’ of 
enzyme action was proposed by Monod (Monod et al., 1963, Monod et al., 1965). 
This model described how small chemical molecules, called ‘effectors’, could alter the 
activity of an enzyme. Effectors called ‘activators’ enhance an enzyme’s activity and 
allosteric ‘inhibitors’ decrease its activity. Effectors may bind away from the active 
site and it has been postulated that part of thier action may be through the induction of 






Figure 1-3: Induced fit hypothesis of enzyme specificty, showing how the enzyme 
(orange), may change shape upon binding of the substrate (green). 
 
Enzymes are distinguished from non-biological catalysts primarily by their high 
catalytic activity (up to 1017 fold improvement in rate of reaction), their specificity and 
the fact that they can be regulated by chemicals. Enzymes may work by lowering the 
energy (Ea) of a transition state, providing a route to a new transition state with a 
lower Ea or by bringing the reactants together into the correct orientation, effectively 
an entropic effect not affecting the enthalpy. 
 
1.2 Flavoenzymes 
The focus of this thesis is the nitroreductase enzymes of Escherichia coli. These 
belong to a family of enzymes called flavoenzymes, a family of yellow coloured 
enzymes that catalyze a wide range of biological processes ranging from energy 
production to biosynthesis (reviewed in (Joosten and van Berkel, 2007)). They 
catalyze a diverse range of one- or two-electron reductions, giving them a key role in 





either flavin adenine dinucleotide (FAD) or flavin mononucleotide (FMN). The flavin 
can also be either non-covalently (e.g. NfsA and NfsB, discussed later) or covalently 
anchored to histidine, cysteine or tyrosine residues (e.g. vanillyl-alcohol oxidase 
(Fraaije et al., 1999)), and more recently it has been discovered that this can also be 
via a dual interaction with two residues (Huang et al., 2005, Winkler et al., 2006, 
Rand et al., 2006). The unique spectroscopic properties of the flavin cofactors make 
flavoenzymes perfect for enzymological study (Massey, 1995), and they are thus one 
of the best characterised families of enzymes. 
 
The 3D structures of many flavoenzymes have been determined. In fact to give an 
indication of the extent of study of flavoenzymes, at present the protein data bank 
(www.pdb.org) contains 1,272 structures containing FAD and 590 structures 
containing FMN (out of a total of 85,212 structures, as of 14/10/2012). There is a 
variety of different structural topologies seen across these structures, with enzymes 
performing similar functions sometimes sharing and sometimes differing in their 
secondary structure motifs (Fraaije and Mattevi, 2000). 
 
1.2.1 Flavin-binding 
The flavin cofactors are the site of catalysis in flavoenzymes. Figure 1-4 a) shows the 
structure of the flavins FMN and FAD. Both contain an identical tricyclic 
isoalloxazine ring, an amphipathic molecule combining a hydrophobic 
dimethylbenzene moiety and a hydrophilic pyrimidine ring. The isoalloxazine ring 





seem to affect the degree of hydrogen bonding to the peptide (Fraaije and Mattevi, 
2000). The ability of flavins (and flavoenzymes) to catalyse redox reactions is due to 
their ability to adopt three different redox states; reduced, oxidised and semiquinone 
(Figure 1-4b) (Mayhew, 1999). It is the flavin’s ability to form the semiquinone that 
allows flavoenzymes to catalyse both one- and two-electron reactions. The two-
electron reduction of free flavin has a redox potential of around -200 mV, but upon 
binding to enzymes this can change greatly, ranging from approximately +60 mV to -
400 mV (Ghisla and Massey, 1989, Fraaije et al., 1999, Mayhew, 1999). Areas of 
positive charge around isoalloxazine rings are thought to increase the redox potential, 
whilst areas of negative charge or hydrophobicity lower it (Massey, 1995, Ghisla and 
Massey, 1989). FAD has been shown to bind covalently in some cases, and site-
directed mutagenesis studies have suggested that covalent interactions could increase 
the oxidative power of the flavin (Fraaije et al., 1999). These alterations to the flavin 
properties, caused by their binding to enzymes, increase the range of reactions that 
flavoenzymes can catalyse and also show the importance of the enzyme itself in the 












Figure 1-4: a) The chemical structure of FMN and FAD. The isoalloxazine ring is 
shown in black. b) The various oxidations states of the isoalloxazine ring of the flavin. 
c) The numbering of the atoms of the isoalloxazine ring. The isoalloxazine ring has 
two faces, re and si, and in all images the si side is facing the viewer (Mayhew, 1999). 
Figure produced using ACD/ChemSketch Freeware, version 10.00, Advanced 
Chemistry Development, Inc., Toronto, ON, Canada, www.acdlabs.com, 2012. 
 
The possible oxidation states of the flavins are shown in Figure 1-4 b). The reduced 





of the isoalloxazine rings), and this delocalised anionic state at the N1-C2=O2 locus is 
usually stabilized through contact (< 3.5 Å distance) with positively charged parts of 
the protein (Fraaije and Mattevi, 2000). This may be due to side chains such as lysine 
or arginine, which are fully charged, or to the N-terminus of an α-helix or a group of 
peptide nitrogens, which are polar. These residues are key to FMN binding and 
increase the redox potential of the cofactor, in dihydroorotate dehydrogenase 
(Bjornberg et al., 1997) and trimethylamine dehydrogenase (Mewies et al., 1996), 
replacing the positively charged sidechain stabilising the N1-C2=O2 locus with a 
neutral one caused the enzyme to become inactive and prevented FMN binding. There 
are multiple types of flavoenzyme, which are discussed in more detail elsewhere 
(Massey, 1995). 
 
1.2.2 Reduction of the flavin 
Many flavoenzymes catalyse dehydrogenation reactions, by which a substrate is 
oxidised and the flavin is reduced (at the N5 nitrogen). This reactive centre is usually 
within hydrogen bonding distance of a hydrogen bond donor from the protein itself 
(Fraaije and Mattevi, 2000). This interaction also has a highly conserved 
stereochemistry, forming an angle of between 116° and 170° from the N10-N5 to the 
donor residue (green in Figure 1-5). The N5 nitrogen of the isoalloxazine ring is one 
of two which are protonated in the reduction reaction displayed in Figure 1-4b and, 
unlike the N1, is unlikely to be deprotonated in solution. When crystal structures of 
flavoenzyme ligand complexes are studied, the N5 shows a highly conserved 
interaction with the ligand at a distance of around 3.5 Å and at an angle of between 





interactions with the N5 and the centre of the isoalloxazine ring system are important 
in binding and activity of the enzyme. The active part of the substrate often binds in a 
buried part of the structure and is thus protected from solvent. 
 
 
Figure 1-5: The distances between the reactive flavin N5 and the hydrogen-bond 
donor (green), and the distance from the flavin of the CH group that is oxidised (red – 
see the reaction mechanism in Figure 1-6). The distances of a range from 0.2 - 1.1 Å, 
and b from 0.5 – 1.4 Å. The distances are based on those of a number of crystal 
structures detailed further in the reference from which this figure is also adapted 






Several crystal structures of reduced flavoenzyme have been determined. These 
include the nitroreductase enzyme from Enterobacter cloacae (Haynes et al., 2002), 
where the isoalloxazine ring of the reduced flavin is in a more strongly bent 
conformation than the oxidised flavin. The angle changes from 16° in the oxidised 
enzyme to 25°, which is similar to that expected for free reduced flavin in solution, as 
the addition of a proton favouring a bent conformation. Oxidised flavin free in 
solution would be expected to be planar, and thus the bent conformation is induced by 
the enzyme in order to favour reduction of the flavin. However, it is possible that the 
flavin could be photoreduced in the X-ray beam. 
 
1.2.3 Mechanism of reactions 
Flavins perform two-electron substrate-dehydrogenation reactions, in which two 
electrons are transferred from the substrate to the flavin and a hydrogen is lost from 
the substrate and gained by the flavin at the N5 nitrogen. There are three potential 
mechanisms for this reaction, one a direct transfer of a hydride, one a carbanion 
mechanism and the final one a radical mechanism. These are reviewed by Fraaije et al. 
(Fraaije and Mattevi, 2000). The three potential mechanisms are detailed in Figure 

































































Figure 1-6: The different reaction mechanisms of flavin-catalysed substrate-dehydrogenation reactions – 1 and 2, the carbanion mechanism, 3, 
direct hydride transfer, and 4 and 5, the radical mechanism. R1 and R2 are non-specific groups attached to the reactive CH, whilst XH is the 





1.3 Nitroreductase Enzymes 
1.3.1 The bacterial nitroreductases 
Nitroreductases are a family of enzymes that catalyze the reduction of many quinone 
and nitroaromatic molecules inside the cell. They are found in bacterial and 
mammalian systems. The bacterial nitroreductases are a family of flavoenzymes that 
catalyse the NAD(P)H dependent reduction of nitro groups on nitroaromatic and 
nitroheterocyclic compounds (Roldan et al., 2008). This reduction can either be via a 
one-electron or a two-electron process; hence the nitroreductases can be grouped into 
two broad classes: Type I or oxygen-insensitive nitroreductases use two electrons from 
NAD(P)H (Figure 1-7) to catalyze the two-electron reduction of nitro groups to 
nitroso (and subsequently hydroxylamine and amino derivatives, although this may or 
may not be enzyme catalyzed) (Bryant et al., 1981, Peterson et al., 1979). The nitroso 
intermediate is usually not observed, as a second two-electron reaction reduces it 
rapidly to the hydroxylamine product, which may be the end point of the reaction. 
There are mammalian enzymes that also catalyze similar reactions, examples being the 
NAD(P)H:quinone reductase or DT-diaphorase (Knox et al., 1993b) and xanthine 
oxidase (Ueda et al., 2003). Type II or oxygen-sensitive nitroreductases use single 
electrons to catalyze the reduction of nitro groups to the nitro anion radical. Oxygen 
can catalyse the reverse reaction creating a futile cycle. A second one-electron reaction 
may occur to form the nitroso intermediate and harmful superoxide radicals can be 
formed. Enzymes that catalyze similar reactions are found in many mammalian 
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Addition
 
Figure 1-7: Chemical structure of NADP+ showing each component. NADH lacks the 
2’ phosphate circled. NAD(P)H is reduced at the site indicated on the Nicotinamide 
ring. Figure produced using ChemSketch (ACD/labs). 
 
The physiological role of the bacterial nitroreductases is still unknown, although it has 
been suggested that such enzymes may protect organisms from oxidative damage 
caused by semiquinones produced from one-electron reductions by other enzymes 
such as cytochrome P450 (Monks et al., 1992). Several enzymes have seen industrial 
or clinical uses; the nitroreductase of S. typhimurium is used as part of the Ames 
mutagenicity test (Hajos and Winston, 1991), whilst the nitroreductases from E. 





since they can reductively break down the explosive TNT (Kitts et al., 2000, Spain, 
1995, Esteve-Nunez et al., 2001). 
 
1.3.2 Discovery of the E. coli nitroreductases 
The first evidence of a nitroaromatic reductase activity in E. coli came when the 
observation was made that whole cell preparations were capable of reducing the 
antibiotic chloramphenicol (Smith and Worrel, 1949). There were later shown to be 
two distinct types of nitroreductase present (Asnis et al., 1957), which were shown to 
be type I and type II nitroreductases (McCalla et al., 1970, Mason and Holtzman, 
1975b, Peterson et al., 1979). Investigation into the mechanism of resistance in 
Escherichia coli to nitrofurazone (NFZ) and other nitrofuran antibiotics led first to the 
discovery that nitrofurazone-resistant strains lacked a ‘nitroreductase’ activity 
(McCalla et al., 1971), and later to the discovery of two ‘nitrofuran sensitivity genes’, 
nfsA and nfsB (McCalla et al., 1978). The genes, later also referred to as nfnA and 
nfnB, were mapped to 79.8 min and 13 min respectively, following the isolation of 
mutants resistant to nitrofurantoin, and thus are under the control of different operons 
(Sastry and Jayaraman, 1984). Mutations in these genes provided resistance to 
nitrofuran antibiotics, including nitrofurazone and nitrofurantoin (Whiteway et al., 
1998). The proteins encoded by these genes are examples of bacterial nitroreductases. 
 
1.3.3 Nitroreductase activity in E. coli 
Of the type I and II nitroreductase activity in E. coli, the oxygen-insensitive 





substrate. Further investigation into the oxygen-insensitive nitroreductase activity in E. 
coli concluded that it was the product of three genes and not just the two previously 
identified (Bryant et al., 1981). The highest of the three nitroreductase activities with 
nitrofurazone was NADPH dependent; this is the product of the previously described 
nfsA gene (McCalla et al., 1978). The other two activities could use either NADH or 
NADPH; one of these was the product of the previously described nfsB gene. The 
NfsA and NfsB proteins, the products of the nfsA and nfsB genes, are discussed in 
more detail later. Unlike nfsA and nfsB, the final gene conferring a type I 
nitroreductase activity had not been previously described and has not been genetically 
mapped. Little is known about the gene, named nfsC, or its product enzyme NfsC, 
other than that it appears to be rendered inactivate by MnCl2, which had previously 
been used in a purification step (Bryant et al., 1981). 
 
E. coli also contains a minimal nitroreductase called ydjA, one of the smallest 
nitroreductase enzymes discovered to date (Choi et al., 2008). YdjA was discovered 
when the genome of E. coli K12 (Blattner et al., 1997) showed the existence of a 
putative nitroreductase of only 190 amino acids (most nitroreductases are >210) that 
was conserved across several organisms (Choi et al., 2007). While it shares very little 
sequence homology with nfsA or nfsB, it is homologous to a putative nitroreductase 
from Haemophilus influenza (Fleischmann et al., 1995), which belongs to a 






1.4 Gene therapy with E. coli Nitroreductase Enzymes 
NfsA and NfsB both have been identified as having a potential for use in gene therapy 
of cancer with the prodrug CB1954 (Knox et al., 1992, Vass et al., 2009). 
 
1.4.1 Principles of Suicide Gene Therapy 
In cancer chemotherapy, drug doses are often limited by fatal side effects. Most 
chemotherapeutic drugs target all rapidly dividing cells, not just cancerous ones. 
Current research into cancer treatment is focussed on finding methods that will 
specifically target only tumour cells. Suicide gene therapy is a potentially viable, 
tumour-focused, technique. An exogenous enzyme is transferred (or produced) 
selectively within tumour cells. Then a non-toxic prodrug is administered, which is 
selectively activated to its cytotoxic product by the enzyme at the site of the tumour. 
The prodrug is converted to a cytotoxic derivative by the prodrug activating enzyme 
(PAE). It is important to use an enzyme not normally found in human cells, so the 
prodrug is only activated in the specific location containing the exogenous enzyme. 
This is illustrated in Figure 1-8 using the example of the nitroreductase/CB1954 
combination discussed in Section 1.4.4. 
 
 
Figure 1-8: Illustration of the principles of GDEPT with nitroreductase and CB1954. The gene encoding the nitroreductase is inserted 
into a cell by means of an adenovirus vector.  The gene is 
later CB1954 is administered intravenously and only becomes active in cells expressing nitroreductase. This leads to the deat
cell and of neighbouring cells through a Bystander Effect
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A potential advantage to this type of treatment over conventional chemotherapy is that 
the local generation of cytotoxic derivatives gives lower levels of systemic toxicity 
(Kerr et al., 1997, Niculescu-Duvaz and Springer, 1997, Russell and Khatri, 2006). 
Since it is unlikely that every cell would express the PAE, the ability of the cytotoxic 
drug to spread and cause toxicity in surrounding cells is vital to any form of suicide 
gene therapy. This is called the ‘bystander effect’ (Freeman et al., 1993). The 
requirement for the spread of the cell-killing compounds is one of the problems 
associated with gene therapy. The spread ideally needs to avoid healthy tissue to 
reduce unwanted side effects. The major challenges of gene therapy remain to the 
method of getting the enzyme into the cell (both the vector for transport and the 
physical method of transporting the vector into the tumour), and the viability and 
efficiency of the enzyme prodrug combination. Even so, gene therapy is a promising 
avenue for cancer research and is showing some good early results (Tietze and 
Schmuck, 2011). 
 
1.4.2 Types of Directed Enzyme Prodrug Therapies 
A vector is required to target the enzyme to the tumour in order for the prodrug to be 
selectively activated at the site of the tumour. This selective targeting of an enzyme to 
a tumour is called Directed Enzyme Prodrug Therapy (DEPT). In Antibody Directed 
Enzyme Prodrug Therapy (ADEPT), the PAE is directed to the outside of target cells 
using a tumour specific antibody (Bagshawe, 1987, Bagshawe, 1990). A number of 
ADEPT combinations have been described that have shown promising results in vitro 
and in vivo, including carboxypeptidase G2 and para-N-bis (2-chloroethyl) 





al., 1992, Senter et al., 1991, Roffler et al., 1991). E. coli NfsB was proposed as a 
potential enzyme for use with ADEPT (Anlezark et al., 1992, Anlezark et al., 1995, 
Knox et al., 1993b, Knox et al., 1995), however as the enzyme is not internalised into 
the cell it does not have access to the first substrate (NAD(P)H). In order for the 
system to be viable alternative methods would be required that would lead to the 
enzyme being produced inside the cell. An alternative tumour directing method would 
be to use a polymer-based system similar to ADEPT called Macromolecule Directed 
Enzyme Prodrug Therapy (MDEPT) (Skelly et al., 2001) or Polymer-Directed 
Enzyme Prodrug Therapy (PDEPT) (Satchi et al., 2001). Several enzyme prodrug 
combinations have also been trialled in Clostridial-Directed Enzyme Prodrug Therapy 
(CDEPT), in which the Clostridia bacteria is used to transfer the enzyme to the tumour 
(Minton, 2003, Theys et al., 2006). This targets the hypoxic areas of tumours by 
exploiting the anaerobic growth of Clostridia. 
 
Gene Directed Enzyme Prodrug Therapy (GDEPT) is a gene therapy system that 
would allow the enzyme to be produced inside the tumour cells themselves. The gene 
encoding a non-human enzyme is inserted directly into the tumour cells, usually using 
either a virus or a plasmid, and the gene is expressed producing the enzyme. GDEPT 
has been trialled for use with several enzyme-prodrug combinations including 
cytosine-deaminase with 5-fluorocytosine (Brown and Lemoine, 2004), herpes 
simplex virus thymidine kinase with ganciclovir (Fillat et al., 2003),  and E. coli NfsB 
with the prodrug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) (Denny, 2002, 
Patel et al., 2009). A variation on GDEPT is Virus Directed Enzyme Prodrug Therapy 





gene encoding a non-human enzyme (Huber et al., 1994). This system had been 
trialled for use with NADPH-cytochrome P450 reductase with cyclophosphamide 
(Tychopoulos et al., 2005), and E. coli NfsB with CB1954 (Patel et al., 2009). 
 
1.4.3 Enzyme Prodrug Combinations 
There have been several enzyme prodrug combinations tested, and a number of these 
are summarised in Table 1-1. Each of the enzymes activates the drug, but the drugs 
cause cell death in different ways. The combination of NfsB nitroreductase and 
CB1954 (as well as Cytochrome P-450 and cyclophosphamide) has the advantage over 
other DNA-alkylating agents that it can form DNA crosslinks, making it more potently 
cytotoxic as these are poorly repaired. This combination for gene therapy also 
produces a DNA crosslinking agent produced that has the ability to kill both dividing 
and non-dividing cells by inducing apoptosis (Drabek et al., 1997, Knox et al., 
1988b). Other advantageous features include the fact that apoptosis occurs via a p53-
independent mechanism (Cui et al., 1999), the fact that only three cycles of prodrug 
administration were required in xenograft models showing the efficacy of this 
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Toxicity 
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Cytosine Arabinoside Generation of 
Anti-Metabolites 








(Marais et al., 
1996) 
Cytochrome P-450 Cyclophosphamide Production of 
DNA-Alkylating 
agents 
(Chen et al., 
1996) 
2-Aminoanthracene Production of 
DNA-Alkylating 
agents 
(Rainov et al., 
1998) 
Paracetamol Interaction with 
tissue 
macromolecules 
(Thatcher et al., 
2000) 
Linamarase Linamarin Production of 
cyanide 
(Cortes et al., 
1998) 





Table 1-1: A summary of various enzyme-prodrug combinations trialled for directed 






1.4.4 Development of Gene Therapy with Nitroreductases and CB1954 
1.4.4.1 DT-Diaphorase and CB1954 
CB1954 was discovered to potently inhibit the growth of Walker rat carcinoma 256, 
but not of other related tumours, which had previously been shown to be inhibited by 
DNA alkylating agents (Cobb et al., 1969). It was shown that inside the Walker 
tumour cells in vitro (but not inside Chinese hamster cells) CB1954 was converted to a 
difunctional alkylating agent that caused DNA-DNA interstrand crosslinks (Roberts et 
al., 1986). It was postulated that there was some activity within the Walker carcinoma 
cells that converted CB1954, and the search was on for a human tumour that would act 
in a similar way. CB1954 was described as “a drug in search of a human tumour to 
treat” (Workman et al., 1986). The enzyme responsible for ‘activating’ CB1954 in 
Walker carcinoma cells was shown to be a 33.5 kDa enzyme called DT-Diaphorase or 
NAD(P)H:quinone oxidoreductase 1(NQO1) (Knox et al., 1988b).  
 
NQO1 is a monomeric FAD-containing flavoenzyme that can use NADH or NADPH 
as a cofactor with equal efficiency (Knox et al., 1988a). The rat enzyme has a 
nitroreductase activity that reduces the 4-nitro group of CB1954 to 5-(aziridin-1-yl)-4-
hydroxylamino-2-nitro-benzamide (Figure 1-9). This occurs by two separate two-
electron reduction steps, first of the nitro group to a nitroso intermediate and then to 
the hydroxylamine product. Upon nitroreduction, CB1954 is converted from a weak 
monofunctional alkylating agent, by means of the aziridine group, to a potent 
difunctional alkylating species through activation of the 4-nitro group (Knox et al., 





benzamide reduction product has been shown to form interstrand crosslinks in the 
DNA of Chinese hamster V79 cells co-cultured with Walker rat carcinoma cells, but 
cannot crosslink naked DNA alone (Knox et al., 1988b). The 4-hydroxylamino 
product must be activated by cellular thioesters, including acetyl-coenzyme A, before 
it can crosslink DNA (Knox et al., 1991). The proposed structure of the crosslink is 
shown in Figure 1-10. The 4-hydroxylamino product is, on a dose basis, 104- to 105-
fold more effective at causing cell death than the prodrug alone (Roberts et al., 1986). 
CB1954 was effective against rat tumours due to the presence of NQO1, however the 
equivalent human enzyme does not reduce the prodrug effectively (Chen et al., 1997). 
The difference has been shown to be primarily due to the presence of a Gln in place of 
Tyr104. Mutating the human enzyme back to Tyr confers similar activity with 
CB1954 to the rat enzyme (Wu et al., 2001). A gene therapy approach such as VDEPT 
would allow the insertion of genes encoding other nitroreductase enzymes including 
bacterial nitroreductases (Knox et al., 1993b), making the prodrug therapy an option 





















































Figure 1-9: Reduction of CB1954 as catalysed by NQO1, two separate two-electron 






























Deoxyguanosine from DNA 
strand 2
Deoxyguanosine from DNA 
strand 1
 
Figure 1-10: The structure of the cytotoxic crosslinking aduct formed by the reaction 
of the reactive 4-N-acetoxy derivative of CB1954 with DNA. Note that the two bases 
are not paired bases. Figure produced using ChemSketch (ACD/labs). 
 
1.4.4.2 Nitroreductase and CB1954 
It was discovered that nitroreductase-deficient E. coli strains showed resistance to 
CB1954 (Venitt and Crofton-Sleigh, 1987), and thus, that in common with NQO1, E. 
coli nitroreductases reduce CB1954 to a potent cytotoxic DNA-crosslinking agent. 
NfsB was isolated and found to reduce CB1954 much more rapidly than NQO1, 






Unlike NQO1, NfsB can reduce either (but not both) of the two nitro groups on 
CB1954 to the corresponding hydroxylamine derivative (Knox et al., 1992) (Figure 
1-11). The reduction of CB1954 by NADH and NfsB produces approximately equal 
proportions of the 2- and 4-hydroxylamine products (Boland et al., 1991, Anlezark et 
al., 1992), unlike DT-Diaphorase which only produced the 4-hydroxylamine (Knox et 
al., 1988a, Knox et al., 1988b). The 4-hydroxylamine product is the more cytotoxic of 
the two products (Knox et al., 1988b, Sunters et al., 1992, Helsby et al., 2003), and it 
has been suggested that it is only this product which can form DNA crosslinks (Knox 
et al., 1991). Both of the hydroxylamine products can be further reduced to amines in 
vivo, and the 2-amine has also shown some significant cytotoxicity (Tang et al., 2005) 
and mediates a greater bystander effect (Helsby et al., 2004) (discussed in next 
section). The O-acetylation of the hydroxylamine derivatives has been shown to be 
catalyzed by N-acetyltransferase (NAT2), and co-expression of NfsB and NAT2 
increases the effectiveness of CB1954 in SKOV ovarian cancer cell lines (Mitchell 
and Minchin, 2008). However co-expression of NfsB and NAT2 led to a lower 
bystander effect and it may be that it lowers the levels of the freely diffusible 
hydroxylamine derivatives. Nevertheless gene therapy with both enzymes may hold a 




















































































































Figure 1-11: Nitroreductase-catalyzed reduction of CB1954. CB1954 can be reduced 
by NfsB at either nitro position (2 or 4). This produces first a nitroso (not shown) and 
then a hydroxylamine derivative. The hydroxylamine may be further reduced to an 
amine, or can go on to react with cellular thioesters to form a DNA alkylating species. 
Figure adapted from (Mitchell and Minchin, 2008). Figure produced using 





1.4.4.3 Bystander effect 
An essential ability of any GDEPT combination would be the ability to cause a so 
called ‘bystander effect’. A bystander effect is the cell death of untransfected cells 
caused by the diffusion of cytotoxic metabolites from the transfected cells. A 
significant bystander effect is essential for a viable GDEPT system because only a 
minority of tumour cells will express the enzyme (Palmer et al., 2004, Patel et al., 
2009). The combination of NfsB and CB1954 has shown a considerable bystander 
effect, both in tissue culture models (Bridgewater et al., 1997, Green et al., 1997, 
Friedlos et al., 1998, McNeish et al., 1998, Nishihara et al., 1998, Westphal et al., 
2000, Wilson et al., 2002, Benouchan et al., 2003) and in experimental tumours 
(McNeish et al., 1998, Djeha et al., 2000, Westphal et al., 2000, Wilson et al., 2002, 
Benouchan et al., 2006). The effect is due to the cell-permeable hydroxylamine 
derivatives of CB1954 reduction by NfsB. Of the two products it was initially thought 
that the 4-hydroxylamine product was responsible for the majority of the bystander 
effect observed, because of its high toxicity in low density cell cultures (Bridgewater 
et al., 1997). More recently it has been shown that the 2-hydroxylamine produces a 
more significant bystander effect (Helsby et al., 2004). Optimizing any GDEPT 
system purely for maximum bystander effect may not be desirable, as too large an 
increase in the spread of the cytotoxic agent is likely to cause an increase in unwanted 
systemic effects (Dachs et al., 2009). 
 
1.4.4.4 Development of the NfsB/CB1954 GDEPT combination 
The enzyme prodrug combination of NfsB and CB1954 was initially suggested for its 





Knox et al., 1995). Since then it has been trialled in CDEPT (Theys et al., 2006), and 
more widely with a GDEPT/VDEPT approach. Replication-deficient retrovirus and 
adenovirus vectors have been used to insert the nfsB gene into cancer cell lines, and 
conferred much greater sensitivity to CB1954 in transfected cells than untransfected 
cells (McNeish et al., 1998, Djeha et al., 2000, Weedon et al., 2000). In vivo 
experiments have also shown anti-tumour activity in Balb-C nude mice (Djeha et al., 
2000, Djeha et al., 2001, Weedon et al., 2000, McNeish et al., 1998). There have been 
a number of early-stage clinical trials, first with CB1954 alone (Chung-Faye et al., 
2001) and second with a replication-defective adenovirus expressing NfsB (Palmer et 
al., 2004). The trial with CB1954 alone revealed potentially dose-limiting 
hepatotoxicity, which may be due in part to reduction of CB1954 by native enzymes in 
the liver (Tang et al., 2005).  
 
The NfsB/CB1954 combination has been tested in phase I/II clinical trials in patients 
suffering from prostate cancer, using direct intraprostatic injection of the 
NfsB-expressing replication-defective adenovirus (Patel et al., 2009). Some patients 
showed a decline in PSA (prostate-specific antigen – a tumour marker), and in a 
number of these this was maintained over a six month period. This suggests an anti-
tumour activity. However not all patients showed a response, and the reductions seen 
in PSA were only partial and transient. The viral vector was well-tolerated with no 
dose-limiting toxicity seen at up to 1 x 1012 virus particles. This study showed that the 
treatment shows promise, in showing some anti-tumour activity, and warrants further 






1.5 Improvements to the Nitroreductase/CB1954 Combination 
1.5.1 Limitations of the NfsB/CB1954 combination 
The published Km of NfsB enzyme with CB1954 is only 17.2 ± 4.8 mM (Jarrom et al., 
2009), whilst the peak serum concentration achievable in humans is much lower at 5-
10 µM (Chung-Faye et al., 2001). The clinical trial results have also suggested that 
improvements would be required in order to create a more effective treatment (Patel et 
al., 2009). The combination requires greater efficacy to be viable.  
 
1.5.2 Alternative prodrugs for nitroreductase suicide gene therapy 
Although CB1954 was the first chemical proposed for use as a prodrug in 
nitroreductase suicide gene therapy (Anlezark et al., 1992), many other prodrugs have 
been studied for their potential for use alongside nitroreductase. Four classes of 
prodrugs for use with nitroreductase have been discussed elsewhere in detail; 
dinitrobenzamide mustards, dinitroaziridinylbenzamides (CB1954 analogues), 
4-nitrobenzylcarbamates and nitroindolines (Denny, 2002). Other classes of potential 
prodrug include acyclic nitrobenzylphosphoramide mustards (Jiang et al., 2006), other 
nitroaromatics and quinones (Bailey et al., 1996). 
 
1.5.2.1 Dinitrobenzamide Mustards 
Aromatic nitrogen mustard alkylating agents, such as melphalan and chlorambucil, 





1979). They kill cells by alkylating bases of DNA, causing inter- and intra-strand 
crosslinks and even strand breaks. Although they have a greater effect on proliferating 
cells (crucially including rapidly-dividing tumour cells), the dosages that can be used 
clinically are still limited due to their effect on non-cancerous cells. Aromatic nitrogen 
mustards can have their activity modified via altering ring substituents. They therefore 
have a potential as prodrugs in cancer gene therapy, as their substituents could be 
enzymatically altered from electron-withdrawing to electron-donating, activating the 
cytotoxic properties of the prodrug (Palmer et al., 1990). SN23862 is the 
bischloroethylamino mustard analogue of CB1954, and can be reduced by NfsB 












































































































Figure 1-12: Structures of the most promising alternative dinitrobenzamide prodrugs 
to date. SN23862 is the bis-chloroethyl analogue of CB1954 and has been most 
extensively studied as an alternative (Michael et al., 1994). SN27686 is the most 
active of a new series of related prodrugs, and its phosphate ester, SN28343, is its 
pre-prodrug with greater aqueous solubility (Singleton et al., 2007). The phosphate is 
removed by phosphatises in the serum. The others have also been tested with NfsA. 





Other dinitrobenzamide mustards have been touted as potential alternative prodrugs 
with nitroreductase (Anlezark et al., 1995, Atwell et al., 1996, Atwell et al., 2007, 
Friedlos et al., 1997). The first of the dinitrobenzamide mustards to be developed for 
PAE were based upon adding or changing the substituents of CB1954. Another 
advantage of SN23862 and related prodrugs is that they are not activated by 
mammalian DT Diaphorases (Anlezark et al., 1995, Palmer et al., 1992, Palmer et al., 
1994), leading to potentially fewer side effects. Unlike CB1954, SN23862 is only 
activated by NfsB at its 2-nitro position (Anlezark et al., 1995) which, it has been 
suggested from preliminary modelling, is because the larger mustard group restricts 
entry of the drug into NfsB’s active site (Parkinson et al., 2000). However reduction of 
the 4-nitro group is fully activating as SN23862 is already a difunctional alkylating 
agent (through its mustard moiety) and the activation by NTR releases electrons 
activating the DNA-alkylating ability of the drug. Related prodrugs have been created 
by replacing the 2-nitro group with non-activating groups of various electrostatic 
properties (Atwell et al., 1996), substituted amides, differently-located nitro groups 
and different halogen mustards (Friedlos et al., 1997). To date the most promising of 
these dinitrobenzamide mustards, have longer carbon chains on the amide moiety and 
make the prodrug more lipophilic and thus more able to pass across membranes 
(Singleton et al., 2007). The water soluble pre-prodrug SN28343 is transformed in 
vivo by serum phosphatases into the prodrug SN27686, which has shown improved 
tissue penetration and bystander effect upon activation by NfsB relative to CB1954 
































Figure 1-13: Fragmentation reaction of 4-nitrobenzyl carbamates by nitroreductase 
(Denny, 2002). The H2NR is the activated drug. Figure produced using ChemSketch 
(ACD/labs). 
 
4-Nitrobenzyl carbamate prodrugs have been shown to be effective substrates for 
NfsB (Mauger et al., 1994). Chemotherapeutic drugs can be coupled to a 4-
Nitrobenzyl carbamate, and reduction by nitroreductase causes a fragmentation (See 
Figure 1-13) leaving the active drug (Hay et al., 1999a). Carbamate prodrugs have 
been synthesised and tested for a variety of classes of chemotherapeutic drugs, 
including aniline mustards (Mauger et al., 1994), enediynes (Hay et al., 1995, Hay et 
al., 1999b), pyrrolobenzodiazepines (Sagnou et al., 2000) and duocarmycin analogues 
(Hay et al., 1999a). Drugs trialled in this system include actinomycin D, mitomycin D 
and doxorubicin (Mauger et al., 1994). Most studies have focussed on ADEPT rather 
than GDEPT/VDEPT but, except with hydrophilic drugs, they should work in a 






1.5.2.3 Nitrobenzylphosphoramide Mustards 
Another related class of prodrugs are the acyclic nitrobenzylphosphoramide mustards. 
The origins of this class were nitrobenzene analogues fused to cyclophosphamide (Li 
et al., 2003). A series of analogues were generated with the nitro group para to the 
benzylic carbon, the most promising of which, LH7 (Jiang et al., 2006) (Figure 1-14), 
has been studied more extensively with NfsB and its most promising mutants 
(Jaberipour et al., 2010). Subsequent studies examined the effect of the position of the 
nitro group on the benzene ring, and the effect of subsequent substitutions (Hu et al., 
2011). It was found that halogens positioned ortho to the benzyl carbon showed the 
greatest improvement in activity in V79 and SKOV3 cancer cell lines, however 
discrepancies were seen when tested in bacterial cell lines. It has been proposed that 
this group of prodrugs are DNA cross-linking agents, and involve cleavage of the 












Figure 1-14: The structure of the nitrobenzylphosphoramide mustard LH7 (Jiang et 






1.5.2.4 Other Classes of Alternative Prodrugs 
A few other classes of drug have been tested for use with E. coli NfsB. These include 
nitroindolines, which have shown some promise in tests (Tercel et al., 1996). These 
work by binding to the minor grove of DNA, but are not greatly activated by 
nitroreduction. Of other nitroaromatic compounds that have been investigated for 
potential use as a prodrug, only the antibiotic nitrofurazone has shown any promise at 
all (Anlezark et al., 1995, Bailey et al., 1996). Quinone substrates have so far proven 
ineffective (Bailey et al., 1996). 
  
1.5.3 Improving the enzyme for the VDEPT combination 
1.5.3.1 Mutating NfsB 
An alternative to improving the prodrug is to change the enzyme used for the 
combination. Mutants of NfsB have been developed which confer greater sensitivity to 
CB1954 in both human and bacterial cell lines (Grove et al., 2003, Guise et al., 2007, 
Jaberipour et al., 2010). These will be discussed in more detail later. The gene has also 
been mutated to optimise its codon usage in mammalian systems, since this differs 
between prokaryotes and eukaryotes (Grohmann et al., 2009). 
 
1.5.3.2 NfsA as a Prodrug Activating Enzyme 
Alternative enzymes could be used in combination with CB1954; indeed the major 
nitroreductase of E. coli, NfsA, has been suggested as an alternative enzyme for 
VDEPT with CB1954 as it confers between a 3.5 and 8-fold increase in sensitivity to 





found to be the most active enzyme for the prodrug in a study comparing multiple 
potential nitroreductase enzymes from E. coli (Prosser et al., 2010a). 
 
1.5.3.3 Other Alternative Enzymes 
Nitroreductase enzymes from other organisms have also been tested in combination 
with CB1954. The mammalian enzyme NRH:quinone oxidoreductase 2 (NQO2), 
which shares 49% sequence identity with NQO1 (DT-Diaphorase) although it is 43 
amino acids shorter (both enzymes share less than 5% identity with either NfsA or 
NfsB, and bind FAD, with the isoalloxazine ring in an opposite conformation), has 
been suggested as a potential prodrug activating enzyme with CB1954 (Knox et al., 
2000, Knox et al., 2003). It is of particular interest as the enzyme is over-expressed in 
several cancer cell lines (Knox et al., 2000). NQO2 reduces CB1954 3000 times faster 
than NQO1, and at a similar rate to NfsB with a lower Km (263 µM for NQO2 and 900 
µM for NfsB (Race et al., 2007)). It also reduces CB1954 only at the 4-nitro position 
(more cytotoxic but reduced bystander effect), unlike NfsB which reduces at both 4-
nitro and 2-nitro. The structure of NQO2 bound to CB1954 has been determined by X-
ray crystallography, but it was not possible to distinguish between two possible 
orientations of the prodrug (AbuKhader et al., 2007). Subsequent NMR studies have 
determined the orientation of the ligand conclusively (Ludwig et al., 2008) (
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A summary of some of the most promising alternative enzymes is shown in 
Several studies have compared various enzymes for use with CB1954
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3.8 (2.2) 5.4 (3.5) Similar rate, with 
lower Km (263 µM 
versus 900 µM) 





43.1 (23.4) 28.6 (15.5) Improvements 
claimed but no 





43.6 (28.4) 30.7 (18.6) Less effective than 
NfsB 





23.6 (12.6) 92.1 (83.8) Less effective than 
NfsB 





33.5 (19.8) 27.1 (18.0) Km of 11.7 µM is 
claimed but no kinetic 
data is shown 




reductase) E. coli 
16.8 (9.5) 4.3 (3.1) Less effective than 
NfsB 





24.9 (15.3) 4.6 (2.7) Less effective than 
NfsB 





13.7 (6.4) 25.6 (14.8) Some initial promise 
shown but more study 
would be required 
(Barak et al., 
2006) 
Table 1-2: Summary of some of the most promising alternative enzymes for use with 






1.6 Properties and Structures of the E. coli Nitroreductase Enzymes 
1.6.1 Mechanism of Reduction by E. coli Nitroreductases 
Both NfsA and NfsB catalyse the flavin-mediated reduction of a broad range of 
nitroaromatic and quinone derivatives (Zenno et al., 1996c, Zenno et al., 1996a); for 
some examples see Figure 1-16. Studies have suggested that both enzymes follow a 
substituted enzyme or ‘ping-pong’ mechanism (Anlezark et al., 1992, Zenno et al., 
1996a, Zenno et al., 1996c). A ping-pong mechanism is where an enzyme, catalysing 
a bi-substrate reaction, interacts with only one substrate at a time, and switches 
between a modified and unmodified form (detailed in the case of NfsB and CB1954 in 
Figure 1-17). The mechanism has two distinct steps; the first step, called the ‘ping’ 
step, is where the first substrate interacts with the native enzyme to create a modified 
form of the enzyme. In second, or ‘pong’, step the modified enzyme interacts with the 
second substrate, forming the products of the reaction and reforming the native form 













































Figure 1-16: Chemical structures of some examples of the known substrates of NfsA 













Figure 1-17: Summary of substituted ping-pong bi-bi reaction catalysed by the FMN 
bound nitroreductase enzymes. 
 
With NfsA and NfsB, the enzyme is a complex with FMN, and the modification is of 
the FMN rather than the enzyme, in common with most flavoenzymes (E-FMN in 
Figure 1-17). The native form of the enzyme contains the FMN in its oxidised form. 
The ‘ping’ step (labelled a) in Figure 1-17) for the enzymes is where the enzyme-FMN 
complex interacts with either NADH or NADPH, and the incoming cofactor donates 
two electrons, reducing the FMN. This produces the modified intermediate form of the 
enzyme-FMN complex, with reduced FMN (E-FMNH2), which goes on to interact 
with the nitroaromatic or quinone substrate in the ‘pong’ part of the reaction. In this 
second interaction (labelled b) in Figure 1-17), the electrons are transferred from the 
FMNH2 to the second substrate, reducing it and reforming the native form of the 
enzyme bound to oxidised FMN (Anlezark et al., 1992). 
 
The initial assessment of a ping-pong mechanism for NfsB was made based upon 
kinetic observations (Anlezark et al., 1992), which were backed up by further more in 





kinetic studies on an E. cloacae nitroreductase that is highly homologous to NfsB also 
supported a ping-pong mechanism (Koder and Miller, 1998). Crystallographic studies 
of NfsA (Kobori et al., 2001), NfsB (Lovering et al., 2001) and the E. cloacae 
nitroreductase (Haynes et al., 2002) support this mechanism, as the active sites are not 
able to accommodate both substrates, NAD(P)H and the nitroaromatic/quinone, 
simultaneously. Crystal structures have been determined of the reduced form of FMN 
complexed with NfsB (Parkinson et al., 2000, Johansson et al., 2003) and with the E. 
cloacae nitroreductase (Haynes et al., 2002), further supporting the proposed 
mechanism. A comparison of steady-state and stopped-flow kinetic rates suggest that 
the rate-determining step is the release of the product for the reduction of CB1954 and 
NFZ by WT-NfsB, as the maximum rate observed in the steady-state is lower than that 
of either step in the stopped-flow (Jarrom et al., 2009). 
 
The reduction of quinones by the nitroreductases occurs via a single two-electron 
reduction step to an alcohol group, while 4 electrons are needed to reduce a nitro 
group of nitroaromatics. The reduction of nitro groups occurs by two successive two-
electron steps, as shown for CB1954 in Figure 1-11 and as discussed in Section 
1.4.4.2. The hydroxylamine is readily reduced in vivo to an amine, but this is not seen 
in vitro. The reduction of the nitro to the nitroso has been shown to be the rate-limiting 
step for the reduction catalyzed by NfsB (Race et al., 2005). The second step is quick 
even without the enzyme and whilst it has been shown that it can occur faster in the 
presence of the enzyme, it may also just involve reduction by free NAD(P)H in 






1.6.1.1 Hydride or Electron Transfer? 
For two-electron reduction of CB1954 catalyzed by NfsA and NfsB a total of two 
electrons and two protons are transferred upon reduction of the nitro to the nitroso. 
Both electrons must come from the FMN and one proton must come from solution, 
but the other proton could come from either FMN or solution (Christofferson and 
Wilkie, 2009). The reaction could thus occur by two mechanisms: hydride transfer or 
electron transfer. In hydride transfer a hydride (two electrons and one proton) is 
transferred directly from the FMN to the nitro group of the substrate, either before 
(Figure 1-18) or after (Figure 1-19) a proton from solution. For hydride transfer either 
the nitrogen or either oxygen from the nitro group must come within van der Waals 
contact of the HN5 of the FMN (for numbering see Figure 1-4 c)). As both CB1954 
and FMN have delocalised aromatic rings, an electron transfer mechanism (where 
only the electrons are transferred from the FMN and the proton comes from solution 
Figure 1-20) only requires some part of the CB1954 wave function to be within range 





















































Figure 1-18: Net hydride transfer followed by proton transfer from solution. A possible mechanism for the reduction of CB1954 







Figure 1-19: Proton transfer from solution followed by net hydride transfer. A possible mechanism for the reduction of CB1954 








































































Figure 1-20: Electron transfer followed by proton transfer in two distinct steps. A possible mechanism for the reduction of 






For transfer of a hydride the reactive centres must be within van der Waals contact 
(~3.6 Å), however electron transfer only requires some part of the wave functions of 
the the electron donor and electron acceptor to overlap allowing it to occur over much 
greater distances (Moser et al., 2010). The electrons can ‘quantum tunnel’ through an 
energy barrier that would classically prevent the transfer, in this case allowing transfer 
over larger distances. Edge to edge distances (of the two conjugated systems) of less 
than 14 Å would allow the transfers to occur at a rate that is not rate-limiting, as the 
rate would decrease exponentially with increasing distance (Page et al., 2003). Thus 
unlike hydride transfer, electron transfer would not require a specific productive 
binding orientation and could occur over longer distances in the protein environment. 
 
Calculations of reactions of CB1954 and FMNH2 in the gas phase  have shown that 
either net hydride transfer or electron transfer are thermodynamically feasible 
reactions with CB1954, but molecular dynamics calculations of the protein bound to 
CB1954 in solution suggests electron transfer with CB1954 is the more likely 
(Christofferson and Wilkie, 2009). The crystal structure of NfsB has been determined 
with nicotinic acid, an analogue of the nicotinamide group of NAD(P)H, bound in the 
active site (Lovering et al., 2001) (Figure 1-21). The nicotinate is bound with what 
would be the nicotinamide hydride donor C4 atom directly over the FMN N5, with the 
ideal geometry and distance for hydride transfer, implying that the reduction of the 
flavin by NAD(P)H occurs by hydride transfer, which would be expected for 
NAD(P)H (Fraaije and Mattevi, 2000). It is likely that quinone reduction also occurs 
by hydride transfer. Another crystal structure of NfsB contains nitrofurazone bound in 





the flavin ring system (Race et al., 2005) (Figure 1-22). If the mechanism of reduction 
were hydride transfer then this structure would be unproductive as the nitro group is 
not within range of the N5. However this structure is compatible with the electron 
transfer mechanism as any part of the conjugated system could be reduced. These 
structures are of the oxidised enzyme, and so are not of active complexes, and there 
may be different binding preferences for the oxidised and reduced forms of the 
enzyme (Race et al., 2005, Barna et al., 2001, Haynes et al., 2002). To conclude it is 





Figure 1-21: Nicotinate bound in the active site of WT
reactive N5 nitrogen of the FMN is circled in black and the carbon equivalent to the atom in NAD(P)H that donates the proton 













Figure 1-22: Nitrofurazone (light blue) bound in the active site of WT
apart. H-bonds are shown as black dashed lines. 
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1.6.2 Properties of NfsB 
NfsB has been extensively studied, focussing on its potential as a prodrug activating 
enzyme (PAE) in cancer gene therapy. NfsB is a homodimer with each monomer 
containing 217 amino acid residues.  It was first isolated and purified by Anlezark et 
al. in 1992, where it was revealed to be an FMN-containing flavoprotein of 24 kDa 
(Anlezark et al., 1992). NfsB can utilise either NADH or NADPH as a cofactor. 
Analysis of the amino acid sequence revealed that NfsB has extensive sequence 
homology with both the “classical nitroreductase” of Salmonella typhimurium 
(Watanabe et al., 1990) and an inducible nitroreductase found in Enterobacter cloacae 
(Bryant et al., 1991). NfsB shares 88.5% identity in terms of nucleotide sequence with 
the two enzymes (Michael et al., 1994).  
 
1.6.2.1 Kinetics of NfsB 
The kinetics of NfsB catalysis has been extensively categorised with CB1954 and 
other substrates, as well as some inhibitors. Due to the low solubility of many of the 
prodrugs it is not possible to get a full Michaelis-Menten curve, and so the initial slope 
of the curve, kcat/Km (the specificity constant), is used to compare the fit of substrate 
for enzyme. NfsB was initially reported to have a Km of 862±145 µM (Anlezark et al., 
1992) making it a poor binding substrate. A later study, estimating the global kinetics 
(simultaneous fitting on multiple parameters, in this case the rate and concentrations of 
both substrates), found the kcat and Km to be ~20 fold higher (Jarrom et al., 2009), but 
found the kcat/Km ratio to be similar to previous studies (~0.007 µM
-1 s-1) (Anlezark et 
al., 1992). Km’s have also been determined for nitrofurazone (Km = 1850 ± 400 µM) 





shows a small 2-fold preference for NADH over NADPH for a cofactor in terms of 
kcat/Km (Vass et al., 2009). 
 
1.6.2.2 Structure of NfsB 
1.6.2.2.1 Overall Structure of NfsB 
The structure of NfsB has been determined by several groups using X-ray 
crystallography (Parkinson et al., 2000, Lovering et al., 2001, Skelly et al., 2001, 
Johansson et al., 2003), and a number of crystal forms have been described. All of the 
structures of NfsB currently available in the protein data bank have a common tertiary 
and secondary structure. The overall structure of the NfsB dimer is shown in Figure 
1-23. Each monomer contains 5 β-sheets and 10 α-helices, with a central core of anti-
parallel β-sheets surrounded by the α-helices. There is an extensive dimer interface, 
with 42 hydrogen-bonds and 418 non-bonded contacts, involving approximately 60 
residues of each monomer (PDEsum - (Laskowski, 2009)). The two FMN-containing 
active sites are found at the dimer interface and residues from both monomers interact 
with substrate (Lovering et al., 2001). The two active sites are identical in terms of the 




Figure 1-23: The Structure of NfsB from
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. The α-helices are labelled A - K and the β-
CCP4 Molecular Graphics. 





1.6.2.2.2 FMN Binding Site of NfsB 
The FMN is tightly bound to the protein in both active sites; the binding site is shown 
in Figure 1-24. There are three areas of interaction with the protein, two of H-bonding 
with the FMN ribityl and phosphate, and the carbonyl containing ring of the 
isoalloxazine ring system. And finally the flavin ring system is bound primarily 
through hydrophobic interactions. In total there are 10 H-bonds from the flavin to the 
protein, with nine to one monomer and one to the other (the backbone nitrogen of Ser 
39 to the ribityl O3’ alcohol). The phosphate is bound in a phosphate binding pocket 
formed mostly of positively charged residues, comprising of Arg 10, Lys 205 and Arg 
207, with additional H-bonds from the backbone and sidechain of Ser 12. The side 
chains of Lys 14, Lys 74 and Asn 71 all interact with the carbonyls and nitrogen of the 
final flavin ring as does the backbone of Gly 166. All the flavin rings some some 
degree of butterflying. The crystals were all formed of oxidised flavin (hence the 
yellow crystals) but the butterflying could be due to photoreduction in the X-ray beam. 
The crystal structure of the highly related nitroreductase from Enterobacter cloacae, 
has been solved in both oxidised and reduced states (Haynes et al., 2002). They see a 
change in the butterfly angle from 16° to 24° upon 2-electron reduction. The 16° is 
similar to the angle seen with all NfsB structures, and this slightly bent conformation 




Figure 1-24: FMN binding site in NfsB, from the Nicotinate bound structure, pdb I.D. 1ICR 
shown as a pink ball and stick model, the nicotinate is shown in grey. All residues within 4.0
chain so it can be seen that residues 





 Å of the FMN are shown, coloured by 
from both halves of the dimer form the binding site. Hydrogen
.  
 
et al., 2001). The FMN is 





1.6.2.2.3 Ligand Binding in NfsB 
Lovering et al. describe three crystal forms of NfsB with bound inhibitor nicotinate. 
(Lovering et al., 2001) (Figure 1-21). Nicotinate is an analogue of the nicotinamide 
group of NAD(P)H and nicotinic acid has been shown to act as a competitive inhibitor 
for NADH (Race et al., 2005). The nicotinate ligand was bound in the same 
orientation as benzoate was found to bind to the crystal structure of NR from E. 
cloacae (Haynes et al., 2002). The crystal structure of NfsB has also been determined 
with the substrate, nitrofurazone (Figure 1-22), bound in the active site as well another 
with the inhibitor acetate (Race et al., 2005). Nicotinate, acetate and nitrofurazone 
form one hydrogen bond to the O2* alcohol group of the FMN ribityl, with nicotinate 
and acetate otherwise bound through van der Waals contacts. The nitrofurazone was 
bound with the amide group over the catalytic N5 nitrogen of the FMN and the 
nitrofuran ring facing out towards the solvent, this may favour the electron transfer 
mechanism as discussed earlier (Section 1.6.1.1). The amide group hydrogen bonds to 
the side chain of Glu165, and the backbone amide of Thr41, while one oxygen of the 
nitro group hydrogen bonds to the backbone amides of Phe70 and Asn71. 
  
Crystal structures of NfsB have also been published where CB1954 and the related 
dinitrobenzamide prodrug SN23862 are modelled to density inside the active site 
(Johansson et al., 2003) (shown for CB1954 in Figure 1-25). The two non-
crystallographically related active sites in the structure each have the prodrugs 
modelled in a different way. In one, the 2-nitro group of the prodrug (same for 
CB1954 and SN23862) is over the catalytic N5 nitrogen; in the other the 4-nitro group 





first, so that the opposite face is oriented towards the flavin. However there are doubts 
over these structures. For example the density is ambiguous and the molecular 
dynamics studies mentioned earlier (Section 1.6.1.1), used the binding shown by these 
structures as a model, but CB1954 came out of the active site in the studies and in two 
cases returned and reoriented itself on re-entry to have the amide over the N5 nitrogen 
(Christofferson and Wilkie, 2009). These molecular dynamics studies favoured a 
binding model based on the position of the amide from the nitrofurazone-bound NfsB 
structure (Race et al., 2005). Furthermore, at the pH of the crystals (pH 4.6), the 
aziridine ring of CB1954 should ring open, and repeated attempts to reproduce these 
crystal soaks failed to remove the acetate from the NfsB active site. The exact 





Figure 1-25: CB1954 (light pink) modelled in two active sites of NfsB by Johansson 
et al. (pdb I.D. 1IDT)
bonds. The top two images are of the first active site and the bottom two of the second. 
Both sets of images are 90° apart. Each active site has a different nitro group above 
the flavin ring system; the first active site has the 2
Figures produced using CCP4 Molecular Graphics.
 
1.6.2.3 Mutants of NfsB
1.6.2.3.1 Generation of M
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are shown in Figure 1-26. Libraries of random mutants were generated at each of these 
residues and the mutants were cloned into a bacteriophage λ vector, which was then 
used to infect NTR-deficient E. coli (UT5600 strain) to produce bacterial lysogens. 
These lysogens were then evaluated for their sensitivity to CB1954 by replica plating 
(Grove et al., 2003). The only residue found to be essential for the catalysis of 
CB1954 reduction was Gly166, whilst no mutants with greater sensitivity to CB1954 
were generated at the neighbouring Glu165. These residues were both identified 
earlier (Section 1.6.2.2.2) as being involved in binding the FMN, through hydrogen 
bonding by the backbone amides (Lovering et al., 2001). Thus mutating Gly166 would 
be unfavourable as there would be no room for a side chain due to the flavin binding 
site, whilst Glu165 may be required for binding NAD(P)H. Mutations at Gly120 also 
provided no significant improvement but at all other sites mutants were found that 
improved sensitivity to CB1954. At Tyr68, Phe70 and Phe124 a diverse range of 
mutants were identified, and Phe124 showed improvement for 14 mutants. The most 
active of these were F124N and F124K. The F124K mutant was tested in SKOV-3 
ovarian cancer cells and showed ~5-fold greater sensitization to CB1954 than WT 
(Grove et al., 2003). 
 
 
Figure 1-26: Location of the nine residues in the active site of NfsB selected for mutation by Grove 
Image from the active site of the nicotinate
used by Grove et al. to identify the residues. The FMN prosthetic group is shown in light pink. The two images are 90° a





-bound (shown in light blue) crystal structure (pdb I.D. 1ICR 
 
 
 (Grove et al., 2003). 






Single mutations at 6 of the 9 sites were combined in a subsequent study that 
generated 53 double mutant combinations (Jaberipour et al., 2010). Lysogenised E. 
coli were replica plated onto media containing various concentrations of CB1954 and 
then assayed for their colony-forming ability. The 7 most promising mutants were then 
cloned into an adenovirus vector and tested for their ability to sensitize SKOV-3 cells 
to three prodrugs; CB1954, the dinitrobenzamide mustard SN23862, and the 
nitrobenzylphosphoramide prodrug LH7. The most active mutants were T41L/N71S 
and T41L/F170A for CB1954 (14-17-fold improvement over WT), T41L/F70A for 
SN23862 (4.8-fold improvement) and S40A/F124M for LH7 (1.7-fold). T41L/N71S 
was tested in two tumour xenograft models (SKOV-3 and human prostate carcinoma 
PC3 cells) and showed greater anti-tumour activity than WT NfsB. 
 
A novel method of selecting successful mutants has been developed, exploiting 
CB1954 triggering the SOS response of E. coli (Guise et al., 2007). DNA damage, 
such as the cross-linking caused by CB1954, activates the SOS response in E. coli, 
which activates the DNA repair mechanism (Sassanfar and Roberts, 1990). This 
occurs through the action of the RecA protein, which also promotes bacteriophage λ’s 
transition into the lytic cycle through proteolytic cleavage of the cI transcriptional 
repressor protein (Roberts and Devoret, 1983). In bacterial lysogens, the phage DNA 
is incorporated into the bacteria and cI inhibits transition to the lytic cycle and so the 
prophage DNA is passed on to subsequent bacterial lysogen generations. Upon cI 
cleavage by RecA following DNA damage, this inhibition is lifted with the result that 
the cells enter the lytic cycle. The prophage is then excised, replicated and multiple 





The induction of lytic cycle, with phage replica-plated, means that one can select for 
mutants with enhanced sensitivity to CB1954. The efficiency of selection was 
improved through repeated cycles of prodrug treatment of lysogens, phage harvest, 
and re-infection to generate more lysogens (Guise et al., 2007). 
 
This method was tested on randomised single mutations at either the N71 or the F124 
sites, and then used to select the best mutants from a library with randomised 
mutations at three out of five sites (Guise et al., 2007). All of these were mutated at 
F124, at either S40 or T41, and either F70 or N71. A lambda library was created of 
these mutants (a possible 1,048,576 nucleotide combinations), and the most active 
mutants were selected via 3 cycles of prophage selection at 100 µM CB1954, followed 
by 4 rounds at 50 µM and 3 rounds at 30 µM. Whereas before selection, ~ 90 % of 
lysogens were resistant at 400 µM CB1954, after selection, none could survive at just 
25 µM. The NfsB genes generated from plaque-purified phage were sequenced to 
determine successful mutations. This selection method discovered one single mutant 
(F124N – previously identified (Grove et al., 2003)), seventeen double mutants, 23 
triple mutants and even 7 quadruple mutants (with mutations at other sites presumably 
incurred through errors in the PCR). The most active of these mutants as judged from 
the apparent IC50 of the lysogens was the triple mutant T41Q/N71S/F124T (IC50 = 3 
µM, WT IC50 = 143 µM), a ~48 fold improvement. Interestingly the T41Q single 
mutant was worse than WT, and so the combination of mutations seen in this triple 
mutant shows cooperativity. Successful mutations at Thr41, Asn71 and Phe124, were 
used as the basis for another mutation library adding in mutations of Met127, His128 





these the most successful mutant was T41Q/N71S/F124T/M127V, which showed a 
similar improvement in IC50 for CB1954 relative to WT as the triple mutant that 
included the first three mutations. 
 
1.6.2.3.2 Analysis of Mutants 
For most mutants, initially the IC50 for CB1954 (the concentration of CB1954 at which 
50 % of cells survive) in E. coli lysogens was measured (Grove et al., 2003, Guise et 
al., 2007, Jaberipour et al., 2010). The mutants with the lowest IC50 were then 
assessed in SKOV-3 cells, to confirm activity in ‘target’ cell lines, and most showed 
similar improvement to the E. coli lysogens over WT, although there were some 
notable exceptions. The most active single mutants, the double mutants N71S/F124K 
and N71S/T41L, and the triple mutant T41Q/N71S/F124T have also been purified and 
assessed in vitro for their ability to reduce CB1954 and nitrofurazone, where the 
specificity constant (kcat/Km) was compared as a measure of the activity of the mutant 
with CB1954 (Searle et al., 2004, Race et al., 2007, Jarrom et al., 2009). The most 
active of these (T41L/N71S) had a ~100-fold higher kcat/Km than WT, and the next 
most active (T41Q/N71S/F124T) was ~45-fold higher. Mutants showing an improved 
kcat/Km for CB1954 showed improved kinetics for menadione but not for nitrofurazone. 
The WT global kinetic parameters for CB1954 were not measured as at high 
NAD(P)H concentration the Kmapp is higher than the solubility of CB1954. Since the 
plateau of the Michaelis-Menten curve is not seen the estimates of kcat and Km are 
poor, but it does give a good estimate of kcat/Km, which is estimated only on the, early, 
linear part of the Michaelis-Menten curve (Jarrom et al., 2009). For a bi-bi ‘ping-





will increase until the NAD(P)H is saturating, but the kcat/Km will stay constant. All the 
mutants in this study appeared to show a greater specificity constant for CB1954 over 
nitrofurazone compared to WT, with the most improved being F124N and 
N71S/F124K showing ~5-fold improvement in specificity. Enhanced selectivity for 
the prodrug may be essential as it is known that NfsB has a broad substrate in vivo 
specificity and it is unknown how many substrates or inhibitors may interact with the 
enzyme. Some of the most active mutants for CB1954, have also been compared to 
WT for their ability to sensitize SKOV-3 cells to the alternative prodrugs SN23862 
and LH7 (Jaberipour et al., 2010) (see Section 1.5.2) 
 
The reaction products of CB1954 reduction by NfsB and some of its mutants were 
assayed by HPLC (Race et al., 2007, Jarrom et al., 2009). The only deviation from the 
1:1 ratio of the 2-hydroxylamine and 4-hydroxylamine products seen with WT was 
witnessed with the two mutants containing T41L, which seems to favour almost 
exclusive reduction of the 4-nitro group over the 2-nitro group. The replacement of 
threonine with leucine may have an effect on selectivity as the hydrophobic leucine 
would be more likely to form favourable interactions with the aziridine group of 
CB1954 and not the amide or nitro groups. 
 
 
1.6.2.3.3 NfsB Mutant Structures 
The crystal structures of four single mutants, T41L, N71S, F124K and F124N and one 





analogue nicotinic acid (Race et al., 2007). They allow some explanation of the 
improvements seen in activity for CB1954. There were no major changes in the 
overall structure, and the differences seen were in the neighbourhood of the mutation 
sites. For the T41L mutant, the backbone atoms are in identical positions to WT and 
hydrogen-bond the bound nicotinate through the backbone nitrogen. The leucine side 
chain in part overlays the threonine, essentially replacing the threonine alcohol group 
with a methyl group, but the leucine is larger and thus causes a slight change in the 
position of the nicotinate in the active site and the F124 side chain. The N71S 
mutation removes two direct hydrogen bonds from the FMN cofactor to the protein 
and replaces them with a hydrogen bond to water which is then in turn hydrogen 
bonded to the FMN (Figure 1-27). Serine was the only residue that showed 
improvement over WT at position N71 in saturation mutagenesis (Grove et al., 2003). 
The F124N mutation moves the sidechain from a hydrophobic pocket for the 
phenylalanine to a more polar pocket for the asparagine. The lysine side chain of the 
F124K mutation is seen in multiple conformations with some being ‘phenylalanine 
like’ and others being ‘asparagine-like’. In the most improved mutants, F124K and 
F124N, this movement of the side chain away from the active site and into a polar 
pocket, creates room for the relatively large CB1954 to move into the active site.  
Most mutations at F124 have been shown to be favourable in improving specificity for 
CB1954; this is most likely due to the sterical removal of a large group from around 




Figure 1-27: Effect of the N71S mutation in 
and the right-hand image is N71S. 
direct hydrogen-bond to the FMN in WT is replaced by one through a solvent water. 
Figures produced using CCP4 Molecular Graphics.
 
1.6.2.3.4 Mutants containing Unnatural Amino Acids
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most active F124 unnatural amino acid substitution tested (pNF - para-
nitrophenylalanine) showed a >30-fold improvement in kcat/Km over WT, and >2.3-
fold better than the best of the natural amino acid substitutions (F124K). Other 
successful unnatural amino acid mutations included pAF (para-aminophenylalanine) 
and NapA (napthylalanine). The mutants were also tested for activity with LH7. Much 
smaller increases in activity were observed compared to WT, but the pNF was still the 
most active. 
 
1.6.3 Properties of NfsA 
The initial purification of NfsB based on its reduction of CB1954 used NADH as the 
assay cofactor (Anlezark et al., 1992), and this may explain why NfsA was overlooked 
as a PAE since NfsA has a preference for NADPH as a cofactor (Zenno et al., 1996a). 
A study in 2006 showed that NfsA can reduce CB1954 (Barak et al., 2006), and a 
more recent study has compared NfsA to NfsB for potential use in suicide gene 
therapy (Vass et al., 2009).  
 
NfsA is a 27 kDa homodimer containing 240 amino acid residues, 23 more than NfsB. 
Alignment of the sequences shows only 28 identical and 32 conserved residues, and 
antibodies that are specific for NfsB do not cross react with the NfsA protein (Vass et 
al., 2009). Whereas there is little sequence homology between the two E. coli 
nitroreductases, NfsA and NfsB, there is some structural homology (discussed in 
Section 6.2.1). NfsA expression is controlled by the soxRS regulon and has been shown 





the MarA regulon (Barbosa and Levy, 2002). Induction with 0.2 mM paraquat caused 
nitroreductase positive bacteria to display a 4.5 times greater nitroreductase activity 
with nitrofurantoin (Lightfoot et al., 2000). NfsA may be expressed to control damage 
caused by oxidative stress, in common with other members of the soxRS regulon, by 
minimising the redox cycling from single electron reduction of nitroaromatics, 
quinones and dyes. 
 
Overexpression of NfsA in E. coli lysogens caused greater sensitivity to CB1954 than 
for NfsB (>2-fold improvement) (Vass et al., 2009). When expressed in SKOV-3 cells 
using a comparable adenovirus vector, NfsA showed between 3.5- and 8.1-fold lower 
IC50 than NfsB (in three experiments) (although antibodies were not available to 
confirm similar levels of expression). HPLC studies revealed that NfsA preferentially 
reduces the 2-nitro group of CB1954 over the 4-nitro, unlike NfsB which produces 
equal proportions of each hydroxylamine product. The 2-hydroxylamine has a 
pronounced bystander effect (Helsby et al., 2004), and this is borne out by 
experiments in SKOV-3 cells when a minority of adenovirus infected cells are mixed 
with uninfected cells, NfsA shows a greater bystander effect than NfsB. NfsA was also 
compared for its ability to sensitise SKOV-3 cells to the dinitrobenzamide mustard 
prodrugs SN24927, SN26209 and SN27653 (Figure 1-12). All of the dinitrobenzamide 
prodrugs require activation of the nitro para to the mustard moiety, this is equivalent 
to the 2-nitro group of CB1954 and so NfsA may be expected to be more effective at 
reducing these prodrugs. NfsA-infected SKOV-3 cells showed 1.8- to 2.8-fold greater 






1.6.3.1 Kinetics of NfsA 
Similarly to NfsB, NfsA has a broad substrate range that includes a variety of 
quinones and nitroaromatics (Zenno et al., 1996a). NfsA shows a strong preference for 
NADPH over NADH as a cofactor in vitro, unlike NfsB which has a very slight 
preference for NADH (Vass et al., 2009). With its preferred cofactor NfsA shows a 
~25-fold higher kcat/Km (0.15 ± 0.01 µM
-1 s-1) when compared to NfsB (0.0058 ± 
0.0004 µM-1 s-1). Though only a ~18-fold improvement was seen when the small 
amount of DMSO used to solubilise the CB1954 is taken into account. With NADPH 
provided as a cofactor, purified NfsA is ~20-fold better at killing SKOV-3 cells than 
NfsB. This was a higher improvement than was suggested from the in vivo studies in 
cancer cell lines; this may be due to the available levels of NADH and NADPH in the 
cell or due to variable inhibition by small molecules inside the cell. In many tumours 
glycolysis is upregulated, the Warburg effect, which leads to an increase in the cellular 
NADH concentration, and indirectly to an increase in NADPH concentration. In order 
to fully understand the relative merits of the enzymes the concentrations in the target 
tissues would have to be assessed. 
 
1.6.3.2 Structure of NfsA 
1.6.3.2.1 Overall Structure of NfsA 
The structure of the NfsA protein has been previously determined to 1.7 Å resolution 
(Kobori et al., 2001). It shows some similarities with NfsB which are discussed in 
greater detail in Section 6.2.1. It is also a dimer with two FMN-containing active sites 





large central helix and 4 stranded antiparallel β-sheets surrounded mostly by α-helices. 
The protein is larger than NfsB (240 versus 217 amino acids) and has a larger dimer 
interface, with 66 hydrogen-bonding and 609 non-bonding interactions involving 
approximately 98 residues from each monomer (PDEsum - (Laskowski, 2009)). 
 
 
Figure 1-28: The crystal structure of the NfsA dimer (pdb I.D. 1F5V 
A ribbon diagram of the protein is shown with one half of the dimer coloured in blue 
succession. The secondary structure elements are labelled from the N





(Kobori et al., 2001)). The two images are separated by 90°. 
and the other by secondary structure 
-terminal, A-K for α-helices and 1
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1.6.3.2.2 FMN Binding Site in NfsA 
Similarly to NfsB, NfsA has two active sites found at the dimer interface (indicated by 
the green FMN models in Figure 1-28). The FMN binding site in NfsA is detailed in 
Figure 1-29. Similarly to NfsB, the flavin is bound primarily through hydrogen bonds 
to the ribityl and hydrophobic interactions with the ring system. There are 7 






Figure 1-29: FMN binding site in NfsA. The Structure shown is the published Pdb I.D. 1F5V (Kobori et al., 2001). The FMN is 
shown in pink, and the protein coloured by chain, to distinguish the dimer halves. H-bonds are represented by black dashed lines. 






1.7 Aims of this project 
This study will increase our understanding of the reduction of CB1954 by NfsA and 
NfsB. X-ray crystallography will be used to elucidate the structures of the NfsB 
mutants, and give insights into how the mutations improve CB1954 binding on a 
molecular level, building on studies with previous single and double mutants (Race et 
al., 2007). Complementary kinetic studies will elucidate the effect the mutations have 
had on the various reaction steps. Finally crystallography will be used to understand 
the binding of ligands including substrates to NfsA, with the aim of identifying 
residues important in ligand binding possibly to guide future mutagenesis of the 
enzyme in a similar manner to that performed with NfsB (Grove et al., 2003), and 







2. Materials and Methods 
2.1 Materials 
All reagents were purchased from Sigma Aldrich (Poole, UK) with the exceptions 
mentioned below. PEG 3000, 4000, and 8000 and the cytochrome c were purchased 
from Fluka Analytical (St. Gallen, Switzerland). CB1954 was kindly provided by ML 
Laboratories, Keele, UK. The other dinitrobenzamide (SN-) prodrugs were kindly 
provided by Dr. A. Patterson, Dr. J. Smaill and Prof. W. Wilson, Auckland Cancer 
Society Research Centre, The University of Auckland, Auckland, New Zealand. The 
unnatural amino acids, L-4-nitrophenylalanine (pNF), L-4-aminophenylalanine (pAF) 
and L-napthylalanine were purchased from PepTech Corp. (Burlington, 
Massachusetts, USA). 
 
2.2 Production and Isolation of NfsB and NfsB Mutants 
2.2.1 Growth of NfsB and Mutant Proteins 
The Wild-type NfsB (Lovering et al., 2001) and the T41L/N71S (Jarrom et al., 2009) 
and T41Q/N71S/F124T (Guise et al., 2007) mutants were made previously, as 
described. The T41Q/N71S/F124T/M127V mutant was identified and made using the 
lambda selection system described for the triple mutant. Successful mutations at 
Ser40, Thr41, Phe70, Asn71 and Phe124 were combined with mutations of Met127, 
His128 and Trp138 to all amino acids (unpublished work by Simon Vass). The mutant 
nfsB genes were cloned into pET11c plasmids under control of T7 RNA polymerase, 





selected for their resistance to kanamycin. Cells were cultured in Luria Broth (LB) at 
37°C and grown until the scattering of light at 550 nm (OD550) of broth solution was 
0.7 - 0.9 units, at which point IPTG was added to a final concentration of 1 mM to 
induce the transcription of the T7 RNA polymerase in the lambda lysogen and hence 
the nfsB gene on the pET plasmid, and the flasks were incubated at 37°C for a further 
4 to 6 hours. The induced cultures were centrifuged at 17,700 x g for 15 min to pellet 
the cells. The pellet was resuspended and washed in a minimal amount of STE buffer 
(10 mM Tris-HCl pH 7.0, 1 mM EDTA, 100 mM NaCl) and centrifuged again at 
17,695 x g for 15 min. 
 
2.2.2 Purification of NfsB and NfsB Mutants 
NfsB and the natural amino acid NfsB mutants were purified following the method 
modified from that described by Anlezark et al. (Anlezark et al., 1992). Cell pellets 
were resuspended in a minimal volume of 10 mM Tris pH 7.0, 10 µg/ml DNaseI, 10 
µg/ml RNaseA, 10 µg/ml PMSF, 0.1% iso-propanol, 20 µM FMN, 10 mM MgSO4, 1 
mM MnCl2. The cells were lysed by sonication with a ‘Heat Systems Sonicator’, at 
power level 5, using three times a programme of 15 second bursts with 20 second rests 
for a total time of one minute, and then centrifuged at 33,000 x g for 30 min. The 
supernatant was collected and ammonium sulphate was added to 0.5 M. The solution 
turned a cloudy golden yellow, and this solution was then filtered. 
 
The solution was loaded onto a Phenyl-Sepharose hydrophobic interaction 





(NH4)2SO4, 20 µM FMN, 10 µg/ml PMSF, 0.1% iso-propanol. A wide golden yellow 
band appeared at the top of the column, due to the nitroreductase-bound FMN (a good 
indicator of the proteins location). The column was then washed with 3.5-4 times 
column-volume of the above buffer. The protein was eluted using 10 mM Tris pH 7.5, 
20 µM FMN, 10 µg/ml PMSF, 0.1% iso-propanol. Fractions were assessed for protein 
content as described in Section 2.2.3. 
 
Selected fractions were pooled and dialysed into 20 mM Tris pH 7.5, 20 µM FMN, 10 
µg/ml PMSF, and 0.1% iso-propanol and then loaded onto a Q-Sepharose 
ion-exchange chromatography column pre-equilibrated in the same buffer. The 
column was washed with 3.5-4 times column-volume of buffer. The column was 
eluted with buffer containing 100 mM NaCl to 500 mM NaCl, followed by  buffer 
with 500 mM NaCl. The NfsB content of samples was assessed and fractions were 
pooled on the basis of specific activity and concentrated as described in Section 2.2.3. 
 
The NfsB quadruple mutant (T41Q/N71S/F124T/M127V) was expressed in E. coli 
and purified by Alex Gavin, a final-year project student. 
 
2.2.3 Assessment of Enzyme Purity and Concentration 
2.2.3.1 SDS-PAGE 
Purity of fractions was assessed by Coomassie brilliant-blue stained SDS–PAGE 





apparatus (Biorad, Hemel Hempsted, UK). All gels contained 12% acrylamide 
(30:0.8% Acrylamide:Bis-acrylamide – pre-mixed), and at least one lane containing 
Biorad Broad-Range molecular weight markers. 
 
2.2.3.2 Protein Concentration Determination 
The concentration of the protein was estimated by measuring the absorption of light at 
280 nm, using an extinction coefficient of 43,000 M-1 cm-1 for NfsB and 52,000 M-1 
cm-1 for NfsA (purification detailed in Section 2.4), and by Bradford Assay, using 
Bovine Serum Albumin (BSA) as a standard (Bradford, 1976). For the Bradford assay, 
500 µl of Bradford reagent was added to a total volume of 1 ml. The absorbance at 
550 nm was then compared to a standard curve created using known concentrations of 
BSA up to 10 µg/ml to assess the protein concentration. 
 
2.2.3.3 Nitroreductase Activity Assays 
The nitroreductase activity was assessed via a menadione-linked cytochrome c activity 
assay, whereby the reduction of menadione by the nitroreductase is linked to the 
reduction of cytochrome c by the product of menadione reduction, menadiol (Figure 
2-1). Typically 1 ml solutions were prepared directly in a cuvette containing 10 mM 
Tris-HCl pH 7.0, 200 µM menadione, 80 µM cytochrome c (from Horse Heart), 100 
µM NADPH, 2% DMSO. The reaction was started by the addition of the enzyme from 
the fraction to be tested, typically 0.5-2 µl. After mixing the solutions, the rate of 
reaction was measured from the change in absorbance of cytochrome c at 550 nm over 
a period of two minutes at 25°C. Rates were calculated assuming a molar absorbance 
 
 
for cytochrome c of 21,100 M
cytochrome c are reduced for each mole of menadione.
concentration of cytochrome c and low NfsB concentrations,
same as the rate for the reduction of m
 
Figure 2-1: Reaction scheme
activity assay. 
 
2.2.3.4 Pooling and Concentration 
Conductivity of fractions from the columns was measured
(Radiometer Copenhagen, Denmark). 
the activity (AU min
highest specific activities were pooled
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2.3 Production and Isolation of His-tagged NfsB and Unnatural 
Amino Acid Mutants 
2.3.1 Source of Plasmids and Cells 
Professor Ryan Mehl (Oregon State University, USA) kindly provided the plasmids; 
pBAD-NTR, pBAD-NTR-124TAG and pDule-Nap, as well as E. coli DH10B cells 
transformed with pBAD-NTR-124TAG and either pDule-pAF or pDule-pNF. Vector 
maps of the generic pBAD and pDule plasmids are shown in Figure 2-2. The 
production of these plasmids is unpublished, but follows a method described by 
Hammill et al. (Hammill et al., 2007) to produce mutants containing the amino acids 
described previously (Jackson et al., 2006). The NfsB gene from the E. coli genome 
was cloned into the pBAD vector, producing pBAD-NTR, and then the 124 residue 
was mutated to a stop codon TAG, producing pBAD-NTR-124TAG. The cloning 
event removes the first codon and adds a large affinity tag to the N-terminal of the 
protein. The full sequence of the tag is shown in Table 2-1. This expresses tagged 
NfsB under the control of the pBAD promoter, which is induced by arabinose (Figure 
2-2). The pDule plasmids encode the aminoacyl tRNA synthetase that adds the 
appropriate unnatural amino acid to the suppressor tRNACUA, which recognises the 






ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG 
Met Gly Gly Ser His His His His His His Gly Met Ala Ser Met 
ACT GGT GGA CAG CAA ATG GGT CGG ACT CTG TAC GAC GAT GAC GAT 
Thr Gly Gly Gln Gln Met Gly Arg Thr Leu Tyr Asp Asp Asp Asp 
AAG GAT CGA TGG GGA TCC                                     
Lys Asp Arg Trp Gly Ser 
 
Table 2-1: Sequence of His-tag attached to NfsB in the pBAD-NTR vector. The DNA 
sequence is shown in italic, and the amino acid sequence in bold. The first underlined 
section is the His-tag, and the second the enterokinase recognition site. The tag is 
cleaved after the Lys, meaning the last 5 amino acids still remain attached to the 








Figure 2-2: Vector map of the pBAD/His plasmid (Invitrogen) and the pDule-tfmF 
plasmid adapted from reference (Hammill et al., 2007). The pBAD plasmid contains 
the inducible promoter and adds a 6xHis tag to the N-terminal of the protein added 
into the multiple cloning site (MCS). An enterokinase (EK) cleavage site is also 
added, allowing the His-tag to be cleaved. The pDule-tfmF plasmid is a plasmid 
designed to work in conjunction with the pBAD plasmid to incorporate the unnatural 
amino acid tfmF (trifluromethylphenylalanine). The pDule plasmids used in this study 
replace the aminoacyl tRNA synthetase tfmFRS, with one specific to the unnatural 
amino acids studied here. 
 
 
The pBAD plasmids contain an ampicillin resistance gene and the pDule plasmid a 
tetracycline resistance gene. E. coli DH10B competent cells, produced by 
electroporation, were transformed with the pNAD-NTR-124TAG and pDule-Nap 
plasmids to provide cells capable of growing the NfsB Nap mutants with 





NfsB were selected by growth in 100 µg/ml ampicillin, and the mutants were selected 
with additional 25 µg/ml tetracycline. 
 
2.3.2 Growth and purification of His-tagged NfsB and Unnatural Amino 
Acid Mutants 
The His-tagged NfsB was grown using an arabinose auto-induction media (Studier, 
2005). This works by using a growth medium containing glucose and arabinose as the 
sources of energy. E. coli has a preference for glucose and so the cells will initially 
grow using the glucose. The nfsB gene is placed under the control of the L-arabinose 
or ara operon, which encodes the enzymes required for the catabolism of arabinose. 
Glucose acts as a repressor of the ara operon, and so while glucose is present 
induction of the operon and the nfsB gene is repressed, but in the absence of glucose 
nfsB is transcribed. The amount of glucose is sufficient to grow the cells to mid-log, 
and then the gene is transcribed. 
 
Growth of E. coli-expressing NfsB and purification of the His-tagged NfsB and 
unnatural amino acids was performed according to the procedure of Hammill et al. 
(Hammill et al., 2007). An overnight culture of the cells was grown in 50 ml L-Broth 
containing 10 g/L Tryptone, 5 g/L Yeast Extract and 10 g/L NaCl.  2.5 ml of the 
saturated culture was added to 500 ml of arabinose auto-induction media (Studier, 
2005), containing 0.05% glucose and 0.05% arabinose as energy sources, along with 
amino acids, salts and trace metal ions. FMN was also added to 20 µM. The unnatural 





inoculation from an overnight culture in LB. The overnight and auto-induction 
cultures also contained 100 µg/ml ampicillin and, for the mutants, 25 µg/ml 
tetracycline. Cultures were shaken at 250 rpm and kept at 37°C. Growth was measured 
from turbidity at 600 nm and NfsB expression was monitored by SDS-PAGE (as per 
Section 2.2.3.1), 0.1 ml of 5 M Urea loading dye (also containing 0.04% Bromophenol 
Blue, 20% Glycerol, 2% β-mercaptoethanol, 0.1% SDS and 150 mM Tris pH 6.8) per 
OD unit of sample was added. The samples were boiled and analysed on SDS PAGE. 
When growth was complete cells were pelleted as described in Section 2.2.1. 
 
Cell pellets were resuspended in a 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 
10 mM imidazole, 20 µM FMN solution containing a single protease inhibitor tablet 
(EDTA free, Roche). This solution was sonicated and cell debris spun down as in 
Section 2.2.2. The supernatant was then loaded onto a Nickel NTA column pre-
equilibrated in 50 mM sodium phosphate pH 8.0, 300 mM NaCl and 10 mM 
imidazole. The column was washed with three column-volumes of buffer. Protein was 
eluted using a gradient of increasing imidazole, 20 mM to 250 mM over four column 
volumes. Protein fractions were analysed for the presence of nitroreductase by 
Bradford assays and SDS PAGE, as in Section 2.2.3. The purest fractions were then 
pooled and dialysed into 20 mM sodium phosphate pH 7.0, 0.5 M ammonium sulphate 
and 20 µM FMN overnight. 
 
Protein fractions were then loaded onto a Phenyl-Sepharose column pre-equilibrated 





previously with non His-tagged NfsB (Lovering et al., 2001) (Section 2.2.2). The 
column was washed with two column-volumes of buffer and protein fractions were 
eluted using 10 mM Tris pH 7.0, 20 µM FMN. Fractions were analysed as described 
in Section 2.2.3 and pooled on the basis of specific activity. 
 
2.3.3 Cleavage of His-tag 
The C-terminal His-tag was cleaved using a recombinant enterokinase (rEK - 50 U 
stock, Novagen, UK). Protein to be cleaved was dialysed into 20 mM Tris pH 7.5, 50 
mM NaCl, 2 mM CaCl2. To test cleavage, protein was diluted to 0.2 µg/ml and 
enterokinase added to a final concentration of 0.02 - 0.1 U in 50 µl. Test samples were 
left at room temperature for 48 hours, with samples taken periodically, to which was 
added protein loading dye (for SDS-PAGE) and 10 µg/ml PMSF was added to the 
samples to inhibit further cleavage. Final cleavage was performed by adding rEK to 
~1 mg/ml NfsB to 0.5 U in 500 µl, leaving at room temperature for 48 hours and then 
adding 10 µg/ml PMSF to prevent further cleavage. 
 
2.4 Production and Isolation of NfsA 
2.4.1 Growth of NfsA 
The nfsA containing pET-24 plasmid pPS1341A1 was made by Dr Peter Searle (Vass 
et al., 2009), and used to transform E. coli BL21 (λDE3) cells. Colonies were grown 
and selected for their resistance to kanamycin. Cells were grown and production of 






2.4.2 Purification of NfsA 
Purification was performed by a method similar to that for NfsB (described in Section 
2.2.2), with the exceptions noted here. After the cell debris had been pelleted, 
ammonium sulphate was added to 208 g/L for a 35% cut. The cloudy golden-yellow 
solution was then centrifuged at 7,500 x g for 10 minutes. The supernatant was 
removed and to it was added 236 g/L of ammonium sulphate for a 35-75 % cut. The 
thick cloudy golden yellow suspension was centrifuged at 7,500 x g for 10 minutes. 
The yellow pellets were redissolved in a minimal amount of 10 mM Tris-HCl pH 7.0, 
1 mM EDTA 1.0 M (NH4)2SO4, 20 µM FMN, 10 µg/ml PMSF, 0.1% iso-propanol 
prior to loading onto the pre-equilibrated Phenyl-Sepharose column. A three step 
elution process followed, all buffers containing 10 mM Tris-HCl pH 7.0, 20 µM FMN, 
10 µg/ml PMSF, 0.1% iso-propanol. The column was washed first with two 
column-volumes of 0.8 M (NH4)2SO4 buffer, then two column-volumes of 0.4 M 
(NH4)2SO4 buffer, and finally with 0.2 M (NH4)2SO4 buffer. The column was finally 
washed with a no salt buffer to remove the final traces of protein. The Q-Sepharose 
column was then used in an identical manner to that used for NfsB. 
 
If further purity was required the pooled fractions were run down a Blue Trisacryl 
affinity chromatography column, and washed through with further sample buffer. The 
column was pre-equilibrated with 40 mM sodium phosphate pH 7.0, 20 µM FMN, 10 





prior to loading. The protein was eluted with a gradient run from the no salt buffer to a 
1.0 M NaCl buffer. 
 
2.5 X-ray crystallography 
2.5.1 Crystallization 
All crystals in this study were grown using a vapour diffusion method. Either by a 
sitting drop method, using CombiClover 96-well crystallization plates (Emerald 
BioSystems, Bainbridge Island, WA, USA), or a hanging drop method, using MD3-11 
XRL plates and CrystalCleneTM cover slips (both - Molecular Dimensions Limited, 
Newmarket, Suffolk, UK). The cover slips were sealed to the tray using high vacuum 
grease. Sitting drop trays were sealed using clear tape. 1 ml mother liquor was used in 
the reservoir of all trays. Equal volumes of protein solution and mother liquor were 
mixed together in the crystal drops. Volumes were varied from 1 µl of each to 4 µl of 
each. All trays were covered with foil (to prevent light damage as the FMN is light-
sensitive) and stored at a constant temperature of 18°C. All chemical solutions for 
crystallization were sterile-filtered prior to use and additives/ligands were added at the 
appropriate pH. Crystal photos were taken ten levels of focus and combined using the 







2.5.1.1 Crystallization of NfsB mutants 
2.5.1.1.1 Crystals trays at pH 4.6 
Initial screening was based on initial conditions reported by Lovering et al. (Lovering 
et al., 2001). The hanging drop set-up was observed to produce higher quality crystals 
than the sitting drop method. Parameters varied included protein concentration, drop 
size, concentration of PEG 4,000 and concentration of sodium acetate. Crystals grew 
in a wide range of conditions, with reproducible crystals grown from 10-18% PEG 
4,000 and 50-200 mM sodium acetate buffer pH 4.6. Protein concentrations that led to 
crystal growth were 8-12 mg/ml. Later conditions included up to 15% ethylene glycol, 
to aid in cryo-protection, or 15 mM nicotinic acid, to obtain ligand complexes, added 
to the mother liquor. 
 
2.5.1.1.2 Crystal trays at pH 7.0 
Crystals grown at pH 7.0 grew from conditions based upon those described by 
Parkinson et al. (Parkinson et al., 2000). Crystals grew from mother liquor containing 
15-22 % PEG 8,000 and 10-20 mM potassium phosphate pH 7.0. The first crystals 
obtained in these conditions were found to be very fragile plates and rarely survived 
attempts to cryo-protect by moving from one solution to another, and so to limit the 
stress on these crystals 15 % ethylene glycol or 15 % DMSO was added to the mother 
liquor when setting up the trays to cryo-protect and allow crystal mounting straight 






Attempting to obtain protein-ligand complexes, NfsB T41L/N71S and 
T41Q/N71S/F124T mutants were co-crystallized with up to 10 mM CB1954 (in a 
solvent of 2:7 NMP:PEG300) and up to 20 mM of the related dinitrobenzamide 
prodrugs SN27419, SN28099, SN27686 (Singleton et al., 2007), S27683 and 
SN29222 (all in acetonitrile) (Figure 2-3). To save material, the prodrugs were added 































































































Figure 2-3: Dinitrobenzamide prodrugs used in crystallization studies. Figure 





2.5.1.2 Crystallization of NfsB Unnatural Amino Acid Mutants 
Crystals of NfsB unnatural amino acid mutants were grown under similar conditions 
to the previous NfsB crystals at pH 4.6 (Section 2.5.1.1.1). For anything other than 
thin needles to form the His-tag had to be cleaved prior to crystallization as described 
in Section 2.3.3. Crystals grew from drops containing 10-15 mg/ml protein. Crystals 
of the pNF mutant were grown by Sophie Englander and of the pAF mutant by Laura 
Goodman (both undergraduate project students). 
 
2.5.1.3 Crystallization of NfsA 
Purified NfsA was concentrated to between 10-16 mg/ml (concentration determined 
by Bradford Assay as before), and then dialysed into 100 mM Imidazole. Some 
protein solutions were dialysed into buffer also containing 10 mM NaCl and/or 20 µM 
FMN. Conditions varied included drop size, precipitant concentration, buffer 
concentration and ratio of protein to mother liquor in drop. Protein concentration was 
varied on many trays, from approximately 5-16 mg/ml, by dilution into 100 mM 
Imidazole pH 7, before mixing with mother liquor. Crystals grew from mother liquor 
for NfsA crystallization contained 50-200 mM Imidazole pH 7 as a buffer and 18-34% 
PEG 3,350 (Sigma Aldrich, Poole, UK) or PEG 3,000 (Fluka Analytical, St. Gallen, 
Switzerland) as a precipitant. 
 
2.5.2 Ligand Soaks 
With NfsB crystals grown in acetate buffer, soaking in new ligands had only proven 





pH 4.6 along with the ligand of interest (Race et al., 2005). Unsuccessful attempts 
were made to use this method to soak in substrates including menadione and 
nitrofurazone (up to 25 mM of each), so the decision was made to include no ligand 
and see the effect of citrate alone. Soaking was not possible with the fragile crystals of 
NfsB grown at neutral pH. With NfsA, it was only once the PEG used as a precipitant 
was changed from PEG 3,350 (Sigma) to PEG 3,000 (Fluka) and the cryo-protectant 
switched from ethylene glycol to DMSO that soaking proved effective. Then soaking 
with Hydroquinone (25 mM) and Benzoquinone (10 mM) in 5% steps gave rise to 
sufficient density in the activity site. 
 
2.5.3 Cryo-protection and Crystal Mounting 
To cryo-protect, the crystals were soaked in mother liquor containing either ethylene 
glycol or DMSO, increasing concentration in incremental steps of 5% for 1-10 
minutes each to minimise osmotic shock, to a total concentration of 15% for ethylene 
glycol and 20% for DMSO. With NfsA crystals for each of these steps it was 
necessary to lower the concentration of the PEG precipitant by 2% (e.g. from 18% to 
16%) alongside each incremental increase in cryo-protectant to prevent the crystals 
from dehydrating (when this occurred crystals showed a different unit cell and the 






2.5.4 Data collection, processing and refinement 
2.5.4.1 X-ray Sources 
X-ray diffraction data sets were collected on either the University of Birmingham’s 
home source (Rigaku 007HF generator with a Saturn CCD detector mounted on a 
4-circle kappa goniometer) or at the synchrotrons of the European Synchrotron 
Radiation Facility (ESRF), Grenoble, France or Diamond Light Source, Oxfordshire, 
UK. The home source was frequently used to screen crystals before taking them to the 
synchrotron. The beamline will be specified in the results chapters for datasets 
collected at ESRF and Diamond. 
 
2.5.4.2 Software used for data processing and refinement 
Diffraction images were indexed, integrated and processed using MOSFLM (Leslie 
and Powell, 2007), iMOSFLM (Battye et al.) or XDS (Kabsch). Datasets were 
combined and scaled using POINTLESS and SCALA (Collaborative Computational 
Project, 1994) and data quality was assessed using XTRIAGE (Adams et al., 2010). 
All structures shown here were solved by molecular replacement with PHASER 
(McCoy et al., 2007), using published structures as starting/search models, pdb entry 
1F5V for NfsA (Kobori et al., 2001) and pdb entry 1ICR for NfsB (Lovering et al., 
2001). The NfsB search model was modified to replace the residues that were mutated 
with alanines so the density for the mutation sites could be judged with a less biased 
electron density map. An alternative search model was used for structures in a new 
space group, using only chain A of the 1ICR structure. Structures were refined using 





PHENIX (Adams et al., 2010). For structures with high resolution (better than 1.1 Å) 
hydrogen atoms were added to the model prior to refinement using phenix.reduce 
(Word et al., 1999). Models were built and modified using Coot (Emsley and Cowtan, 
2004). Final models were validated using MOLPROBITY (Chen et al., 2010) and 
POLYGON (Urzhumtseva et al., 2009). 
 
2.6 Enzyme Kinetics 
All data sets were fitted to the stated equations by nonlinear regression with equal 
weighting of all points using SIGMAPLOT 12 (Systat Software Inc., Richmond, CA, 
USA). Statistical analysis was performed by means of the t-test, with t values giving 
the ratio of the regression coefficient and its standard error and P values giving the 
probably of the t value occurring by chance. For reliable data statistics, high t values 
(> 5) and low P values (< 0.05) are desirable. 
 
2.6.1 Steady-State Enzyme Kinetics 
2.6.1.1 Data collection and analysis 
Experiments were performed using a Kontron Uvikon 923 spectrophotometer, using 
cuvettes with a 5 mm or 10 mm path length. Solutions were prepared directly in the 







2.6.1.2 Experimental conditions 
All experiments were performed in 10 mM Tris-HCl pH 7.0, 50 mM NaCl and at 
25°C. Reactions were initiated by the addition of a small quantity of enzyme (~10 
nM). Nitrofurazone, nitrofurantoin and menadione were all dissolved in 90% DMSO, 
10 mM Tris-HCl pH 7.0, while CB1954 was in a 2:7 mixture of NMP:PEG 300. 
Kinetic experiments involving menadione, NFN and NFZ all included final 
concentrations of 4.5 % DMSO. Experiments with CB1954 had final concentrations of 
1.1 % NMP and 3.9 % PEG 300. Concentration ranges for substrate and inhibitors are 
detailed in the kinetics parameters tables for each experiment. Substrate concentration 
was either measured by monitoring the extinction coefficient as detailed in Table 2-2 
or by weight. The wavelengths the reactions were followed at, the extinction 








Monitored λ (nm)  
ε at λ (M-1 cm-1) Reference 
NAD(P)H 340 6,200 (Galante and Hatefi, 1978) 
CB1954 327 11,600 (Knox et al., 1993a) 
NFN 373 18,481 Merck Index 
NFZ 400 12,960 (Peterson et al., 1979) 
Quinone 246 25,420 Unpublished work 













Menadione Cytochrome c reduction 550 21,100 
Nitrofurantoin Nitrofurantoin reduction 400 13,807 
Nitrofurazone Nitrofurazone reduction 400 15,780 
Quinone NADPH reduction 340 6,200 
Table 2-3: Spectroscopic details of reactions followed in Steady-State enzyme 
kinetics experiments.  
 
2.6.1.3 Determination of kinetic parameters 
For each reaction the initial rate (vi) was calculated for a range of concentrations of 
one substrate (A) whilst keeping the concentration of the other substrate (B) constant. 
The concentrations used of the variable substrate ranged from ~0.2-10 x Km, unless 
solubility meant higher concentrations could not be reached. The approximate Km was 
initially estimated by use of a direct linear plot (Cornish-Bowden, 2004). The data 
could then be fitted to the modified single-substrate Michaelis-Menten equation 
(Equation 2-1); where [E] is the enzyme concentration, [A] the concentration of the 
variable substrate, vi the initial rate, kcatapp is the apparent kcat and KmApp the apparent 





constant (kcat/Km) for the variable substrate, data sets were fitted to a modified form of 
the Michaelis-Menten equation (Equation 2-4). 
Equation 2-1 
E  	 A +	A 
 
This provides an estimate of kcatapp and KmAapp, where kcatapp is the apparent maximum 
number of catalytic cycles the enzyme can catalyse per unit time, and KmAapp is the 
apparent concentration of substrate A that produces an initial rate of half of the 
maximum initial rate. For a ping-pong reaction the true values of kcat and Km are 
dependent of the concentration of the fixed substrate, B, as described by Equation 2-2 
and Equation 2-3 (hence the values at single substrate concentrations are described as 
kcatapp and KmAapp).  
Equation 2-2 
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Equation 2-3 
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B 
The second order rate constant (kcat/Km) (Engel, 1981) is independent of the 
concentration of the fixed substrate for a ping-pong reaction. Where kcat or Km cannot 





concentrations, kcat/Km can be estimated accurately by fitting to a modified Michaelis-
Menten equation (Equation 2-4). 
Equation 2-4 
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To get a global fit for the nitroreductase bi-bi enzyme mechanism, kinetic 
measurements were collected over a range of concentrations of both substrates and fit 
to Equation 2-5 describing the overall kinetics for a ping-pong reaction.  
Equation 2-5 
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As for the one substrate equation, the second-order rate constants can be calculated by 
fitting to a modified equation (Equation 2-6). 
Equation 2-6 
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2.6.1.4 Inhibition studies 
Reactions were recorded as described for each substrate, but each experiment was 
repeated at various concentrations of the inhibitor. The type of inhibition relative to 
the first and second substrates was determined by its affect on the apparent 
Michealis-Menten parameters. The inhibition constants, KiU for uncompetitive 
inhibition, and KiC for competitive inhibition could then be estimated by fitting all the 
datasets at each inhibitor concentration to Equation 2-7 and Equation 2-8 respectively. 
The inhibition constants of both KiU and KiC for mixed inhibition were calculated using 
Equation 2-9.  
Equation 2-7 
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2.6.2 Stopped-Flow Enzyme Kinetics 
2.6.2.1 Apparatus 
Stopped-flow experiments on engineered NfsB mutants were performed on an Applied 
Photophysics DX17MV spectrophotometer. The machine was set in absorbance mode 
with an optical pathlength of 1 mm. The monochromator slit widths were set to 4 mm. 
The two reaction components were split into the two drive syringes of 1 ml each, and 
the concentrations were halved upon mixing. A stop volume of 120 µl was used. 
 
NfsA stopped-flow experiments were performed at the University of Bristol, UK; on 
an Applied Photophysics SX20 stopped flow spectrophotometer, with the help of Dr 
Ross Anderson and Dr Craig Armstrong. Experiments were performed within an 
anaerobic Belle technology glove box. A stop volume of 200 µl was used. A single 
wavelength spectrophotometer mode was used for monitoring the reduction of the 
flavin by NADPH with monochromater slit widths of 0.5 mm. For the reductive half 







2.6.2.2 Test reaction and determination of instrument Deadtime 
The mixing chamber and observation chamber of the stopped-flow instrument are 
separated within the spectrophotometer setup, thus it is inevitable that some part of the 
reaction will take place in the time it takes to travel between them. So for accurate 
readings to be taken this ‘deadtime’ must be accurately known so that data before this 
point is not used in data fitting and the amount of product formed by the reaction can 
be determined by extrapolation. 
 
A suitable test reaction has been described involving the simple first-order reaction of 
L-ascorbate with 2,6-dichlorophenolindophenol (DCIP), performed at pH 2.0 to 
minimise errors (Tonomura et al., 1978) (Figure 2-4). All reactions had final 
concentrations of 250 µM DCIP, 200 mM NaCl, 10 mM HCl and 5% propanol. The 
final concentration of L-ascorbic acid ranged from 1 – 60 mM. L-ascorbate was in a 
large excess over DCIP to ensure true first-order kinetics. The reaction was monitored 
by monitoring the disappearance of DCIP at 524 nm. Five reactions were run at each 
L-ascorbate concentration and the results were averaged, the results are shown in 
Figure 2.5. Data sets for each run were fitted to Equation 2-10 with fitting limited to 
data post 2 ms (to ensure no bias from data during the dead time), where A is the 
absorbance (A0 the initial absorbance after mixing), C  the amplitude, kobs the observed 
































Figure 2-4: Reaction of DCIP and L-ascorbic acid. The reaction monitored during the 
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If the calculated rate constants are plotted against the concentration of ascorbate 
(Figure 2-6) then a straight line is seen which begins to curve off at high 
concentrations of ascorbate (this can be seen in Figure 2-6 as where the standard error 
increases, the value for 60 mM ascrobate is missing as the reaction was complete 
within the deadtime). This plot gives an estimation of the maximum rate that the 
instrument can observe (~1500 s-1). 
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Figure 2-5: The reduction of DCIP (monitored by absorbance change at 524 nm) by 
various L-ascorbic acid concentrations. A black line is shown indicating the 2 ms point. 







The dead time can be defined by Equation 2-11, where td is the dead time. From this 
we can get Equation 2-12, where ∆Aobs is the observed amplitudes and ∆Atot is the 
actual total absorbance change of the reaction. This equation allows a linear plot of 
ln(∆Aobs) against kapp, where the gradient of the line gives the deadtime and the 
intercept with the y-axis gives the natural log of the absorbance at the start point of the 
reaction. The plot for the data shown above is shown in Figure 2-7. The gradient of the 
graph gives the deadtime of the instrument at 1.0 ms. The instrument at Bristol also 
had a deadtime of 1.0 ms (Dr Ross Anderson, personal communication). Therefore for 
all stopped-flow kinetics studies, data points before this were not included in fitting.  
[L-Ascorbic Acid] (mM)
















Figure 2-6: Effect of increasing ascorbate concentration on the apparent rate constant 















































Figure 2-7: Graph used for deadtime calculation of the stopped-flow instrument at the 






2.6.2.3 Experimental conditions for stopped-flow experiments 
Experiments at Bristol were performed at 25°C, and at Birmingham at room 
temperature (~24-25°C), all in 10 mM Tris pH 7.0. In all experiments, one syringe 
contained enzyme and the other substrate. The reaction was followed by monitoring 
the oxidation/reduction of the enzyme-bound FMN prosthetic group at 454 nm. All 
enzymes were dialysed into the Tris buffer to remove any excess FMN. Each enzyme 
was diluted to 10 µM (for a 5 µM final concentration). Keeping the substrate in excess 
ensured the reaction was pseudo-first-order. To measure the first/oxidative half 
reaction NAD(P)H concentrations were varied from 25-1000 µM. At each substrate 
concentration 4-8 duplicate reactions were performed. For the second/reductive half 
reaction the enzyme FMN complex was reduced by slow addition of dithionite within 
the anaerobic chamber, monitored at 454 nm using an Ocean Optics USB2000+UV-
Vis spectrometer, until the solution was almost colourless. All substrates were made 
up in buffer containing 10% DMSO (5% final). Final concentrations of CB1954 
ranged from 25-1000 µM, and menadione from 10-500 µM.  
 
2.6.2.4 Determination of kinetic parameters 
Figure 2-8 shows the breakdown of the reaction scheme of the bi-bi ping-pong 
reaction catalysed by both the E. coli nitroreductase enzymes. Each individual step can 
be seen and the rate constants are labelled. Each half reaction has a dissociation 
constant (KdA for the first substrate, NAD(P)H, and KdB for the second substrate, e.g. 
CB1954) shown in Equation 2-13 for the oxidative half reaction and Equation 2-14 for 
the reductive half reaction. For the purposes of the stopped-flow experiment the 





and not by the release step. So it is assumed the rates we see equate to k2 (or k5), and 




































Figure 2-8: Reaction scheme of the bi-bi ping-pong reaction catalysed by the E. coli nitroreductases using the example of the 
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2.6.2.4.1 Oxidative half-reaction 
For the oxidation of NAD(P)H by E-FMN, the absorbance of FMN was monitored and 
this decreases as the reaction progresses. Each individual plot of absorbance against 
time was fit to Equation 2-10, a single exponential, giving a pseudo-first-order rate 
constant, k, for each plot. These rate constants were then plotted against substrate 
concentration and fitted to a hyperbola, which is analogous to the Michaelis-Menten 
equation (Equation 2-15), where kobs is the observed rate constant and A is the first 


















2.6.2.4.2 Reductive half-reaction 
For the reductive half reaction, the absorbance of FMN increases so each reaction was 
fitted to a single exponential (Equation 2-17). Then as for the oxidative half reaction 
the rate data could be fitted to hyperbolas, Equation 2-18 and Equation 2-19, where 
[B] is the concentration of the second substrate. 
 
Equation 2-17 
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Equation 2-18 



















3. NfsB Mutant Structures 
3.1 The Structure of NfsB 
The E. coli minor nitroreductase, NfsB, has been analysed using X-ray crystallography 
with the aiming of understanding the chemical environment of the active site to guide 
future design of prodrugs or mutants improving the efficiency of the combination for 
GDEPT (Section 1.5). The structure of wild-type NfsB has been published previously 
both in its native form (Parkinson et al., 2000) and complexed with inhibitors nicotinic 
acid (Lovering et al., 2001) and acetate and the substrate nitrofurazone (Race et al., 
2005) (Section 1.6.2.2). The overall structure of the NfsB dimer is shown in Figure 
1-23 and the FMN binding is detailed in Figure 1-24. Structures have also been 
determined for several single mutants and a double mutant (Race et al., 2007). The 
most improved single, double and triple mutants for the reduction of CB1954 have 
been studied by stopped-flow and steady-state kinetics (Jarrom et al., 2009). In this 
work the structures of the most active double (T41L/N71S), triple 
(T41Q/N71S/F124T) and quadruple (T41Q/N71S/F124T/M127V) mutants are 
determined by X-ray crystallography. The structures of each of these mutants, 
complexed with the inhibitor and NADH analogue, nicotinic acid, are presented here. 
Also presented are structures of several of these mutants bound to citrate or acetate, 
and other structures found in previously uncharacterized crystal forms. And finally the 
results of attempts to co-crystallize the mutant proteins with CB1954 and related 




3.2 Purity of purified samples
The NfsB WT, T41L/N71S, T41Q/N71S/F124T and T41Q/N71S/F124T/M127V 
proteins were grown and purified as described in Section 
sulphate precipitatio
chromatography, as described previously 
shown for the double mutant fractions from the phenyl
Figure 3-1 a), and from the Q
  
a) 
Figure 3-1: SDS-PAGE gels of T41LN71S NfsB mutant fractions a) after purification 
using a Phenyl Sepharose matrix and b) after
Sepharose matrix. A marker lane is shown (second from the left on each image), and 
visible bands are labelled for size in kDa.
pooled fractions of protein.
 
3.3 Crystal Growth at pH
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b) 
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 The other lanes contain analysis of various 
 
 4.6 
et al., 2001) at pH 4.6 containing PEG 4,000 and sodium acetate. 
, using ammonium 
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. SDS-PAGE gels are 






The first crystals were seen in sitting drop trays and were small yellow plates (Figure 
3-2 a)). The hanging drop method produced more reproducible crystal growth and, 
once optimised for drop size and constituent concentrations, produced much larger 
crystals (up to 500 x 500 x 40 µm plates) (Figure 3-2 b)). All crystals appeared within 
24 hours and reached full size within 72 hours. All crystals in this acetate buffer were 
tetragonal yellow plates of various thickness, the most common form previously 
observed (Lovering et al., 2001). There was no sign in any of the > 50 crystal trays set 
up in these conditions of either the monoclinic or orthorhombic crystal forms 
previously described. When attempting to co-crystallize with ligands in these 
conditions, crystals did not grow in the presence of high concentrations of most 
ligands that were tested. These included NFZ, NFN, menadione, quinone and CB1954, 
where crystals did not grow in the presence of more than 5 mM. Where crystals did 
grow in the presence of low ligand concentrations, no ligand density was observed in 











Figure 3-2: Crystals of NfsB mutants grown at pH 4.6. a) Initial crystal growth, 
T41Q/N71S/F124T mutant crystals grown via sitting drop method. b) Optimised 






Attempts were made to repeat the successful soaking experiments used to solve the 
structure of WT-NfsB bound to nitrofurazone (Race et al., 2005). In these experiments 
the acetate buffer was replaced with a citrate buffer (both at pH 4.6), to remove the 
acetate from the active site. This was not successful with the crystal forms shown here, 
which are all tetragonal (the previously successful soak was of a monoclinic form), 
however a crystal frozen after the citrate soak step did produce a structure containing 
citrate in the active site. 
 
3.4 Crystal Growth at pH 7.0 
It is most desirable to obtain crystals of NfsB at neutral pH, as this is close to the 
conditions in which it would be working in its GDEPT setting. Also when attempting 
to obtain NfsB/CB1954 complexes, the aziridine ring would rapidly ring open at the 
lower pH (pH 4.6), and so any complex would not be physiologically relevant. Initial 
screens at neutral pH were based around the published conditions of Parkinson et al. 
(Parkinson et al., 2000), containing PEG 8,000 and potassium phosphate. Crystals 
grown in these conditions initially grew in two forms; plates as with the acetate 










Figure 3-3: Crystals of NfsB mutants grown at pH 7.0. a) Initial crystals showing 
multiple crystal forms of T41L/N71S. b) T41L/N71S mutant crystals co-crystallized 
with SN27683, tetragonal plates can be seen as well as a larger monoclinic form (also 
seen in d)). c) T41L/N71S double mutant crystals co-crystallized with SN27686, a thin 
monoclinic form. d) T41Q/N71S/F124T mutant crystals co-crystallized with 








The first crystals grown at pH 7.0 were fragile and so the decision was made to co-
crystallize with the cryo-protectant ethylene glycol (at 15-20 %) to remove the 
necessity of handling the crystals before mounting. These crystal of NfsB were also 
temperature sensitive as seen when they dissolved after a failure in the crystal room 
allowed the temperature to rise from 18°C to 22°C. Attempts to crystallize at room 
temperature were unsuccessful and at 4°C the protein precipitated too readily. 
 
In an attempt to obtain protein complexes with CB1954 and related prodrugs, co-
crystallization experiments were undertaken. Previous attempts in this lab with WT-
NfsB had failed to give a complex, but it should be possible with the mutants as they 
bind CB1954 much more tightly than WT (Section 1.6.2.3). Crystals grew in the 
presence of up to 10 mM of each prodrug (see Table 3-1 for an idea of the solvent 
concentrations used). In the presence of CB1954 (in a 2:7 NMP:PEG300 solvent - 
Figure 3-4), tetragonal plates were seen, as before. However in the presence of the 
other dinitrobenzamide prodrugs, three new crystal forms were also observed (Figure 
3-3 b-d)) (in acetonitrile (Figure 3-4), see Table 3-1 for an idea of the concentrations). 
The most common of these new forms was a monoclinic form which resembled a 
thick wedge (Figure 3-3 b) and d)), observed primarily in the presence of SN27683 
and SN27686. These crystals were robust, easy to handle and diffracted to around 1 Å, 
greater than any published data for NfsB. Another monoclinic space group, which 
formed smaller crystals, was seen with most of the dinitrobenzamide prodrugs but was 
much more fragile (Figure 3-3 c)). These crystals diffracted to around 1.6 Å, similar to 





thin uneven crystal form, which was only a pale yellow, was seen only with the 
T41LN71S mutant in the presence of SN29222 (not shown). This plate-like form did 













Figure 3-4: The chemical structures of the solvents used for CB1954 and the other 
dinitrobenzamide prodrugs. PEG 300 is a combination of polyethylene glycol 
molecules with an average molecular weight of 300 Da. 
 
 
3.5 Summary of datasets 
Datasets were collected for three mutants of NfsB: the most active double mutant to 
date (T41L/N71S), the most active triple mutant (T41Q/N71S/F124T) and the most 
active quadruple mutant (T41Q/N71S/F124T/M127V) with different ligands. Nearly 
100 datasets were collected and 12 were fully refined and analysed. Structures for all 
three mutants were solved complexed to the inhibitor nicotinic acid. The structure of 
the triple mutant was also determined with bound acetate and with the tricarboxylic 
acid citrate, as was that of the double mutant with nothing bound in the active site. All 





with CB1954 and other dinitrobenzamide prodrugs and neutral pH are shown. The 
crystallization conditions are summarised in Table 3-1, the data collection statistics in 
Table 3-2, the processing statistics in Table 3-3 and the refinement statistics in Table 
3-4. The datasets shown here include previously unobserved crystal forms of NfsB, 
including one that provided a structure at higher resolution than any previously seen, a 
primitive monoclinic form in the space group P 1 21 1 seen with the triple mutant when 
co-crystallized with SN27683 and SN27686. The highest resolution NfsB structure in 
the pdb to date is at 1.7 Å (Lovering et al., 2001, Race et al., 2005), whilst the highest 





  Crystallization  Soak 
Dataset Identifier 
 
 Tray Type Precipitant Buffer Additive Cryo. Prot. Protein Conc. 
(mg/ml) 
 Cryo. Prot. Ligand 
           








- 12  20% Ethylene 
Glycol 
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10  - - 








- 6  15% Ethylene 
Glycol 
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15  2.7% NMP* 9.3% PEG 
300* 




10 mM K 
Phosphate 




11  36% 
Acetonitrile* 
- 




20 mM K 
Phosphate 




13  20% 
Acetonitrile* 
- 




10 mM K 
Phosphate 




14  20% 
Acetonitrile* 
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11  36% 
Acetonitrile* 
- 
Table 3-1: Crystallization conditions for crystals giving rise to NfsB mutant datasets. All acetate buffers are at pH 4.6, and all 
phosphate buffers at pH 7.0. * Further contents of the mother liquor used to solubilise prodrugs rather than soak contents. These 









  General  Unit Cell 
Dataset Identifier  Active Site 
Contents 






a (Å) b (Å) c (Å) β (°) 
            
Double Nicotinate  Nicotinate ESRF ID14-1 0.934 90  P 41 21 2 56.9 56.9 264 - 
Triple Nicotinate  Nicotinate ESRF ID23-1 1.00 80  P 41 21 2 57.6 57.6 265 - 
Quad Nicotinate  Nicotinate ESRF ID14-1 0.934 120  P 41 21 2 57.3 57.3 266 - 
Double Empty  None ESRF ID14-1 0.934 90  P 41 21 2 57.2 57.2 263 - 
Triple Acetate  Acetate ESRF ID14-1 0.934 81  P 41 21 2 57.3 57.3 263 - 
Triple Citrate  Citrate ESRF ID14-1 0.934 90  P 41 21 2 57.3 57.3 264 - 
Double CB1954  Unidentified Diamond I03 0.976 83  P 41 21 2 56.9 56.9 257 - 
Double SN27419  Unidentified Diamond I03 0.920 139  P 41 21 2 57.5 57.5 267 - 
Double SN27683  Unidentified Diamond I03 0.920 375  C 1 2 1 115 43.0 95.0 115 
Triple SN27683  Unidentified Diamond I03 0.976 153  P 1 21 1 54.1 60.6 75.0 99.9 
Triple SN27686  Unidentified Diamond I04 0.979 152  P 1 21 1 54.0 50.6 75.0 100 
Table 3-2: Data collection statistics for NfsB mutant datasets.  ESRF refers to the European Synchrotron Radiation Facility, 
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Table 3-3: Processing statistics of NfsB mutant datasets. Values in parentheses are for the highest resolution shell. 








  Refinement Mean B Factors (Å2)  










Protein Ligand FMN Water 
            
Double Nicotinate 
 
 22,344 58 18.31 26.29 0.81 0.005 
 
50.7 60.1 38.7 50.1 
Triple Nicotinate 
 
 53,495 582 17.84 22.69 0.93 0.006 18.9 21.2 13.2 33.6 
Quad Nicotinate 
 
 31,128 190 16.18 21.32 0.93 0.007 36.6 53.7 22.3 42.0 
Double Empty 
 
 49,533 534 15.46 18.68 0.91 0.006 17.4 - 10.9 31.9 
Triple Acetate 
 
 57,878 497 15.42 18.85 0.91 0.006 16.8 - 10.6 29.3 
Triple Citrate 
 
 27,018 352 16.4 22.37 0.92 0.007 23.9 84.2 16.6 31.1 
Double CB1954 
 
 54,623 400 17.53 21.43 0.91 0.006 18.9 17.0 11.0 33.2 
Double SN27419 
 
 41,671 431 19.25 24.55 0.93 0.006 30.5 44.1 23.6 38.4 
Double SN27683 
 
 61,115 511 19.46 23.76 0.97 0.006 29.8 31.8 19.7 39.0 
Triple SN27683 
 
 155,379 567 15.32 16.87 1.22 0.009 18.9 13.7 8.85 28.9 
Triple SN27686 
 
 140,746 647 12.39 14.33 1.19 0.008 12.8 11.3 7.03 29.3 
Table 3-4: Refinement statistics for NfsB mutant datasets. R-factor = (Σ| |Fobs|-|Fcalc||)/Σ|Fobs|.The R-free is the R-factors 





The structures were solved by molecular replacement using a modified version of the 
pdb I.D. 1ICR structure (Lovering et al., 2001), which was in the tetragonal crystal 
form (See Section 2.5.4.2). Most of the datasets have refined well, with R-factors 
appropriate for the resolution. Statistics were compared to those in the protein data 
bank using POLYGON (Urzhumtseva et al., 2009). All of the structures presented 
here compare favourably, although the double nicotinate structure is worse than most. 
The double nicotinate structure is at the lowest resolution (2.2 Å), and correspondingly 
has the poorest statistics (highest R-factors and B-factors). The electron density map is 
less clear than the other structures, but still allowed unambiguous assignment of side 
chain rotamers and the active site nicotinate. The statistics of the double nicotinate 
structure are worse due to the high mosaicity and anisotropy of the data. The citrate 
ligand in the triple citrate structure also has high B-factors relative to the protein, 
representative of the fact that the density suggests movement and perhaps multiple 
conformations. 
 
3.6 Overall Structure of NfsB Mutants 
The overall structure of the NfsB dimer is shown in Figure 1-23 and discussed in 
Section 1.6.2.2.1. The monomers of all published structures and all structures 
presented in this chapter were compared using THESEUS (Theobald and Wuttke, 
2008). There are no major conformational differences when the backbones are aligned, 
but there is some variation (at most 5-10 Å) in the positions of three loops. The most 
variation is seen with the loop between helices C and D (residues 64-71), which 
contains the flexible Phe70 residue. Other differences are seen in the loop between 





195-202). The variations were analysed to compare mutants to WT and to contrast 
different space groups and no patterns were observed, implying that these are all areas 
of natural variation in the protein structure. 
 
3.7 Overview of Mutant Structures 
3.7.1 Mutation Sites 
The mutations at Thr41, Asn71 and Phe124 all showed very clear electron density in 
all 11 structures, allowing unambiguous assignment of side chain rotamers (Figure 3-5 
a)-c)). This was true with all the mutant structures presented here. The M127V 
mutation was less clear (Figure 3-5 d)), although with such a small side chain the 





Figure 3-5: Density of mutated r
c) F124T all from the Triple Nicotinate structure, and d) M127V from the Quad 
Nicotinate structure. Mutated residues are shown 
2Fo-Fc electron density map
the residue. Figures were produced using CCP4 Molecular Graphics.
 
3.7.2 Summary of Side Chain Differences
3.7.2.1 T41L Mutants
In the crystal structure of the T41L single mutant 
the threonine to the larger leucine caused a slight shift in the surrounding residues
(Figure 3-6). This shift is seen in all the double mutant structures presented here, to a 
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esidue side chains. a) T41Q mutation, b) N71S, and 
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 of Individual Mutations
 










similar degree to those previous structures of the T41L single mutant. The shift is only 
significant (above the coordinate error of 0.1 Å) for Arg121, Lys122, Phe123 and 
Phe124, with the maximum change seen in the position of the side chain of Phe124 of 
just below 1.0 Å. This shift is caused by the effective movement of the side chain of 
Leu41 upon mutation from threonine, and is a steric effect. When all the monomers in 
each of the T41L-containing structures are overlaid, the Leu41 residues are well 
aligned as are most other active site residues. The only residue which shows any 
difference between all mutant structures containing T41L is Phe123, which rotates by 
up to 60° about the Cβ - C1 bond.  
 
 
Figure 3-6: Shift of Phe124 and surrounded residues in the presence of the T41L 
mutation. Comparison of
et al., 2001)) and T41L
are shown. Structures were aligned using THESEUS 




All triple and quadruple mutant structures presented 
mutation. Aligning the monomers of all these structures on the backbone showed that 
the position of the T41Q was identical in all these structures. Similarly to the T41L, 
 
145 
 nicotinate-bound WT NfsB (blue – pdb I.D. 1ICR 
/N71S double mutant (purple). Residues with
(Theobald and Wuttke, 2008)





in 5 Å of Phe124 
 





when the T41Q is compared to the wild-type structure the backbones are perfectly 
aligned and the only difference is in the side chains, with the smaller threonine 
replaced with the larger glutamine. There appears to be no other effect on the local 
environment, other than the region around the 124 residue, as with the T41L. This will 
be discussed in more detail later.  
 
3.7.2.3 N71S Mutation 
Previous crystallographic analysis of the N71S single mutant and the N71S/F124K 
double mutants (Race et al., 2007) showed that the only changes seen when compared 
to wild-type were in the Ser71 and neighbouring Phe70. When all the monomers from 
all N71S-containing mutant structures (i.e. the N71S and N71S/F124K mutants 
determined previously and the mutants described here) are overlaid, the Ser71 
positions are identical in each one, the additional mutations in the double, triple and 
quaternary mutants having no effect on the Ser71 residue. It was previously suggested 
that the Phe70 side chain rotamer was changed in the presence of the N71S mutation 
(Race et al., 2007), however when all these structures are aligned it is seen that the 
Phe70 side chain can adopt several different rotamers. As was previously observed in 
the N71S and N71S/F124K mutants, the majority of the structures have the OH 
hydroxyl group of Ser41 hydrogen bonded to a water molecule, which in turn 
hydrogen bonds to the Flavin ring and to Lys74 (Figure 1-27). The Ser41 also 
hydrogen bonds to the backbone carbonyl oxygen of Gly166. This effectively replaces 







3.7.2.4 F124T Mutation 
All F124T mutation sites were clear in each triple mutant structure. The effect of the 
mutation becomes clear when combined with the T41Q mutation and is discussed in 
Section 3.9.1. 
 
3.7.2.5 M127V Mutation 
The one structure of the quadruple mutant contains two monomers. These overlay well 
(RMSD = 0.71 Å) and the valines are both in the same conformation. The quadruple 
mutant will be discussed in more detail later (Section 3.8.4). 
 
3.8 NfsB Double and Triple and Quadruple mutant structures bound 
to Nicotinate 
3.8.1 Structures compared to wild-type 
Since all the mutants and wild-type structures have been determined with bound 
nicotinate this is a good form to compare the effects of the mutations. When all the 
structures determined here are aligned with all previously determined wild-type NfsB 
structures it can be seen that, as with previously described mutations (Race et al., 
2007), there is little change in the backbone structure of the protein. Small differences 
are seen in the loop between helices F and G (for labelling see Figure 1-23), which is 
solvent exposed and the maximum differences between backbone atoms is less than 






The main differences between the mutants are all seen in the active site. The FMN and 
nicotinate molecules are all well aligned including the butterfly angle of the flavin 
rings. It is the side chains of the mutated residues themselves that show the largest 
differences between the structures (Figure 3-7). The two separate mutations in the 
T41L/N71S mutant have been seen in previously determined single (T41L and N71S) 
and double (N71S/F124K) mutant crystal structures (Race et al., 2007), although not 






Figure 3-7: Active Site of NfsB, showing a comparison of the mutated residues and 
other key residues. The wild
coloured according to atom type, whilst only the four residues mutated in this study 
and Phe123 (as it shows variation across) 
mutant is shown in blue, the triple mutant in green and the quadruple mutant





-type structure (pdb I.D. 1ICR)(Lovering 
are shown for three mutants. The double 
° apart. Figure produced using Swiss-
 
 
et al., 2001), is 






3.8.2 T41L/N71S Double Mutant Structure 
The only differences seen between the nicotinate-bound structure of the wild-type 
protein and that of the double mutant are those observed for the single mutants (Race 
et al., 2007), discussed earlier (Section 3.7.2).  
 
3.8.3 T41Q/N71S/F124T Triple Mutant Structure 
When comparing the nicotinate-bound wild-type and triple mutant structures, the two 
align very well indeed (RMSD (all atoms): 0.15 Å – compared to 0.33 Å for both the 
double and quadruple mutants). In comparison to the double mutant this may be in 
part due to the higher resolution of the triple mutant structure (1.65 Å compared to 
2.20 Å), leading to less ambiguous assignment of side chain positions. The N71S 
mutation appears to have the same effect as in the double mutant and all previous 
N71S-containing mutants (Race et al., 2007), as stated previously. However it is the 
locus of the T41Q and F124T mutations that is much more interesting. Glutamine is 
larger than leucine (double mutant) or threonine (wild-type), and is a polar residue 
unlike the double mutant’s leucine. Figure 3-8 shows a comparison of the 41 and 124 
residues of the mutants compared to WT, and it can be seen how the side chain of the 
glutamine is placed so as to sandwich the nicotinate ring with the flavin ring system. 
The NE2 nitrogen is in van der Waals contact with the nicotinate C2 (3.59 Å). 
 
 
Figure 3-8: Comparison of residues 41 and 124 in T41L/N71S (blue), 
T41Q/N71S/F124T (yellow) and T41Q/N71S/F124T/M127V (purple) compared to 
wild-type NfsB (green). 
position of the 124 residue in 
produced using CCP4 Molecular Graphics. 
 
Whilst the T41L mutation causes a slight shift of the Phe124 and 
away from the Leu41 (
have a slight effect the other way, pulling the backbone of th
Gln41 by 0.8 Å (coordinate error 
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Figure 3-6), the combination of the T41Q and F124T mutations 
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3.8.4 T41Q/N71S/F124T/M127V Quadruple Mutant Structure 
The first three mutations of the quadruple mutant are the same as the triple mutant. 
The Ser41 residues align perfectly, and the Gln41 and Thr124 residues are also very 
similar. Small changes in the backbone position of the Phe124-containing loop mean 
that the hydrogen bond distance between Gln 41 and Thr 124 is slightly smaller in the 
quadruple mutant structure (2.7 Å) than the triple mutant (3.1 Å). The additional 
mutation in the quadruple mutant is M127V, and was poorly modelled in comparison 
to the others (Figure 3-5 d)). The side chain change is shown in Figure 3-7  and is too 
far away to have a direct effect on the active site and there are no changes seen in the 
other active site. The major change caused by the M127V mutation is to open up the 
smaller of the two channels leading to the active site. A comparison of the small 
channel in the triple and quadruple mutants is shown in Figure 3-9, where the first 
image shows the two channels, the smaller one to the right of the FMN and nicotinate 
and the other through which the active site is viewed. The M127V mutation causes the 
smaller channel to open up as shown in Figure 3-9 b). This is caused in part through 
replacing the methionine with a smaller valine, but this also caused a shift in the side 
chain position of Asn67 (shown in Figure 3-10) and results in a slight shift in the 
position of helix F (residues 111-130) (0.5 Å at max). There is also a shift of 1.3 Å in 
the position of the loop between helices F and G and one of 1.4 Å in the loop between 
sheet 2 and helix E.  These changes have the effect of widening the channel, causing it 







Figure 3-9: Molecular surface 
mutant b) (red). The FMN (purple) and nicotinate (yellow) molecules are represented by 
spheres and show the location of the active site. The two
the largest is the one through which 
in the dark square. This smaller channel is opened up and merged with the larger in the quad 
mutant, b). The surface show
using PyMOL.  
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one looks towards the FMN and nicotinate, the smaller is 
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Figure 3-10: M127V mutation (light blue) in the active site of the 
T41Q/N71S/F124T/M127V quadruple mutant. Nearby residues are shown in green 
including Asn67, which is shifted to open the smaller channel
(surface shown). Figure produced using CCP4 Mo
 
3.9 Ligand Soaking 
Up until this point the only structures elucidated 
the active site. In a previous study it was found that soaking a crystal in a citrate buffer 
first, followed by ligand solut
the active site (Race 
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the crystal soaked in the previous study to produce the nitrofurazone complex was of a 
monoclinic form, which did not appear in the same conditions in this study. As 
mentioned earlier, the only crystal form observed in the acetate buffer at pH 4.6 in this 
study were tetragonal plates. 
 
In all of these soaking attempts, the active site contained some density but not enough 
to model a ligand confidently. Citrate has previously been used to help remove acetate 
from the active site of the enzyme to allow NFZ to be soaked in (Race et al., 2005). 
Crystals of both the T41L/N71S and T41Q/N71S/F124T mutants were soaked in 
mother liquor but containing citrate buffer instead of acetate buffer (both 100 mM at 
pH 4.6) before flash freezing, to attempt to soak citrate into the active site. This gave 
different results for the two mutants. The citrate ligand could be modelled into the 
active site of the triple mutant but not of the double mutant. In the double mutant there 
was no longer density for the acetate directly over the flavin ring system, but rather a 
molecule of acetate was modelled further out of the active site, close to the side chain 
of Phe124. This was not in a position where it could clash with citrate if it were bound 
identically to the triple mutant. 
 
3.9.1 T41Q/N71S/F124T Triple Mutant Bound to Citrate 
In the citrate-bound triple mutant structure, the residues align almost perfectly with the 
nicotinate bound structure, with the exception of the poorly modelled and flexible 
Phe70. Citrate has been modelled into both active sites of the protein but in different 





hydrogen bonds to the alcohol group of citrate in both active sites (2.72 Å and 2.82 Å 
respectively). The hydrogen bond between the Gln41 and Thr124 can also be clearly 







Figure 3-11: Electron density of c
T41Q/N71S/F124T mutant. 
(light blue citrate); 
purple and blue (ribbons and carbon atoms). 
for the citrate. The Gln41 
cylinders and the H
electron density map (contoured to ~2.0 




itrate bound in the active site of NfsB 
The two active sites are shown in a) 
each with two images 90 ° apart. The two monomers are colour
Ball and stick diagrams have been used 
(light blue) and Thr124 (yellow) residues
-bond (dashed line) between is annotated. The 
σ) has been clipped to within 2.5 
  
 
(pink citrate) and b) 
ed 
 are shown as 
σA-weighted 2Fo-Fc 





The citrate is primarily bound to the active site through hydrogen bonding to protein 
and FMN. The pattern of hydrogen bonding for each active site is shown in Figure 
3-12. The citrates in the two different sites effectively have the central carbon atom 
and alcohol group in similar positions, and differ in terms of which of three sites 
(labelled ‘A-C’ in Figure 3-12) contains the shorter chain carboxylate. Site A is close 
to the amine or Lys14, site B is over the flavin ring system, and site C is more towards 
the phosphate binding pocket. In the first active site (Figure 3-12 a)) the short 
carboxylate chain is in position C, while in the second (Figure 3-12 b)) it is in position 
A. Due to the different lengths of the arms of the citrate (two contain methylene 
groups), the change in conformation impacts on the overall position of the citrate. At 
pH 4.6, two of the carboxylic acid groups of citrate should be protonated and one 
should be negatively charged. For the first active site it is likely that the carboxylate in 
the ‘A’ position in Figure 3-12 a) will form a salt bridge with the positively charged 
Lys14 amine. For the second active site the situation is less clear as the distance 
between the Lys14 amine and the carboxylate is greater (3.1 Å vs. 2.6 Å), though 
since it is the only residue binding the citrate that is positively charged it is still likely 
that that the carboxylate in position ‘A’ would be negatively charged although the pKa 








Figure 3-12: Hydrogen bonding pattern of citrate in NfsB T41Q/N71S/F124T. Each 
active site is shown, a) and b), with images separated by 90°. Residues and water 
molecules are shown that hydrogen bond to the citrate ligand. The three possible 
positions of the carboxylic acid groups are labelled A-C. Figure produced using Swiss-






The binding pattern of citrate would not be possible without the T41Q mutation which 
might explain why it was not found in the double mutant. Citrate was tested as an 
inhibitor at neutral pH, but showed no significant inhibition at 25 mM. Above this 
concentration the effect of raising the ionic strength begins to dominate the 
interactions, making testing inhibition difficult. However the crystals were grown at 
pH 4.6 (measured with pH paper), where only one of the carboxylic acid groups would 
be expected to be deprotonated in solution (although pKa’s can be much different in 
proteins). Since the binding shown is primarily through hydrogen bonding to the 
protonated carboxyl groups, this would not be possible at pH 7 and so it is plausible 
that this would explain why no inhibition was seen. 
 
3.9.2 Double Mutant Empty Form and Triple Mutant Acetate Bound 
Attempts to soak citrate into the double mutant produced an empty active site (Figure 
3-13 – green). There was a molecule of acetate bound but it was not in the same 
position as any previous acetate bound structures (Race et al., 2005). This acetate was 
not bound above the aromatic ring system but was found closer to the Phe124 residue. 
The density above the flavin ring system was less clear, a single water molecule was 
modelled in but it is probable that the citrate had caused the acetate to be removed 
from the active site but did not bind strongly enough to be seen in the electron density. 
So the electron density in the active site was caused by a mixture of citrate, acetate and 
solvent. The fact that citrate was seen with the triple mutant and not the double mutant 
may be explained by the hydrogen bond from the triple mutant Gln 41 residue to the 





old position without changing the buffer to citrate (data not shown), but would lack 




Figure 3-13: Comparison of the active site
empty active site (green), and the T41Q/N71S/F124T triple mutant bound to acetate 
(blue) and citrate (red). Only residues which vary are shown for all the mutants. 
Ligands are labelled in purple, citrate (CIT), acetate (AC





 of the NfsB T41L/N71S double mutant 
T) and ethylene glycol 







For the triple mutant, a complex with acetate was determined from a crystal in acetate 
buffer, in the absence of nicotinate. Acetate is bound in the triple mutant structure in a 
different conformation than had been seen with previous structures. It is rotated 
around 120° and is further away from the flavin ring system. There is a hydrogen-
bond from the acetate to the side chain of Gln41. 
 
3.10 Attempts to Co-Crystallize with Prodrugs 
With crystals obtained at neutral pH, the decision was made to attempt co-
crystallization with prodrugs. Soaks were not possible due to the fragile nature of the 
crystals. Co-crystallization with the dinitrobenzamide prodrugs (the ‘SN-‘ prodrugs in 
Figure 2-3) led to the formation of new crystal forms, some larger and better 
diffracting than the previous ones (Section 3.4). One previously-unseen crystal form 
led to a structures at higher resolution than has previously been reported at 1.08 Å (the 
previous highest being 1.7 Å (Lovering et al., 2001)). With all the dinitrobenzamide 
prodrugs (including CB1954) a limiting concentration of prodrug was seen, above 
which no crystals formed. The datasets presented here are with the highest 
concentrations of prodrug that still allowed crystals to form.  
 
With the crystals that had been co-crystallized with CB1954 and each of the other 
dinitrobenzamide prodrugs detailed in Figure 2-3, the active site contained definite 
density above the flavin ring system. This density was nearly identical for all the 
prodrugs, but was not seen with lower concentrations of the prodrugs or in their 





prodrugs should have four ring substituents, but even at low contour levels of 0.4 σ 
there are no peaks in the electron density map allowing the substituents to be located. 
Since for CB1954 all substituents are of a similar size, the possibility was considered 
that the molecule was in multiple orientations and angles, however there should 
always be a substituent opposite the one that is seen. Also the same density was seen 
with the ‘SN’ prodrugs, implying that it would be unlikely to be due to a contaminant 
in the prodrug solution. Since the solvents were different for CB1954, which was in a 
2:7 solution of NMP:PEG 300, and the ‘SN’ prodrugs, which were in acetonitrille, it is 
unlikely that a contaminant in the solvent could have caused the density. The ring and 
substituent observed in the structures are identical in shape to nicotinate, and are found 
in a nearly identical position to nicotinate in the structure. However, these crystals 
were never in the presence of nicotinate. It is possible that the prodrugs have been 
degraded in the solution or X-ray beam, causing all but one of the substituents to react 







Figure 3-14: Examples of the unbiased electron density in the active sites of NfsB 
mutant crystals co-
SN27683, c) Triple SN27683 and d) Triple SN27686. The model of a benzene ring 
and single substituent (amide) is shown as grey ball and sticks, modelled into the 
density. The σA-weighted 2F
clipped to within 2.5 Å of the residue. Figures were produced using CCP4 Molecular 
Graphics. 
 
3.11 Analysis of New Crystal Forms
Four different crystal forms of NfsB have previously been observed
2001, Race et al., 2005)
additional, previously unseen





crystallized with prodrugs. Figure a) Double CB1954, b) Double 
o-Fc electron density map (contoured to ~1.5 
 
. In this study are presented crystal structures from two 
 crystal forms. These are all summarised in 
 
 
σ) has been 






in the ASU. Whether it was the presence of the prodrug or the acetonitrile (used as a 
solvent) that prompted the growth of these new crystal forms is unclear. However the 
new forms did not appear when acetonitrile was used on its own. The Monoclinic 3 
form has a similar solvent content to the tetragonal (both ~ 45-46 %), but the 
Monoclinic 2 form is more tightly packed having a solvent content of around 41 %. 
 
 






β (°) Copies in 
ASU 
Example 
Tetragonal P 41 21 2 55 55 260 - 2 pdb I.D. 1ICR  
(Lovering et al., 2001) 
Orthorhombic 1 P 21 21 21 55 120 145 - 4 pdb I.D. 1ICV 
(Lovering et al., 2001) 
Orthorhombic 2 P 21 21 2 155 45 55 - 2 pdb I.D. 1YLU 
(Race et al., 2005) 
Monoclinic 1 P 1 21 1 70 55 115 105 4 pdb I.D. 1ICU 
(Lovering et al., 2001) 
New forms: 
 
       
Monoclinic 2 P 1 21 1 55 60 75 100 2 Triple SN27683 
 
Monoclinic 3 C 1 2 1 115 45 95 115 2 Double SN27683 
 
Table 3-5: Summary of the crystal forms seen with NfsB and natural amino acid 
mutants. For previously seen forms examples are given from the literature, for the new 
forms examples are given from this study. Average cell dimensions are given to the 







    
3.12 Stopped-Flow Kinetics 
To analyse the rate of reduction and Kd of NADH independently of the second 
substrate, stopped flow kinetic experiments were performed. The nature of the bi-bi 
mechanism of catalysis by the nitroreductase enzymes is such that it is formed of two 
half-reactions (labelled a) and b) on Figure 1-17). The steady-state kinetics presented 
in this study monitor this reaction overall, but not the steps in isolation. The individual 
steps can be studied by employing stopped-flow kinetic measurements. Stopped-flow 
kinetic data for the reductive half reaction, step b) in Figure 1-17, of WT-NfsB, 
F124N, T41L/N71S and T41Q/N71S/F124T with CB1954 and nitrofurazone has been 
published (Jarrom et al., 2009). The oxidative half-reaction, the reduction of NADH, 
step a) in Figure 1-17, as catalysed by WT-NfsB, T41L/N71S and T41Q/N71S/F124T, 
is described here.  
 
The oxidative half reaction was followed by monitoring the change in absorbance of 
the tightly bound FMN cofactor at 454 nm. Data sets were collected over a period of 
0.05 s, and data before 1 ms was not including in fitting. The averaged traces for the 
NfsB T41L/N71S double mutant are shown in Figure 3-15. The exponential decay 
gets steeper at higher concentrations of NADH. An oscillation was observed, at 
approximately 50 Hz, which was consistent across all traces, implying interference, 
possibly electrical. However all the traces fit well to Equation 2-13, with high t values 
































100 µM NADH 
200 µM NADH 
500 µM NADH 
10 ms
 
Figure 3-15: Stopped-flow kinetics traces for the reduction of FMN bound to the 
NfsB T41L/N71S double mutant by varying final concentrations of NADH. Data post 
10 ms, indicated by the dashed line, was fitted to Equation 2-10 giving the lines 
shown. 
 
The rate constants for each run were plotted against the concentration of NADH, and 
this was done for NfsB WT, T41L/N71S and T41QN71SF124T (Figure 3-16). The 
data was fitted to a hyperbola, either to Equation 2-15, to determine k2 (the rate of 
oxidation of NADH by the NfsB bound FMN, see Figure 2-8) and Kd, or to Equation 







The kinetic parameters for the oxidation of NADH by NfsB WT, T41L/N71S and 
T41Q/N71S/F124T are shown in Table 3-6. The apparent second order rate constants 
(k2/Kd) should be comparable with the specificity constants (kcat/Km) for NADH, 
previously determined through steady-state kinetics (Jarrom et al., 2009), although 
they all appear to be roughly twice as large. The values of both k2/Kd and kcat/KmNADH 
are approximately 2-fold larger for Wild-type than both the double and triple mutants. 
This could be due to accuracies in assessing protein concentrations for the steady-
state, or due to the extinction coefficient being incorrect. Thus when comparing both 
[NADH] (µM)






















Figure 3-16: NADH oxidation rates of WT, double and triple NfsB mutants as measured 
by stopped-flow kinetics. The insert shows a close up of the double and triple mutant data, 





mutants to WT it becomes apparent, that as mutants have been selected for increased 
activity with CB1954, they have lowered the specificity constant for NADH. 
Comparing the steady-state rate constants (kcat) with the k2 rate constants gives a clue 
as to the rate-determining step. For WT-NfsB, kcat is well below k2 implying that the 
oxidation of NADH is not the rate determining step. The maximum rates seen for the 
reduction of CB1954 in WT, double and triple mutants are also higher than the 
steady-state kcat values (Jarrom et al., 2009). This implies that the rate limiting step is 
the release of products. However for the double and triple mutants we can now see 
that the difference between kcat and k2 is much less, and if this trend were to continue 





 k2  
(s-1) 
t P Kd 
(µM) 
t P k2/Kd  
(s-1 µM-1) 
t P kcat/KmNADH (s
-1 µM-1) 





WT-NfsB 1340  
± 84 
16 <0.0001 224 
± 30 
7.4 <0.0001 5.98 
± 0.47 
13 <0.0001 3.46 ± 0.6 140 





25 <0.0001 158 
± 15 
11 <0.0001 1.70 
± 0.098 






22 <0.0001 96.2 
± 12 
8.1 <0.0001 3.01 
± 0.26 




Table 3-6: Kinetic Parameters for the oxidation of NADH by NfsB WT, T41L/N71S and T41Q/N71S/F124T as determined by stopped-







The crystal structures of the double, triple and quadruple mutants of NfsB that show 
the greatest improvement of WT for the reduction of CB1954 have been determined. 
Each was determined bound to the NAD(P)H analogue, nicotinate, and the differences 
in the side chain positions give insights into the improvements seen in kinetics. 
Attempts to solve prodrug bound structures of each mutant were unsuccessful, 
although the density present in these experiments suggested that the drug was being 
degraded. Stopped-flow kinetic studies have also been used to analyse the oxidation of 
NADH by WT, double and triple mutant NfsB, indicating that as the mutants have 
been selected for their ability to reduce CB1954, they have become less active for 
NADH. 
 
The improvements in kcat/Km in the mutants over wild-type could be caused by two 
factors. These improvements are either caused by altering the properties of the FMN, 
such as in the case of the N71S mutation, which has been shown to alter the redox 
potential of the FMN (unpublished work by Dr Ross Anderson, University of Bristol), 
or by changing the ligand binding site. The other mutations would appear to primarily 






4. NfsB Unnatural Amino Acid Mutants 
 
4.1 Incorporation of Unnatural Amino Acids 
The activity of NfsB with CB1954 has been shown to be improved upon incorporation 
of several unnatural amino acids residues in place of the Phe124 residue (Jackson et 
al., 2006). The most active of these unnatural amino acid mutants were para-
nitrophenylalanine (pNF), para-aminophenylalanine (pAF), and naphthylalanine (Nap) 
(Figure 4-1). Dr Ryan Mehl (Oregon State University, USA) provided the plasmids 
encoding these mutants, for the purpose of crystallographic studies.  Different plasmids and 
purification methods were used from those described previously for the NfsB mutants 
containing natural amino acids, and the purifications were performed exploiting an N-terminal 
















Figure 4-1: Structures of the unnatural amino acids used in this study. Figure 





4.2 Growth and Induction of Unnatural Amino Acid Mutants 
Small scale (50 ml) cultures of auto-induction media (see Section 2.3.2) with WT-
NfsB and the three unnatural amino acid mutants were made to test growth and 
induction. Cell growth was monitored by following turbidity at 600 nm. Cell growth 
peaked at around 22 hours post-inoculation. Growth of E. coli expressing WT NfsB 
peaked at between 8-9 OD units, whilst cell growth for E. coli in the presence of 
unnatural amino acids peaked at around 5-6 OD units. NfsB expression was monitored 
by SDS-PAGE (with samples all having the same OD, as described in Section 2.3.2) 
and peaked by 22 hours in all cases (Figure 4-2). The WT (not shown) and pNF 










Figure 4-2: SDS-PAGE analysis of protein expression. Images are labelled by 
unnatural amino acid at position 124 in NfsB. Time of sample is indicated for each 






4.3 Purification of His-tagged NfsB 
Unlike previous NfsB and mutant proteins purified by this group (including those 
detailed in Chapter 3), the unnatural amino acid mutants were purified by means of an 
N-terminal His-tag. They were purified first with a Nickel-NTA column, eluting with 
increasing imidazole (Figure 4-3), and then, since further purification was required, 
the protein was purified on a Phenyl-Sepharose column as for the natural NfsB 
mutants (Figure 4-4). Figure 4-5 shows SDS-PAGE analysis of the final protein 
fractions used in this chapter. A poor yield of the Nap mutant (see expression 
experiment in Figure 4-2) meant that there was insufficient protein for a single 
column. This did not purify the protein sufficiently to allow quantitive analysis. 
Repeated growth experiments (varying conditions including concentration of 
components and addition of glucose) showed poor expressions of the Nap mutant and 
so no subsequent experiments were performed.  
 
 
Figure 4-3: Analysis of WT-NfsB protein fractions eluted off Nickel column (












see section 2.3.2, insert 

















Figure 4-4: Analysis of WT-NfsB protein fractions eluted from Phenyl-Sepharose column (insert - SDS-PAGE). Fraction size was 2ml 





















Figure 4-5: SDS-PAGE of final 
Marker, lanes 1-5 + 12 
pNF mutant. Each separate lane is of a separate pool.
 
4.4 Initial crystal growth
The first attempts to crystallize His
those previously used for natural mutants
al., 2000, Lovering 
needle-shaped crystals
were not suitable for X
seen (in conditions that usually gave more suitable crystal forms) the decision was 
made to cleave the His
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pooled protein fractions purified with His
- WT-NfsB, 6-7 - Nap mutant, 8 – pAF mutant, and 9
 
 
-tagged NfsB were based on the same conditions
 and WT protein (Section 
et al., 2001). In both of these sets of conditions 
 growing in clusters were found (Figure 
-ray diffraction studies, and since this form was the only one 
-tag and then attempt to crystallize again. 
 
-tag. M – 
-11 – 
 as 
3.3) (Parkinson et 
only tiny 






Figure 4-6: Initial crystal growth of His












4.5 Cleavage of His-tag 
The N-terminal 6 His-tag was cleaved using a recombinant enterokinase (rEK). A test 
cleavage was performed with 0.02 – 0.1 U rEK in 50 µl and 0.2 µg/ml NfsB over 48 
hours. The cleavage tests are shown in Figure 4-7. Once ideal conditions were 
identified (detailed in Section 2.3.3) further tests were performed, including for the 
pNF and pAF mutants at the proportions identified as best. Beyond 48 hours 
secondary digestion was seen in some tests (low molecular weight bands on the gel, 
but at 48 hours most of the His-tag cleavage had been performed. So for large scale 
cleavage the reaction was halted at 48 hours with 10 µg/ml PMSF (and 1 % iso-
propanol as a solvent). 
 
 
Figure 4-7: SDS-PAGE showing the digestion of the His-tag on 0.2 µg/ml WT-NfsB 
by rEK after 48 hours. Lanes 1-2 show His-tagged protein, 3-4 NfsB plus 0.1 U rEK, 
5-6 NfsB plus 0.02 U rEK (all in total 50 µl solutions). Lanes 1, 3 and 5 were diluted 
1/10 in 10 mM Tris pH 7.0. The bands in lanes 3 and 4 are lower showing that in these 
conditions the His-tag has been successfully cleaved.  
 
4.6 Further crystal trials 
Crystals were grown as described in Section 2.5.1.2, and appeared within 3-5 days and 
reached full size within a week. Thus these crystals grew more slowly than the natural 
amino acid mutants. Crystals of the pAF mutant grew in the presence of 15 mM 
nicotinic acid, whilst crystals of the pNF mutant did not. Several different crystal 







multinucleated. These crystals only diffracted to around 8.5 Å, and showed high levels 
of mosaicity, which made indexing of diffraction patterns impossible. Another crystal 
form found was a variation on a monoclinic form previously observed for NfsB 
natural mutants (Lovering et al., 2001). The individual crystals (Figure 4-8 d)), were 
mostly found in groups shaped somewhat like a flower bud where the individual 
crystals were like petals (Figure 4-8 b) and c)). In order to mount these crystals the 
clusters were broken up and individual crystal plates were selected; this was difficult 
as the crystals were very fragile. It was this crystal form that gave rise to the two 
structures detailed in this chapter; however the two crystals (of the different mutants in 
the different conditions) were in different space groups. There were other crystal 







Figure 4-8: Crystals of His
needles, b) pNF mutant crystals, monoclinic clusters, c) pAF mutant crystals, 
















4.7 Summary of Datasets 
Two datasets are presented here, one of the pNF mutant with bound acetate, and 
another with the pAF mutant with bound nicotinate. The collection statistics are shown 
in Table 4-1, processing statistics in Table 4-3 and refinement statistics in Table 4-4. 
The pAF nicotinate structure is in a monoclinic crystal form (pdb I.D. 1ICU) observed 
previously (Lovering et al., 2001), however the pNF acetate structure is in a crystal 
form never before seen with NfsB.  Both diffracted to a similar resolution (~2.7 Å), 
which is poorer than seen with all previously observed crystal forms but enough to see 
any major active site differences. Unlike all the natural amino acid mutant structures 
presented in Chapter 3, these forms do not contain two copies of the monomer in the 
ASU. The pNF-Acetate structure contained 8 copies of the monomer, whilst the pAF-
Nicotinate contained 4 (as did previous structures in this space group). The five amino 






  Crystallization  Soak 
Dataset Identifier  Precipitant – [PEG 4,000] Additive Protein Conc. 
(mg/ml) 
 Cryo. Prot. 
       
pNF Acetate  12% - 11  15% Ethylene Glycol 
pAF Nicotinate  13% 15 mM Nicotinic Acid 14  15% Ethylene Glycol 
Table 4-1: Crystallization conditions for the crystals giving rise to the NfsB unnatural amino acid mutant crystal structures detailed in 
this chapter. All crystals were grown via a hanging drop method with 100 mM Sodium Acetate pH 4.6 
 
  General  Unit Cell 










a (Å) b (Å) c (Å) β (°) 
             
pNF Acetate  Acetate Diamond I04 0.979 180  P 1 21 1 58.2 139 122 90.2 
pAF Nicotinate  Nicotinate Diamond I04 0.979 171  P 1 21 1 71.5 58.0 117 104 







  Processing 








































Table 4-3: Processing statistics of NfsB unnatural amino acid mutant datasets. Values in parentheses are for the highest resolution 
shell. Rsym = (ΣhklΣj|Ihkl,j - <Ihkl>|)/ ΣhklΣjIhkl,j. 
 
  Refinement Mean B Factors (Å2)  










Protein Ligand FMN Water 
            
pNF Acetate 
 
 49,768 272 16.42 23.35 1.03 0.007 34.7 66.1 43.1 35.7 
pAF Nicotinate 
 
 32,937 239 16.23 22.99 0.99 0.007 25.9 28.9 17.5 24.0 
Table 4-4: Refinement statistics for NfsB unnatural amino acid mutant datasets. R-factor = (Σ| |Fobs|-|Fcalc||)/Σ|Fobs|.The R-free is the 






4.8 Structure of pNF mutant bound to acetate 
The pNF mutant structure contained eight copies of the NfsB monomer in the ASU. 
The 124 residue of interest was not as clear in the density as many of the other active 
site residues. However since the pNF side chain is large and rigid, unambiguous 
assignment of side chain rotamer was possible. The electron density around the 
mutation sites in each of the 8 chains is shown in Figure 4-9. In chains F and G the 
pNF residue was modelled in two alternate conformations, although the dominant 






Figure 4-9: Electron density for the mutation sites of pNF NfsB mutant. The pNF124 (pink) is shown for each chain (labelled A
H). The σA-weighted 2Fo-Fc electron density map (contoured to ~1.0 















Of the eight active sites, seven contain a bound acetate ligand and the other (site C) 
contains just water. The electron density for the modelled ligands is shown in Figure 
4-10. The conformations of the ligands are difficult to assign unambiguously at this 
resolution (2.7 Å), but it is clear that there are differences between the positions of the 




Figure 4-10: Electron density for acetate in the structure of the pNF NfsB mutant. The chain identifier is in the top left hand corner 
of each image. Active site C was empty and so is not shown. Residues within 5.0 Å of the acetate molecules are shown. The 
weighted 2Fo-Fc electron density map (contoured to ~2.5 











The mutation of Phe to pNF causes a change in its side chain rotamer. The dominant 
position of the pNF has changed relative to the position of the Phe ring as shown in 
Figure 4-11; this is a change from an m-85 rotamer to a t80 rotamer. This shift also 
causes a 1.0 Å change in the Cα position of Phe124 and less pronounced changes in 
surrounding residues. The electron density is not sufficient to allow assignment of the 
exact position of the nitro group of pNF, so the active site H-bonding patterns cannot 
be described unambiguously. However, comparison of the eight active sites allows us 
to identify the nature of the interactions that have caused the shift in side chain 
position. The pNF mutation replaces a hydrophobic residue (Phe) with a more polar 
residue that is likely negatively charged. The most conserved interaction for pNF is an 
end-on, π-π stacking interaction between the aromatic ring of the pNF and His128 (~ 
3.2 Å). Over each of the seven pNF containing active sites there are other residues that 
interact with the nitro group; the backbone carbonyl and side chain of Glu165, the side 
chains of Trp68, Met127, His128 and Trp138 (all shown in Figure 4-11). Of these 
residues, it would be expected that Trp68, His128, Trp138 would be able to form H-
bonds to the oxygens of the nitro group. The movement of the pNF side chain relative 
to the Phe sidechain also causes the bound acetate to move by around 1.5 Å, away 






Figure 4-11: Change in the position of the 124 residue when mutated to pNF
1YLR, (Race et al., 2005)) is shown in 




 (light green). WT-NfsB bound to 
purple and the pNF-Acetate structure in light blue. Structures aligned using THESEUS 
re 90° apart. Figures produced using CCP4 Molecular Graphics.
 







When the backbone structures are compared to WT-NfsB there are two differences 
seen. The first of these is a shift in the position of helix F, the helix containing the 124 
residue, which is at its most pronounced at the outer edge, where the loop from 
Arg129 to His133 shifts ~1.5 Å. This can be seen to be caused by the change in 
effective rotamer caused by the mutation to pNF, forcing the helix away from the 
adjacent Glu165 and Gly166. There is also a slight change (~1.0 Å) in the position of 
the Phe70 containing loop, moving it towards the active site and the pNF, as the 
change in effective rotamer has left space to be filled.  
 
4.9 Structure of pAF mutant bound to nicotinate 
The crystal structure of the pAF mutant bound to nicotinate has four copies of the 
NfsB monomer in the ASU, and thus four crystallographically unrelated active sites. 
All four copies of the monomer (including the FMN prosthetic group and the 
nicotinate inhibitor) align well and there are no major differences. The pAF mutations 
are in clean density comparable with other active site residues and show little variance 
across the active sites. The electron density of the four mutation sites is shown in 
Figure 4-12. In all four active sites the pAF has shown the same rotamer change seen 
with the pNF mutant. The density for the four nicotinate ligands is shown in Figure 




Figure 4-12: Electron density of the pAF 
the pAF Nicotinate Structure. 
electron density map (contoured to ~1







(pink) mutation sites in each monomer of 
Images are labelled by chain. The 










Figure 4-13: Electron density for nicotinate ligands
Images are labelled by chain. The 
to ~1.5 σ) has been clipped to within 2.5 Å of the residue. Figures were produced 






 (all in pink)










When the pAF mutant is compared to WT-NfsB there is only one consistent 
difference, which is a slight shift (< 2.0 Å) in the position of helix F containing the 
pAF124 residue (residues 111-120) (Figure 4-14). This shift is caused by the change 
in the side chain rotamer upon mutation to pAF, clearly seen in Figure 4-14, which 
pushes the helix slightly away from the FMN. The conformational change may be 
explained by the presence of two H-bonds from the amino group of the pAF to 
Glu165, one to the backbone carbonyl and one to the side chain carboxylic acid 
(Figure 4-15). Other residues that interact with the side chain of pAF in this 
conformation are Met127, His128 and Trp138 (visible in Figure 4-14 and Figure 4-15, 







Figure 4-14: Comparison of pAF Nicotinate structure (
(Lovering et al., 2001)). Structures aligned using THESEUS 




light blue) with nicotinate bound WT-NfsB (purple 
(Theobald and Wuttke, 2008). The pAF is shown in light green.








Figure 4-15: Interactions of pAF124 with surrounding residues. Residues shown are 
within 4.0 Å of pAF124. H













4.10 New Crystal Form 
Of the various new crystal forms seen with the cleaved His-tagged NfsB, only one, 
pNF-Acetate, led to a structure that was solved. Table 4-5 shows a comparison of all 
the currently known crystal forms of NfsB, with the new ‘Monoclinic 4’ form seen 
with the pNF mutant with bound acetate. Since the crystals of pNF-acetate are very 
similar in appearance to those of the pAF-nicotinate, which was in the Monoclinic 1 
space group, attempts were made to reprocess the pNF-acetate data in other space 
groups including those similar to previously seen forms. Molecular replacement failed 











β (°) Copies in 
ASU 
Example 
Tetragonal P 41 21 2 55 55 260 - 2 pdb I.D. 1ICR  
(Lovering et al., 2001) 
Orthorhombic 1 P 21 21 21 55 120 145 - 4 pdb I.D. 1ICV 
(Lovering et al., 2001) 
Orthorhombic 2 P 21 21 2 155 45 55 - 2 pdb I.D. 1YLU 
(Race et al., 2005) 
Monoclinic 1 P 1 21 1 70 55 115 105 4 pdb I.D. 1ICU 
(Lovering et al., 2001) 
pAF Nicotinate 
Monoclinic 2 P 1 21 1 55 60 75 100 2 Triple SN27683 
 
Monoclinic 3 C 1 2 1 115 45 95 115 2 Double SN27683 
 
New Forms:        
Monoclinic 4 
 
P 1 21 1 58 139 122 90.2 8 pNF Acetate 
Table 4-5: Summary of the crystal forms seen with NfsB, natural amino acid mutants 
and unnatural amino acid mutants. For previously seen forms examples are given from 
the literature, for the new forms examples are given from this study. Average cell 
dimensions are given to the nearest 5 Å as there is up to 5 Å difference between 
crystals of the same form, other than for the new monoclinic form since there is only 
one current structure. 
 
4.11 Steady-State Kinetics 
Steady-state kinetics have been measured for various substrates of WT-NfsB and its 
natural mutants (Race et al., 2005, Race et al., 2007, Jarrom et al., 2009). For the 
unnatural mutants, only experiments comparing the specificity constant (kcat/Km) for 





CB1954 and Menadione, for these proteins, both at two NADH concentrations. In 
order to see whether the His-tag or cleavage of the His-tag has any effect on the 
activity, three stocks of WT enzyme were tested: - first one expressed with a His-tag 
and purified as described in Section 2.3, second WT-NfsB with His-tag cleaved as 
described in Section 2.3.3, and finally native WT-NfsB expressed without a His-tag as 
described in Section 2.2. Finally the steady-state kinetics of the pAF and pNF mutants 
have been studied. Both of these preparations had the His-tag cleaved off and 
comparisons with WT are with the cleaved form. All cleaved samples showed single 
band purity on SDS-PAGE and were in the presence of enterokinase for the same 
time, however any His-tagged protein was not removed using Nickel NTA. This 
would ensure that only the cleaved protein remained and should ideally be done before 
any future experiments. Experiments were performed for WT NfsB by Asha Hassan 
(MRes project student), for the pNF mutant by Sophie Englander and for the pAF 
mutant by Laura Goodman (both undergraduate project students). All under the 
authors direct supervision. 
 
4.11.1 CB1954 Kinetics 
When analysing the steady-state kinetics of NfsB and CB1954, it is often not possible 
to get a full Michaelis-Menton curve due to the low solubility of CB1954 in solution 
and its high Km. The later part of the curve is often not seen at all for WT NfsB, but as 
the Km of the mutants increases, more of the curve is seen. If the Km is very high it is 
not possible to fit the data to Equation 2-1 accurately to determine kcat and Km 
separately. However the data can still be fitted to Equation 2-4, and kcat/Km (the 





slope of the curve. The kcat/Km is equivalent to the initial gradient of the Michaelis-
Menten curve, and for an enzyme displaying ping-pong kinetics it should be 
independent of NADH concentration. So comparing the kcat/Km gives an indication of 
the relative binding strengths. 
 
4.11.1.1 Effect of His-tag on the Kinetics of WT NfsB  
The reduction of CB1954 by the untagged (native), His-tagged and cleaved WT-NfsB 
at 60 µM NADH is shown in Figure 4-16 and at 200 µM NADH in Figure 4-17. The 
statistics of the fit to the hyperbola are summarised in Table 4-6. The curve fits are 
good with the exception of the untagged protein with 60 µM NADH. The rates are all 
higher at the higher NADH concentration as would be expected. When comparing the 
different WT proteins, there is not a large difference between any of them. However 
the His-tagged protein does have the lowest kcat/Km of the proteins, implying there is a 
slight, negative effect of the His-tag on the activity of the enzyme which is restored 





























Figure 4-16: Comparison of the steady-state reduction of CB1954 by WT-NfsB at 60 





























Figure 4-17: Comparison of the steady-state reduction of CB1954 by WT-NfsB at 










-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
Untagged 
NfsB 
141-2820 60 10.9 ± 2.7 4.0 0.0017 3560 ± 1370 2.6 0.023 0.0031 ± 0.0004 7.0 <0.0001 
Untagged 
NfsB 
141-3525 200 25.7 ± 3.5 7.4 <0.0001 9910 ± 1710 5.8 <0.0001 0.0026 ± 0.0001 26 <0.0001 
His-tagged 
NfsB 
141-3525 60 10.7 ± 3.4 3.1 0.0064 4780  ± 2270 2.1 0.052 0.0022 ±  0.0004 6.0 <0.0001 
His-tagged 
NfsB 
141-3525 200 ND - - ND - - 0.0019 ±  0.0002 8.4 <0.0001 
Cleaved 
NfsB 
141-3525 60 9.5 ± 2.3 4.2 0.0011  3710 ± 1410 2.6
  




141-3525 200 ND - - ND - - 0.0032 ± 0.0004
   
8.5 <0.0001
  
Table 4-6: Steady-state kinetic parameters for the reduction of CB1954 by WT-NfsB (untagged, His-tagged and cleaved) with 
NADH. Each set of experiments were performed at a constant NADH concentration and at variable CB1954 concentration. ND – 





4.11.1.2 Steady-State Kinetics of pNF and pAF mutants with CB1954 
The cleaved pNF and pAF NfsB mutants were both assayed for the reduction of 
CB1954 at 60 µM and 200 µM. A comparison of the two mutants and the cleaved WT 
NfsB at 60 µM is shown in Figure 4-18, and at 200 µM in Figure 4-19.  Apparent 
Michaelis-Menten parameters for pNF and pAF are detailed in Table 4-7 and Table 
4-8 respectively. Both mutants show improvement over WT as expected from 
previous reports (Jackson et al., 2006), although the exact kcat/Km values (consistent 
across the two NADH concentrations) are about 2-fold lower than reported Jackson et 
al.. As previously seen both mutants appear to be about 20-fold more active than WT, 























Figure 4-18: Reduction of CB1954 by cleaved WT NfsB and pNF and pAF mutants. 

























Figure 4-19: Reduction of CB1954 by cleaved WT NfsB and pNF and pAF mutants. 










-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
60 141-2820 25.0 ± 1.0 25 <0.0001 341 ± 48 7.1 <0.0001 0.073 ± 0.0080 9.2 <0.0001 
200 141-3525 60.9 ± 1.9 32 <0.0001 797 ± 70 11 <0.0001 0.076 ± 0.0046 17 <0.0001 







-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
60 141-3525 41.8 ± 2.8 15 <0.0001 716 ± 140 5.0 <0.0001 0.058 ± 0.0083 7.0 <0.0001 
200 141-3525 51.6 ± 4.2 12 <0.0001 1070 ± 220 5.0 0.0001 0.048 ± 0.0062 7.7 <0.0001 






4.11.2 Menadione Kinetics 
4.11.2.1 Effect of His-tag on the Steady-State Kinetics of WT NfsB 
The three WT proteins (untagged, His-tagged and cleaved) were tested with 
menadione as a substrate, as they were with CB1954 (Section 4.11.1.1). The steady-
state kinetics results are shown at 60 µM NADH in Figure 4-20 and at 200 µM NADH 
in Figure 4-21. The statistics of the fit to the Michaelis-Menten equation are shown in 
Table 4-9. The specificity constants show again that the His-tagged NfsB has less 
activity than untagged protein, but cleavage of the His-tag does not appear to restore 
the full activity with menadione, unlike with CB1954 as a substrate. This may be 
because menadione is a better substrate so small differences are more noticeable. The 
values for the cleaved protein at 60 µM NADH are much lower than would be 
























Figure 4-20: Comparison of the steady-state reduction of menadione by WT-NfsB, in 





























Figure 4-21: Comparison of the steady-state reduction of menadione by WT-NfsB, in 











-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
Untagged 
NfsB 
0.5 - 100 60 7.65 ± 0.51 15 <0.0001 9.66 ± 2.1 4.6 0.0003 0.79 ± 0 .13 6.0 <0.0001 
Untagged 
NfsB 
0.5 - 100 200 15.9 ± 1.2  13 <0.0001 26.2 ± 4.7 5.6 <0.0001 0.61 ± 0.071 8.6 <0.0001 
His-tagged 
NfsB 
0.5 - 100 60 9.26 ± 0.73 13 <0.0001 34.0 ± 5.9 5.7 <0.0001 0.27 ± 0.029 9.4 <0.0001 
His-tagged 
NfsB 
0.5 - 100 200 15.6 ± 1.5 10 <0.0001 57.6 ± 11 5.4 <0.0001 0.27 ± 0.026 10 <0.0001 
Cleaved 
NfsB 
0.5 - 100 60 2.97 ± 0.20 15 <0.0001 15.1 ± 2.9  5.1 <0.0001 0.20 ± 0.028  15 <0.0001 
Cleaved 
NfsB 
0.5 - 100 200 12.4 ± 0.73 17 <0.0001 30.6 ± 4.2 7.3 <0.0001 0.40 ± 0.035 12 <0.0001 
Table 4-9: Steady-state kinetic parameters for the reduction of menadione by WT-NfsB (untagged, His-tagged and cleaved) with 






4.11.2.2 Mutant Kinetics 
The reduction of menadione by the pNF and pAF mutants was also measured and 
compared to WT at 60 µM (Figure 4-22) and 200 µM NADH (Figure 4-23). The 
steady-state parameters are detailed in Table 4-10 and Table 4-11 respectively. Both 
displayed substrate inhibition above 25 µM and 50 µM respectively, and so data 
points beyond this were not used for fitting. This has the effect that the full curve is 
not seen at 200 µM NADH for the pNF mutant, making the estimates of kcatapp and 
Kmapp in particular poorer than other experiments. However the P values are still below 
0.0001 and the t values above 5. The improvement in kcat/Km seen for the pAF mutant 
over WT is greater than those seen with CB1954, but the pNF mutant shows a similar 
degree of improvement (~ 20-fold). The most improved mutant for menadione is the 























Figure 4-22: Reduction of menadione by cleaved His-tagged WT NfsB and pNF and 
























Figure 4-23: Reduction of menadione by cleaved His-tagged WT NfsB and pNF and 











-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
60 0.01- 10 13.0 ± 0.67 20 <0.0001 0.789 ± 0.14 5.5 <0.0001 16.5 ± 2.4 6.8 <0.0001 
200 0.01 - 25 139 ± 10 13 <0.0001 16.6 ± 2.3 7.1 <0.0001 8.39 ± 0.61 14 <0.0001 







-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
60 0.1 – 50 33.5 ± 0.85 39 <0.0001 1.24 ± 0.12 11 <0.0001 27.1 ± 2.1 13 <0.0001 
200 0.1 – 50 51.5 ± 1.5 34 <0.0001 1.71 ± 0.18 9.3 <0.0001 30.2 ± 2.7 11 <0.0001 






4.11.3 Comparison of Kinetics with Previous Mutants 
Table 4-12 compares the enzyme fractions presented in this chapter with previously 
published data for WT and the most active single, double and triple mutants. There is 
variation in the WT NfsB results between this study and previously published data, but 
each of the previous mutants has a specificity constant kcat/Km. for CB1954 at least an 
order of magnitude higher than for the WT NfsB in this study. The two unnatural 
amino acid mutants studied here show a greater improvement with CB1954 than the 
best natural single mutant (F124N), but are not as good as the best double and triple 
mutants (T41L/N71S and T41Q/N71S/F124T). With menadione, the pAF mutant is 
the most active of those detailed, with the pNF mutant also showing greater 
improvement than with CB1954. Thus the selectivity for CB1954 is worse for pAF 
than for WT protein, although they do bind CB1954 more tightly. The pNF mutant 







Protein kcat/KmCB1954  
(µM-1 s-1) 
kcat/Kmmenadione 







0.0026 ± 0.0001 0.61 ± 0.071 0.0043 This Study –  
(200 µM NADH) 
WT NfsB  
(His-Tagged) 
0.0019 ± 0.0002 0.27 ± 0.026 0.0070 This Study –  
(200 µM NADH) 
WT NfsB 
(Cleaved) 
0.0032 ± 0.0004 0.40 ± 0.035 0.0080 This Study – 
 (200 µM NADH) 
WT NfsB 
(Previous) 
0.007 ± 0.0006 0.69 ± 0.05 0.010 (Race et al., 2005) 
F124N 
 








0.318 ± 0.016 18.8 ± 3 0.017 (Jarrom et al., 
2009) 
pNF 0.076 ± 0.0046 8.39 ± 0.61 0.0091 This Study –  
(200 µM NADH) 
pAF 0.048 ± 0.0062 30.2 ± 2.7 0.0016 This Study –  
(200 µM NADH) 
Table 4-12: Comparison of specificity constants (kcat/Km) of the WT NfsB used in this 
study, previous WT NfsB, the most improved single double and triple mutants, and the 
unnatural amino acid mutants, pNF and pAF. Selectivity is the values for CB1954 







In Section 1.6.2.3.4 the use of unnatural amino acids to improve the activity of NfsB 
with CB1954 was discussed. In this chapter the structure of the two most improved 
unnatural amino acid mutants, replacing Phe 124 with pNF and pAF, was shown. The 
structures show how an effective change in side chain rotomer allows the new 
chemical groups to interact with the flavin and ligands. The pNF mutant is the most 
improved single mutant to date for CB1954, whilst pAF is the most improved for 
menadione. Both mutants show greater improvements with menadione than with 
CB1954. In both unnatural amino acid mutants there is an effective change of side 
chain rotamer compared to WT; this change places the new polar group adjacent to the 
active site where it could interact with a substrate. The change is almost the opposite 
of the changes caused by previous Phe124 mutations, F124K and F124N, moving 
towards the FMN prosthetic group rather than away. The rotamer change also causes 
slight shifts which open the mouth of the active site. The pAF side chain modelled 
much more clearly and with the relative improvements seen with CB1954 and 
menadione, it would appear that this change in conformation is more significant to the 
reduction of the larger menadione, perhaps providing a larger area for the substrate to 
enter the active site. These new chemical groups may affect catalysis by interacting 
with the FMN, creating more space in the active site or by providing a group to 
H-bond to the substrate. 
 
To date (07/10/12) there are fewer than 50 crystal structures in the protein data bank 
incorporating unnatural amino acids and many of these are duplicates. These few 





2009). There is one structure containing pAF, an Anti-HIV antibody, pdb I.D. 3IDN 
(Bryson et al., 2009). In this structure, the pAF replaces a Lys and changes to mimic 
the interactions of a His residue from another chain, which was used as evidence for 
the importance of conservation of function in that region of the protein.  At the time of 
writing there is no structure in the protein data bank containing pNF. 
 
Unnatural amino acids present opportunities for scientists to investigate the chemistry 
within the protein environment. Substitution of amino acids with synthetic equivalents 
expands the range of chemical and steric groups that can be inserted (beyond the 20 
natural amino acids). These groups can introduce new chemistry into the active site, 
and aid our understanding of enzyme mechanisms. However, these unnatural amino 
acid mutants would be unfeasible for use in GDEPT with CB1954 (Section 1.4). It 
would involve the addition of extra genes, allowing their incorporation, and would 
require delivery of the synthetic amino acid, creating new challenges in delivery. The 
cost of such a treatment would also be high, as the synthetic amino acids are 
expensive. So whilst unnatural amino acids offer opportunities to gain insights into the 






5. NfsA Structures and Kinetics 
 
5.1 NfsA as a Prodrug-Activating Enzyme 
The major nitroreductase of E. coli, NfsA, has recently been proposed as an alternative 
enzyme for use in GDEPT with CB1954 (Vass et al., 2009). The crystal structure of 
NfsA has previously been determined to 1.7 Å resolution with no ligand modelled in 
the active site (Kobori et al., 2001). Previous work in our group has elucidated the 
structure in new conditions, but an unknown ligand was found in the active site 
(Jarrom, 2008). The density most closely resembled the dicarboxylic acids succinate 
and fumarate, both later found to be inhibitors of NfsA, but neither was included in the 
crystallization solution and the density was not clear enough to be unambiguous. 
Addition of succinate was found to improve the quality of the crystals. In this chapter 
we present the crystal structures of NfsA without ligands and bound to a number of 
ligands, including inhibitors and two substrates, further aiding our understanding of 
the residues involved in the active site and giving clues to mechanism of reaction.  
 
5.2 Purity of purified samples 
The NfsA protein was expressed in E. coli and purified as described in Section 2.4, 
using ammonium sulphate precipitation followed by phenyl-sepharose and Q-
sepharose chromatography, as described previously (Vass et al., 2009). If further 
purification was required a Blue Trisacryl affinity chromatography column was used, 





after each column are shown in Figure 5-1. Attempts to purify further with 







Figure 5-1: SDS-PAGE gels of the purification
after purification with a) Phenyl
matrices. The left hand lane shows the molecular marker with the weights of v
bands marked in kDa. a) A
other lanes contain fractions eluted from each column.
 
224 
 of NfsA (the brightest band on each), 
-Sepharose b) Q-Sepharose and c) Blue












5.3 Crystal growth 
Commercial crystallization screens and screens based around previously published 
conditions (Kobori et al., 1999) produced no crystal growth. However conditions 
based upon those used previously in this laboratory (Jarrom, 2008) led to crystal 
formation. Crystals appeared within 24 hours and generally reached full size within 48 
hours. Typical NfsA crystals are shown in Figure 5-2. All crystals were grown by a 
sitting-drop method. In general, larger drops produced fewer crystals and less 
precipitate so the most common successful drop size was 1 µl of protein solution 
mixed with 1 µl of mother liquor.  
 
 






Crystals grew in the presence of up to 10 mM CB1954 (along with 3 % NMP and 11 
% PEG 300 used as solvent) and up to 10 mM of the other dinitrobenzamide prodrugs 
shown in Figure 2-3 (along with 10 % acetonitrile used as a solvent). However the 
electron density seen in the active site of the crystal structures was ambiguous and 
didn’t improve upon refinement and so these structures were not fully refined. 
 
5.4 Summary of datasets 
The crystallization conditions and soaking details for the crystals that give rise to the 
structures detailed in this chapter are shown in Table 5-1. The data collection statistics 
for NfsA crystal structures are shown in Table 5-2, the data processing statistics in 
Table 5-3 and the refinement statistics in Table 5-4. Chemical structures of the ligands 





  Crystallization – Mother Liquor  Soak 
Dataset Identifier  Precipitant Imidazole Buffer 
pH 7.0 (mM) 
Additive 1 Additive 2 Protein Conc. 
(mg/ml) 
 Cryo. Prot. Ligand 
          
NfsA Succinate 1  30%  
PEG 3,350 




12   15 % 
Ethylene Glycol 
n/a 
NfsA Succinate 2 
 


























n/a n/a 11   15 % 
Ethylene Glycol 
n/a 
NfsA Ethylene Glycol 
 
 30%  
PEG 3,350 
























n/a n/a 9  
 












n/a 7  
 




 22%  
PEG 3,000 





11   n/a n/a 
Table 5-1: Crystallization conditions for crystals giving rise to NfsA datasets. The active site contents are indicated in the dataset 
identifier. All buffers and additives were at pH 7.0. *For the NfsA Ethylene Glycol structure there was also 2.8 % NMP and 10 % 







  General  Unit Cell 




Degrees of Data 
Collected (°) 
 Space Group a (Å) b (Å) c (Å) β (°) 
           
NfsA Succinate 1  Home Source 1.54 360  C 1 2 1 91.6 51.6 64.7 134 
NfsA Succinate 2  ESRF ID14-1 0.934 360  C 1 2 1 92.2 51.8 64.8 134 
NfsA Fumarate  Home Source 1.54 360  C 1 2 1 92.1 52.2 65.0 134 
NfsA Empty  ESRF ID23-1 1.00 160  C 1 2 1 91.9 52.1 64.8 134 
NfsA Ethylene Glycol  Home Source 1.54 360  C 1 2 1 91.3 51.9 64.4 134 
NfsA FMN  ESRF ID14-1 0.934 360  C 1 2 1 91.9 52.0 64.7 134 
NfsA Quinol  Home Source 1.54 220  C 1 2 1 92.0 52.0 64.8 134 
NfsA Quinone  Home Source 1.54 360  C 1 2 1 91.8 51.9 64.7 134 
NfsA Nitrofurantoin  ESRF ID23-1 1.00 180  C 1 2 1 91.4 51.9 64.6 134 
Table 5-2: Data collection statistics for NfsA datasets. The active site contents (according to what has been modelled in) are 
indicated in the dataset identifier. Home Source, refers to the University of Birmingham’s home source ‘Rigaku HighFlux 






  Processing 











          

























































































































































Table 5-3: Processing statistics of NfsA datasets. Values in parentheses are for the highest resolution shell. Rsym = (ΣhklΣj|Ihkl,j -






  Refinement Mean B Factors (Å2)  










Protein Ligand FMN Water 
            
NfsA Succinate 1 
 
 142,450 327 11.06 13.01 1.569 0.015 15.9 10.8 6.7 27.1 
NfsA Succinate 2 
 
 59,481 389 14.96 16.27 1.054 0.005 14.7 11.2 6.6 28.7 
NfsA Fumarate 
 
 57,566 381 14.57 15.90 1.062 0.005 12.8 9.0 6.8 26.7 
NfsA Empty 
 
 80,944 416 12.69 14.13 1.469 0.010 13.3 n/a 5.9 25.8 
NfsA Ethylene Glycol 
 
 33,483 305 14.31 17.02 1.178 0.008 12.8 18.3* 6.4 27.0 
NfsA FMN 
 
 101,426 404 11.43 13.88 1.332 0.009 13.9 22.6 6.1 25.7 
NfsA Quinol 
 
 59,267 410 15.14 17.3 1.043 0.005 13.9 27.0 6.3 29.5 
NfsA Quinone 
 
 23,814 293 14.95 18.31 0.976 0.006 13.3 25.3 5.5 25.6 
NfsA Nitrofurantoin 
 
 83,276 394 11.67 13.76 1.709 0.009 17.7 14.4 6.7 27.4 
Table 5-4: Refinement statistics for NfsA datasets. * This is an average of two conformations of two ethylene glycol molecules 





























































Figure 5-3: The chemical structures of the ligands found in the NfsA structures 
presented in this chapter. Figure produced using ChemSketch (ACD/labs). 
 
All the structures show low R-factors and B-factors, and the majority of the density 
was very clear. All the ligands have full occupancy, with the exception of the quinol, 
which was 50:50 in two conformations, and the second FMN where the atoms were 
each individually refined for occupancy in PHENIX (Adams et al., 2002) and ranged 
from 50% to 100%. Ligand B-factors are lower than the protein average for all the 
FMN prosthetic groups and the succinate, fumarate and nitrofurantoin ligands. The B-
factors for the other ligands are less than twice as high as the protein average. All the 






5.5 Overview of NfsA Structures 
In common with NfsB, NfsA exists as a homodimer, with two FMN containing active 
sites located at the dimer interface. The structure is shown in Figure 1-28, where the 
two halves of the dimer can be seen, and described in Section 1.6.3.2. The only 
previously published crystal structure of NfsA (Kobori et al., 2001) was processed in a 
triclinic space group and contained one copy of the dimer in the ASU. The structure 
presented here was of a form previously observed in this group (Jarrom, 2008), a 
monoclinic space group containing a single monomer in the ASU. The dimer is 
formed through crystallographic interactions with an adjacent unit cell. A comparison 
of the structures presented in this chapter (except NfsA FMN which will be discussed 
later) with the previous structure is shown in Figure 5-4. The only significant variation 
in backbone position is seen in the loop between helices G and H (residues 197-211), a 
loop which is always poorly modelled in the structures in this chapter and has high B-
factors (generally at least twice the average for the protein). The published structure 
(green in Figure 5-4) has a different loop conformation from that of all the other 
structures determined here. There are no differences in the side chain conformations of 








Figure 5-4: An overlay of the smoothed Cα traces of the published structure of NfsA (green - pdb I.D. 1F5V (Kobori et al., 2001)), 
and all the structures determined in this chapter (except the NfsA FMN structure). The published structure is a dimer, whilst all the 
structures from this chapter are monomers and so have been aligned to one half of the dimer using THESEUS (Theobald and 
Wuttke, 2008). The second half of the dimer of the published structure aligns perfectly with the first. The insert shows the flexible 





5.6 NfsA Crystallized in the Presence of Succinate and Fumarate 
As has been mentioned earlier, our group had previously solved the structure of NfsA 
showing density in the active site that resembled succinate or fumarate (both found to 
be inhibitors) (Jarrom, 2008). Because of this the decision was made to add first 
succinate and then fumarate to the crystallization solution. In both cases a succinate-
like molecule was found bound in the active site of NfsA above the flavin ring system 
as shown in Figure 5-5. One of the carboxylates of the succinate forms a salt bridge 
with the guanidinium group of Arg225, with the two NH2 groups lining up with the 
oxygen of the succinate. The guanidinium of Arg 133 is also in a position to hydrogen 
bond this carboxylate at a similar distance. The other carboxylate hydrogen bonds to 
both the backbone NH of Ser 41 and to the O2’ alcohol of the FMN ribityl. The 
central bond, which is oxidised in the conversion of succinate to fumarate (and 
reduced in the reverse reaction) is seem directly above the reactive N5 nitrogen of the 




Figure 5-5: Succinate bound in the active site of the 
is shown in pink. The σA-weighted 2Fo-F




NfsA Succinate 1 structure. The two images are separated by 90
c electron density map (contoured to ~2.5 σ) has been clipped to
  
 
 °. The succinate 





However, initial crystals grown in the absence of succinate (or fumarate), also showed 
identical density in the active site. In fact NfsA co-crystallized with malonate showed 
density indistinguishable from NfsA co-crystallized with either succinate or fumarate 
(Figure 5-6 c)-e)). Similar density was also seen when NfsA was co-crystallized with 
L-ascorbic acid, histidine and tryptophan (data not shown), which were added as part 
of an unpublished additive screen aiming to improve crystallization. All the structures 
had low R-factors and the B-factor for the ligand was always lower than the average 
for the protein. It was only when the precipitant was changed from PEG 3,350 (Sigma) 
to PEG 3,000 (Fluka) that the succinate-like density was no longer seen in the active 
site (the active site contained ethylene glycol, see section 5.7). The density was only 
then regained by co-crystallizing with succinate or fumarate. This implied that the 
original succinate-like density was as a result of the contaminant from the PEG 3,350 





Figure 5-6: a) and b) A comparison of the active sites of the NfsA Succinate 1
structures aligned using THESEUS (Theobald and Wuttke, 2008)
in c) NfsA Succinate 1, d) NfsA Succinate 2 and d) NfsA Fumarate. The 





 (yellow), Succinate 2 
. Two images are 90 ° apart. Electron density of the active site ligand 











5.7 NfsA bound to ethylene glycol 
When the PEG was changed to PEG 3,000 (Fluka), short soaks (1-2 min steps of 5 %, 
10 % then 15 %) with ethylene glycol were sufficient to cryo-protect the protein 
crystals and gave a structure with nothing above the FMN in the active site. With 
longer soaks (5-10 min steps) ethylene glycol was seen in the active site. Two 
alternative conformations of two ethylene glycol molecules were found above the 
flavin ring system, as shown in Figure 5-7. One ethylene glycol molecule mirrors the 
interaction of the succinate/fumarate carboxylate with the guanidinium group of Arg 
225, only forming hydrogen bonds rather than ionic interactions. The second ethylene 
glycol interacts with either the backbone nitrogen of Ser 41 or the O2’ alcohol of the 
FMN ribityl group, mirroring the interactions of the other carboxylate of 
succinate/fumarate (Section 5.6). It is possible that the solvent plays some part in the 





Figure 5-7: Active site of the NfsA Ethylene Glycol. The two alternate conformations 
of the two active site ethylene glycols
The FMN and another 
electron density map (contoured
ligands. Figure was 
 
In order to obtain complexes with any substrates ethylene glycol could not be used as 
a cryo-protectant as it bound in the active site. To prevent this DMSO, was used as a 
cryo-protectant, in which role it could double as a solvent for substrates including 
nitrofurantoin. Using DMSO as a cryo
the active site (data not shown).




 (labelled EG1 and EG2) are shown in 
ethylene glycol are shown in grey. The 
 to ~1.5 σ) has been clipped to with
produced using CCP4 Molecular Graphics. 
-protectant gave a structure with only water in 











5.8 NfsA bound to a second FMN 
An NfsA crystal soaked with hydroquinone showed electron density in the active site 
that did not fit hydroquinone, but showed at least 2 fused aromatic rings. The only 
molecule in the crystallization mixture with more than one ring was the FMN, and the 
density seemed to suggest that ribityl and phosphate were present, so a second copy of 
the cofactor was modelled into the active site. The flavin fit the density well as shown 
in Figure 5-8. The ring system’s density is all in a plane and there is clear density for 
each atom of the ribityl tail. The density for the isoalloxazine ring system is clear 
enough that the holes in the centre of each ring can be clearly seen. The R-factors of 
the structure are low and the average B-factor for the FMN is around twice the average 




Figure 5-8: Active site of NfsA FMN. Two images are separated by 90 °. The second ‘substrate’ FMN is shown as a light blue ball 
and stick model. The FMN prosthetic group is shown as grey cylinders
direction of rotation around the N3 nitrogen.




. The black arrow on the left hand image shows the suggested 
 The σA-weighted 2Fo-Fc electron density map (contoured to ~
  
 





FMN has previously been shown to inhibit NfsA (but not NfsB) (Zenno et al., 1996a). 
The second, inhibitor FMN is bound so that its isoalloxazine ring system is stacked 
above the prosthetic FMN’s ring system, but is displaced so that only two rings 
overlap. In comparison to the prosthetic FMN, the second FMN is rotated 180 ° 
around an axis perpendicular to the N10-C1* bond (separating the ring system and the 
ribityl tail). This leaves the second flavins pyrimidinedione ring above the centre ring 
of the prosthetic group, and the central ring above the dimethylbenzene ring. The 
electron density is stronger towards the centre of the active site, i.e. at the 
pyrimidinedione ring, and weakest towards the outside of the enzyme at the 
dimethylbenezene ring. There are areas of positive (unmodelled) density all around the 
FMN ligands, and the second FMN was refined for individual atom occupancy 
showing that atoms further from the centre of the active site had lower occupancy, 
suggests that the inhibitor-like FMN molecule exists in several orientations effectively 
performing a rigid anti-clockwise rotation around an axis perpendicular to the ring 
system roughly through the N3 nitrogen (show with a black arrow in Figure 5-8). The 
electron density is all in a plane showing that the second FMN does not display the 
butterflying of the isoalloxazine ring system that is seen with the FMN prosthetic 
group.  
 
The second FMN forms a series of H-bonds to the O2’ and O4’ alcohol groups of the 
prosthetic FMN ribityl, through its own O4’ alcohol and the O2 carbonyl oxygen. The 
two carbonyl oxygens of the isoalloxazine ring hydrogen bond to the protein; the O2 
to the backbone nitrogen of Ser 41 and the O4 to the guanidinium of Arg 225. The 





structure seen with any of the structures shown in this chapter. The poorly modelled 
loop between 197 and 211 has moved to create a phosphate-binding pocket. This shift 
is compared to all the other structures in Figure 5-9. In the NfsA FMN-bound structure 
the loop has two alternate conformations. The occupancies were 50:50 but the B-
factors would suggest that there is a dominant conformation (conformation A), which 
is the new one, and a secondary conformation (conformation B), that is identical to 
that seen in all the other structures. The second FMN’s phosphate atoms have ~50% 
occupancy, further suggesting that the driving force behind the loop movement is the 
formation of the phosphate binding pocket.  
 
To remove model bias the loop was removed from refinement and an omit map (i.e. 
density calculated from refinement from a model lacking the loop residues) produced 
before both new and old loop conformations were remodelled. The distances between 
these two conformations and the average B-factors of these residues are detailed in 
Table 5-5. The main chain B-factors (Table 5-5) are lower for the new conformation 
(A – mostly between 9 and 11.5 Å2) than the old (B – ranging from 8.8 to 47.3 Å2). 
Most other structures have average B-factors for the loop between 15 and 30 Å2, 








Figure 5-9: An overlay of the smoothed Cα traces of all the monomer structures detailed in this chapter. Structures were aligned using 
THESEUS (Theobald and Wuttke, 2008). The dominant conformation of the flexible loop in the NfsA FMN structure is shown in 






Residue Cα(A) - Cα(B) 
Distance (Å) 
Average B-factor – 
(Å2) Conformation A 
Average B-factor – 
(Å2)  Conformation B 
Ala 197 0.5 10.1 12.3 
Glu 198 1.0 10.0 15.0 
Tyr 199 1.5 9.5 13.1 
Tyr 200 1.7 9.0 13.8 
Leu 201 2.2 11.4 24.3 
Thr 202 3.7 13.2 25.5 
Arg 203 6.2 10.2 17.8 
Gly 204 10.8 11.5 16.5 
Ser 205 10.7 10.4 28.1 
Asn 206 11.0 11.3 44.9 
Asn 207 9.5 11.0 47.3 
Arg 208 7.2 10.5 31.4 
Arg 209 3.8 12.6 15.3 
Asp 210 1.2 11.0 14.0 
Thr 211 0.5 9.3 8.8 
Table 5-5: Comparison of the two conformations of the NfsA flexible loop in the 
NfsA FMN structure. The dominant conformation (A) is the changed conformation 
seen only in this structure. The distance between the α-carbons of each conformation 
is given as is the average B-factor for main chain atoms of the residue. The average for 
the whole protein is 9.1. The resolution of the structure is 1.09 Å, and the maximum 
likelihood based coordinate error is 0.1 Å.  
 
 
The maximum shift between equivalent Cα’s is 11 Å and this movement seems to be 
driven by the creation of a phosphate-binding site for the second FMN. The binding 
site and change in position of the residues involved is shown in Figure 5-10. The Arg 
203 and Arg 208 guanidinium groups have moved to hydrogen bond to the phosphate 





salt bridging with the salt bridge between Lys 167 and the FMN cofactor being 
replaced by a salt bridge between Lys 167 and the substrate FMN, requiring a 2.9 Å 
shift in the position of the Lys 167 NZ. The side chains of the residues which form the 





Figure 5-10: The flexible loop change in the NfsA FMN structure
(B) in pink. The second FMN is shown with 




. The new loop conformation (A) is shown in light blue and the old 
carbon atoms in green. Image a) shows the overall loop change, while
d using CCP4 Molecular Graphics.
 






While quinol was soaked into this crystal it was not seen in the active site, however 
there was density that appeared to match quinol near two surface cysteines, Cys 9 and 
Cys 90, neither of which are near the active site. Initial attempts to model quinol into 
the density led to the model being forced away from the density during refinement. If 
the model was fitted to the density with no restraints the nearest carbon atom of the 
quinol to the cysteine sulphur was actually closer than the β-carbon bonded to the 
sulphur, suggesting a covalent adduct. Quinone can modify surface cysteines of 
proteins forming S-cysteinyl-benzoquinol adducts (Mason and Liebler, 2000) (Figure 
5-11), and, while it was quinol in the soak, it is possible that some of the quinol could 
be converted to quinone in the presence of the crystallization solution or free radicals 
produced by X-ray damage. Of the two surface cysteines in NfsA that showed extra 
density in was clearest with Cys 90 (Figure 5-12), which was refined with full 
occupancy and had an average B-factor of 11.5 Å2 (protein average = 13.9 Å2). This 










Figure 5-11: The reaction of quinone with surface peptide cysteinyl thiols forming S-
cysteinyl-benzoquinol adducts. Figure adapted from Figure 1 in reference (Mason and 
Liebler, 2000). Figure produced using ChemSketch (ACD/labs). 
 
 
Figure 5-12: Modification of Cys 90 in the NfsA FMN structure showing the new S
images are 90 ° apart. H-bonds are represented by black dashed lines. 




-cysteinyl-benzoquinol adduct (pale pink). Two 
The σA-weighted 2Fo-Fc electron
 






The second residue (Cys 9) showed further density in addition to the quinol adduct, 
indicating an addition of a 5-membered ring to the quinol. The only chemical in the 
crystallization solution containing such a ring is the imidazole used as a buffer. 
Imidazole can be added to benzoquinones (Escolástico et al., 1994) (Figure 5-13), and 
in such a way that a single addition would match the density seen next to Cys 9. An 
adduct of both quinol and imidazole has been modelled to Cys 9 in the FMN-bound 
NfsA structure (Figure 5-14). The residue was refined for occupancy of individual 
atoms, showing the cysteine at 100 %, the cysteinyl-benzoquinol at 70 % and the 
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Figure 5-13: Reaction of quinone with imidazole in dioxane at room temperature. Proportions of products given are those 





Figure 5-14: Modification of Cys 9 in the NfsA FMN structure showing the new adduct (pale pink). Two images are 90 ° 
apart. The σA-weighted 2Fo-Fc electron 




density map (contoured to ~2.0 σ) has been clipped to within 2.5 
  
 





FMN was added to the protein solution to 20 µM after purification to ensure full 
occupancy of the prosthetic group and thus fully active enzyme. After the PEG was 
changed, FMN was seen in the active site. So for further experiments excess FMN was 
dialysed out of the protein solution prior to crystallization. 
 
 
5.9 NfsA bound to quinol and quinone 
NfsA catalyzes the reduction of quinone, to give quinol (see Figure 5-3 for structures). 
NfsA was co-crystallized with both substrate and product, with both returning similar 
density in the active site (Figure 5-15). The density suggested that quinone could 
rotate in the active site. As mentioned in Section 5.8 the is is possible that some or all 
of the quinone could be converted to quinol in the X-ray beam, and so both structures 
may be quinol. This rotation is around a point in the centre of the benzene ring, within 
a plane roughly parallel to the flavin ring system. One carbonyl oxygen (or alcohol) of 
the quinone (quinol) interacts with a combination of the FMN O2’ alcohol and the 
backbone nitrogen of Ser 41, whilst the other interacts with the guanidinium of Arg 
225 and/or the amine of Gln 67. In the quinol-bound NfsA structure the ligand has 
been modelled in two conformations about this rotation point. The same modification 
of Cys 90 as the NfsA FMN structure (but not Cys 9) was seen with the quinol soak, 
but not with the quinone soak (although some extra density was seen), even though the 
quinone is the reactive species. This could be due to the much shorter soak times used 










Figure 5-15: The active sites of a) NfsA Quinol a
light pink in a) and one of quinone in 






nd b) NfsA Quinone. Two conformations of quinol are shown in light blue
light blue in b). The FMN is shown as grey. The σA-weighted 2F
Å of the residue. Figures were produced using CCP4 Molecular Graphics.
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5.10 NfsA bound to nitrofurantoin 
The only successful attempt to obtain an NfsA complex with a nitroaromatic substrate 
was with the antibiotic nitrofurantoin. Figure 5-16 shows the electron density in the 
active site and the binding of nitrofurantoin. The density was clear, and the ligand had 
full occupancy and its B-factor was lower than the average for the protein. The ligand 
was bound with the nitro group bound away from the FMN ring system and the 
reactive centre of the N5 nitrogen (see Figure 1-4 c) for numbering). The imidazole 
ring rather than the nitrofuran ring is above the centre of the flavin ring system, with 
the ketone oxygens of the ligand hydrogen bonding to the backbone nitrogen of Ser 41 
and the guanidinium of Arg 225. The nitrogen of the imidazole ring is in the active 
position above the FMN N5. In addition to the aromatic stacking interactions of the 
rings, the alcohol groups of the FMN ribityl moiety also hydrogen bond to various 




Figure 5-16: Active site of NfsA Nitrofurantoin.
in light blue. H-bonds are shown as black dashed lines. The 




 Two images are separated by 90 °. The FMN is shown in 
σA-weighted 2Fo-Fc electron density map (contoured to ~
 
 
grey and the nitrofurantoin 





5.11 Steady-State Kinetics 
5.11.1 Succinate Inhibition 
As succinate was found in the active site of the crystal structure of NfsA, the effect of 
sodium succinate on the NfsA-catalysed reduction of NFZ with NADPH has been 
investigated. The steady-state kinetics of the reduction of NFZ with NADPH have 
been described previously (Jarrom et al., 2009). In all experiments the ionic strength 
was kept constant, equivalent to 50 mM NaCl. The effect of addition of succinate at 
varying concentrations of NFZ is shown in Figure 5-17, and at varying NADPH 
concentrations in Figure 5-18. Succinate was a competitive inhibitor relative to 
NADPH (constant kcatapp, higher Kmapp) and an uncompetitive inhibitor relative to NFZ 
(lower kcatapp, lower Kmapp, constant kcat/Km). Global fits to Equation 2-7 for the NFZ 
titrations and Equation 2-8 for the NADPH titrations gave the parameters in Table 5-6 







































Figure 5-17: Global fit of data for succinate inhibition of the reduction of NFZ in the 
presence of NADPH by NfsA. NFZ titration data fitted to Equation 2-7. NFZ titrations 
were performed at 0, 5, 10, 20, and 30 mM succinate. All experiments performed at 








































Figure 5-18: Global fit of data for succinate inhibition of the reduction of NFZ in the 
presence of NADPH by NfsA. NADPH titration data fitted to Equation 2-8. NADPH 
titrations were performed at 0, 1, 5, 10, and 20 mM succinate. All experiments 












-1 t P Kmapp µM t P KiU  mM t P 
0 - 52 100 0 - 30 34.5 ± 1.5 23 <0.0001 32.9 ±2.7 12 <0.0001 11.1 ± 0.67 17 <0.0001 
Table 5-6: Global kinetic parameters for the inhibition of the NfsA catalysed reduction of NFZ by sodium succinate at pH 7.0. 











-1 t P Kmapp µM t P KiC  mM t P 
100 0 - 500 0 - 20 8.82 ± 0.44 20 <0.0001 68.8 ± 8.9 7.7 <0.0001 4.90 ± 0.54 9.0 <0.0001 
Table 5-7: Global kinetic parameters for the inhibition of the NfsA catalysed reduction of NFZ by sodium succinate at pH 7.0. 







5.11.2 Fumarate Inhibition 
Similar experiments were performed with fumarate as an inhibitor. The effect of 
fumarate at varying concentrations of NFZ is shown in Figure 5-19, and varying 
NADPH in Figure 5-20. Fumarate was a competitive inhibitor relative to NADPH and 
showed mixed inhibition relative to NFZ. The global fit parameters are shown in 








































Figure 5-19: Global fit of data for fumarate inhibition of the reduction of NFZ in the 
presence of NADPH by NfsA. NFZ titration data fitted to Equation 2-9. NFZ titrations 














































Figure 5-20: Global fit of data for fumarate inhibition of the reduction of NFZ in the 
presence of NADPH by NfsA. NADPH titration data fitted to Equation 2-8. NADPH 
titrations were performed at 0, 0.5 and 1 mM fumarate. All experiments performed at 













-1 t P Kmapp 
µM 
t P KiC  µM
 t P KiU  µM t P 
0 – 100 100 0 – 1000 14.1 ± 
0.85 
17 <0.0001 10.3 ± 
1.9 
5.4 <0.0001 546 ± 
240 
2.3 0.0267 653 ± 
120 
5.6 <0.0001 
Table 5-8: Global kinetic parameters for the inhibition of the NfsA catalysed reduction of NFZ by sodium fumarate at pH 7.0. 










-1 t P Kmapp µM t P KiC  µM
 t P 
75 0 – 580 0 - 2000 17.6 ± 0.85 21 <0.0001 18.1 ± 3.0 6.0 <0.0001 119 ± 17 6.9 <0.0001 
Table 5-9: Global kinetic parameters for the inhibition of the NfsA catalysed reduction of NFZ by sodium fumarate at pH 7.0. 
Relative to NADPH, fumarate shows competitive inhibition and so the data was fitted to Equation 2-8 in order to calculate the KiC 





5.11.3 FMN Inhibition 
Hana Ganan has performed some initial kinetic experiments investigating the 
inhibition of NfsA by FMN. Single titrations were performed of NFN (Figure 5-21) 
and NADPH (Figure 5-22), each with and without FMN. The estimates of the kinetic 
parameters are given in Table 5-10 and the errors and statistics are relatively poor due 
mostly to the low number of points. However it would appear that FMN is a 
competitive inhibitor with respect to NFN and uncompetitive with respect to NADPH. 






























































-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
50 0 – 17 0 9.60 ± 2.4 4.0 0.0162 1.38 ± 1.0 1.4 0.2427 6.94 ± 3.6 1.9 0.1288 
50 0 – 17 90 7.42 ± 2.1 2.1 0.0120 6.22 ± 4.3 1.5 0.1970 1.19 ± 0.52 2.3 0.0626 
0 - 30 25 0 4.48 ± 0.69 6.5 0.0029 11.1 ± 4.3 2.6 0.0595 0.402 ± 0.098 4.1 0.0148 
0 – 30 25 45 3.39 ± 0.41 8.3 0.0011 8.66 ± 2.9 3.0 0.0398 0.392 ± 0.089 4.4 0.0115 





5.11.4 Quinone/Quinol Kinetics 
Initial experiments performed by Hana Ganan attempted to analyse the kinetics of the 
reduction of quinone as catalysed by NfsA. Accurate Km values proved difficult to 
measure as at concentrations of both NADPH and quinone that would give the lower 
part of the Michaelis-Menten curve the reaction was often completed within the time 
required to mix the solutions and begin monitoring the reaction. This leads to accurate 
estimates of kcatapp, but poorer estimates of Kmapp and kcat/Km. Attempts were made to 
couple the reaction to the reduction of cytochrome c as described for menadione in 
Section 2.2.3.3; however quinone reduces cytochrome c at a fast rate in the absence of 
the enzyme. The quinone titration is shown in Figure 5-23 and the NADPH titration is 
shown in Figure 5-24, and the kinetic parameters obtained are detailed in Table 5-11 





















Figure 5-23: The initial rates of the reduction of quinone by NfsA in the presence of 
























Figure 5-24: The initial rates of the reduction of quinone by NfsA in the presence of 








[Quinone] µM kcatapp s
-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
50 0 - 23 23.9 ± 0.84 28 <0.0001 2.98 ± 0.37 8.1 0.0002 8.01 ± 0.76 11 <0.0001 






[Quinone] µM kcatapp s
-1 t P Kmapp µM t P kcat/Km µM
-1s-1 t P 
0 - 22 50 30.9 ± 0.74 42 <0.0001 1.33 ± 0.18 7.3 0.0019 23.3 ± 2.8 8.4 0.0011 
Table 5-12: Kinetics parameters for the oxidation of NADPH by NfsA in the presence of quinone. Data for the NADPH titration at 





5.11.5 Nitrofurantoin Kinetics 
In obtaining global kinetic data for the reduction of NFN by NfsA and NADPH there 
were difficulties getting readings at high NFN concentrations (due to high background 
absorbance) and at low NADPH concentrations (due to the reaction being complete 
within the mixing time). The reaction was monitored at 400 nm and fitted to Equation 
2-5 giving the global fit seen in Figure 5-25. The global kinetics values are given in 








































Figure 5-25: The effect of varying [NADPH] and [NFN] on the rate of reduction of 








  t P 
kcat (s
-1) 80.8 ± 3.1 26 <0.0001 
Km NFN (µM) 20.6 ± 1.6 13 <0.0001 
Km NADPH (µM) 10.9 ± 1.6 6.9 <0.0001 
kcat/Km NFN (s
-1 µM-1) 3.92 ± 0.18 22 <0.0001 
kcat/Km NADPH (s
-1 µM-1) 7.40 ± 0.97 7.6 <0.0001 
Table 5-13: Global kinetic parameters for the reduction of NFN by NfsA and 
NADPH, monitored at 400 nm. 
 
5.12 Stopped-Flow Kinetics 
Figure 2-8 details the stages of the bi-bi ping-pong reaction catalysed by NfsA. 
Stopped-flow kinetics has been used to analyze the individual stages involved in this 
reduction as described in Section 2.6.2. 
 
5.12.1 Oxidative Half-Reaction 
In order for the reaction to be pseudo first-order, the concentration of substrate should 
be >2-fold higher than the concentration of enzyme. Since the reactions were followed 
by monitoring the reduction of the NfsA-bound FMN prosthetic group the 





absorbance. However since the Km for NADPH with NfsA is around 10 µM is was not 
possible to see the early part of the hyperbola binding curve and only the plateau was 
observed. A range of NADPH concentrations from 25 µM – 500 µM gave rates at ~ 
160 s-1. 
 
5.12.2 Reductive Half-Reaction 
For the reductive half-reaction, the reduction of CB1954, menadione and NFZ was 
analysed within an anaerobic chamber to prevent oxidation of the NfsA-FMN 
complex. There was a small degree of oxygen leakage causing slow oxidation, 
however data was fitted to the faster rates. For NFZ, two rates were seen at many 
concentrations, a quick rate (too quick to be measured at high NFZ concentration), and 
a slow rate seemingly independent of NFZ-cencentration. Thus it was not possible to 
get stopped-flow kinetic parameters for NFZ with NfsA. 
 
5.12.2.1 CB1954 Reduction 
Examples of the stopped-flow kinetic traces for each CB1954 concentration are shown 
in Figure 5-26. Each trace was fitted to a first-order reaction, Equation 2-17, and the 
rate constants were then plotted against CB1954 concentration in Figure 5-27. Only 
the early part of the kinetic curve from Figure 5-27 was measured, and above 500 µM 
CB1954 the reaction seemed to be complete within the deadtime. These rate constants 
were then fitted to Equation 2-18 and Equation 2-19 (Michaelis-Menten kinetics) to 
determine the rate constants and  dissociation constants for the reductive half reaction, 



































Figure 5-26: Stopped-flow kinetics for the reduction of CB1954 by reduced NfsA. 





























Figure 5-27: Plot of rate constants versus [CB1954] for the stopped-flow kinetic 










t P Kd 
(µM) 
t P k5/Kd  
(s-1 µM-1) 
t P kcat/KmCB1954 (s
-1 µM-1) 
(Jarrom, 2008) 
330 ± 28 
 
12 <0.0001 659 ± 88 7.5 <0.0001 0.501 ± 0.025 20 <0.0001 0.23 ± 0.02 
Table 5-14: Stopped-flow kinetic parameters for the reduction of CB1954 by reduced NfsA. The kcat/Km for CB1954 is taken 






5.12.2.2 Menadione Reduction 
Examples of the stopped-flow kinetic traces for the reduction of menadione by 
reduced NfsA are shown in Figure 5-28. Each of these was fitted to Equation 2-17. 
The determined rate constants were plotted against menadione concentration (Figure 
5-29). The fits of the kinetic traces were worse than for CB1954, as can be seen in 
Figure 5-28. As with CB1954, at high concentrations of substrate (>100 µM) the 
reaction was complete within the deadtime and so only the initial part of the curve is 
seen. This is reflected in the statistics in Table 5-15, where the estimates of k5 and Kd 
are poor, but the estimate of k5/ Kd is better. 
Time (s)





























Figure 5-28: Stopped-flow kinetics for the reduction of menadione by reduced NfsA. 



























Figure 5-29: Plot of rate constants versus concentration of menadione for the stopped-









t P Kd 
(µM) 
t P k5/Kd  
(s-1 µM-1) 
t P kcat/Kmmenadione (s
-1 µM-1) 
(Jarrom, 2008) 
485 ± 140 3.5 0.0027 328 ± 120 2.8 0.0112 1.48 ± 0.10 14 <0.0001 
 
0.8 ± 0.07  







5.13.1 Analysis of Steady-State kinetics 
The statistics presented for the steady-state inhibition by succinate and fumarate show 
that the Ki’s for fumarate (0.5-0.6 µM) are ~10-fold lower than those for succinate. 
This increased binding strength with fumarate would be expected to be due to an 
addition π-π interaction of the central double bond in fumarate with the FMN aromatic 
ring system. The quinone reduction data is limited by the tight binding of the substrate 
to NfsA resulting in poor estimates of Kmapp but good estimates of kcatapp. The FMN 
inhibition data also presented relatively poor statistics, and further study is warranted. 
The global data presented here for NFN, shows it to have a >2-fold larger kcat than is 
seen for either CB1954 or NFZ, and a higher Km than NFZ, but lower than CB1954 
(Jarrom, 2008).  
 
5.13.2 Analysis of Stopped-Flow kinetics 
Much of the stopped-flow data presented in this chapter showed some degree of 
fluctuation or a second rate. Also the maximum rate observed was not what would 
have been expected from the deadtime calculated for the machine in Bristol (see 
section 2.6.2.2), at around 160 s-1. There were subsequently found to be several 
problems with both the machine and the anaerobic chamber (personal communication, 
Dr Ross Anderson), however the data presented here would still appear to be accurate 






The plots of rate constants against substrate concentration for CB1954 (Figure 5-27) 
and menadione (Figure 5-29) do not show complete hyperbolas, only the initial 
roughly linear phase is seen. It was possible to fit the data to a hyperbola but the 
estimates of Kd and k5 (for menadione especially) are relatively poor, low t values and 
high P values. The estimates of the initial slope of the curve, which gives k5/Kd, are 
much better, allowing a comparison with previously determined kcat/Km values from 
steady state kinetics (Jarrom, 2008). The k5/Kd values are 2-fold higher than the kcat/Km 
values for both CB1954 (Table 5-14) and menadione (Table 5-15). Even with the 
previously mentioned problems in observing fast rates of reaction, it is clear that for 
each of the substrates (including NADPH) that the stopped-flow rates are at least 4-
fold higher than those seen in the steady-state (Table 5-16). This implies that, as was 
seen for WT NfsB (Jarrom et al., 2009), the rate limiting step is likely to be product 
release. 
 
 Max. Stopped-Flow rate (s
-1) kcat (s
-1) 
NADPH >160 - 
CB1954 >160 42 ± 1 
Menadione >120 9.0 ± 0.4* 
NFZ >160 29.6 ± 0.9 
Table 5-16: A comparison of the rates of NfsA catalysed reaction seen in the 
stopped-flow with the global steady-state rates previously determined (Jarrom, 2008). 






5.13.3 FMN as a Potential Substrate 
A single amino acid substitution, E99G, turns NfsA into a flavin reductase with a 
similar activity to FRP, the flavin oxidoreductase from Vibrio harveyi (Zenno et al., 
1998). This makes the structure of NfsA bound to FMN that of a pseudo-substrate. 
Figure 5-30 shows the position of Glu 99, and we can see that it H-bonds to Arg 133 
and Arg 225. Arg 225 appears to be the most important residue in substrate binding, 
interacting with FMN, nitrofurantoin, and the inhibitors succinate and fumarate, whilst 
Arg 133 interacts with the prosthetic FMN. Glu 99 anchors these residues spatially 
and would have an electrostatic effect on the region of the protein. Mutating the Glu 
99 residue to glycine would likely have two effects; firstly through the moving Arg 
133, it would likely change the redox potential of the FMN. Secondly, it would 
remove the anchor of Arg 225 and allow this residue greater flexibility, possibly 
allowing the large ‘substrate’ FMN to completely enter the active site. 
 
 
Figure 5-30: Location of the Glu 99 residue (pink) in the NfsA 
shown in grey and the ‘substrate’ FMN is shown in yellow. The two images are 90 ° apart. Figures have been 











5.13.4 Clues to NADPH Binding 
The change in the flexible loop in the NfsA FMN structure may hint at the mode of 
NADPH (structure in Figure 1-7) binding in NfsA, as the loop moves to form a 
phosphate binding pocket for the FMN phosphate. The mode of NADPH binding was 
investigated by Kobori et al. who proposed that the flexible loop (which had high B-
factors) between helices I and J was involved in binding (for labelling see Figure 
1-28). In their studies Arg 203 and Arg 208 were chosen for mutation as they appeared 
to be involved in NADPH binding in the NfsA analogue FRP (Tanner et al., 1996). 
These residues are conserved across NfsA analogues, and while Arg 208 is facing 
away from the active site in all other structures of NfsA, it has been seen with other 
NADPH-binding enzymes that arginines can be moved to form phosphate-binding 
pockets (Wilson et al., 1992, Reyes et al., 1995, Adams et al., 1994, Thorn et al., 
1995, Bolin et al., 1982)]. The mutation R203A increased the Km of NADPH ~33-fold, 
but had little effect on the Km of NFZ, implying that Arg 203 is involved in NADPH 
binding, but the R208A mutation had little effect. Neither mutation had an effect on 
the Km of NADH (although this is high) implying that Arg 203 interacts with the 2’ 
phosphate of NADPH. 
 
Kobori et al. proposed a binding mode for NADPH with NfsA based upon their 
experiments (Kobori et al., 2001) and using the NADPH in the crystal structure of 6-
phosphogluconate dehydrogenase (PDB I.D. 1PGO) (Adams et al., 1994). This model 
has the nicotinamide moiety in a conformation opposite to that seen with nicotinate in 
NfsB (Lovering et al., 2001), and the 2’ phosphate of NADPH interacting with Asp 





FMN structure presented here shows Arg 203 and Arg 208, along with Lys 167, Tyr 
199 and Tyr 201 forming a binding-pocket for the flavin phosphate. This structure and 
the orientation of nicotinate in the NfsB active site have permitted production of 
another potential binding model of NADPH in NfsA (Figure 5-31). This model uses 
the major conformation of the NfsA FMN structure, and places the 2’ phosphate into 
the density of the ‘substrate’ FMN phosphate. It differs from the model previously 
described in several ways. The change in the position of the flexible loop allows the 
NADPH to be much less stretched and the nicotinamide moiety to be placed in a 
conformation that is more amenable for hydride transfer (see section 1.6.1.1). The 
binding pocket for the 2’ phosphate is much smaller and the ribose ring attached to the 
nicotinamide interacts with both the central and pyrollidinedione rings of FMN and 
Gln 67. Unlike the previous model, the adenine and the two central phosphates are out 
in solution. This would be logical given that this loop is present in NfsA but not in 
NfsB and given the preference of NfsA for NADPH. This implies that this loop should 
bind the 2’ phosphate, with NfsA having extra interactions with phosphate in order to 
show a preference in cofactor. Effectively in this binding mode the binding would be 
primarily bidentate with the 2’ phosphate bound in the phosphate binding pocket and 
the nicotinamide above the flavin rings. 
 
 
Figure 5-31: Proposed binding mode 
NADPH in yellow. The protein is in the same conformation as the NfsA FMN structure, with the dominant loop conformation 
shown. The 2’ phosphate of the NADPH has been mod




of NADPH in the active site of NfsA. The FMN prosthetic group is shown in grey and the 







With the loop between helices I and J being flexible, having been seen in two different 
conformations and always with the highest B-factors, the loop could move in a 
different way to accommodate the NADPH from that with FMN. It would seem likely 
that the movement would involve the formation of a phosphate binding-pocket 
involving Arg 203, and possibly Arg 208. 
 
5.13.5 Modification of Cysteines 
The NfsA FMN structure also contained modifications of two surface cysteines of 
NfsA, Cys 90 modified with the addition of a quinol (Figure 5-12) and Cys 9 modified 
with an imidazole modified quinol (Figure 5-14). The quinol-modified cysteine was 
also seen at Cys 9 in the NfsA Quinol structure, and density suggested another 
modification at Cys 9 but was inconclusive as to what was added in the NfsA Quinone 
structure. It is likely that further modification was not seen as the soaking times were 
decreased for each (10 min for NfsA FMN, 5 min for NfsA Quinol and 90 s for NfsA 
Quinone). Other structures including the NfsA Succinate 2 structure showed some 
modification of these cysteines, although always with density that was not clear 
enough to allow anything to be modelled. It is possible that something in the 
crystallization conditions somehow ‘activates’ these cysteines or that free radical 
damage from the X-rays causes modification of the residue. It is possible this is a 






5.13.6 Succinate/Fumarate as Clues to NfsA Evolution. 
The structures of succinate and fumarate bound to the active site of NfsA may suggest 
an evolutionary history for the enzymes. The physiological role of the bacterial 
nitroreductases is unknown, and it may be that they have evolved from enzymes 
involved in redox reactions with dicarboxylic acids such as succinate and fumarate. 
The bond that is reduced in fumarate from succinate is in an ‘active’ position in the 
crystal structures presented here above the FMN N5 nitrogen. 
 
5.13.7 NfsA Substrate Binding 
The NfsA Quinone and NfsA Nitrofurantoin structures presented here are the first 
crystal structures of NfsA with known substrates bound in the active site. The most 
important residues in binding appear to be (i) Arg 225 through its guanidinium group, 
and (ii) the backbone of Ser41. Most other interactions of the substrate and other 
ligands seen here are with the FMN prosthetic group, although Arg 15 and Lys 167 
also bind to some of the ligands. The crystal structures have given us insights into the 
important residues in the active site of NfsA, which residues are important for binding 









6. Conclusions and Potential for Future Study 
6.1 Summary of the Research Presented 
Crystal structures have been determined of three NfsB natural amino acid mutants 
(Chapter 3) and two unnatural amino acid mutants (Chapter 4). These structures have 
allowed us to understand the chemical nature of the improvements in CB1954 
reduction seen with these mutants. The T41Q/N71S/F124T mutant structure showed a 
hydrogen bond between the newly mutated Gln41 and Thr124 (Figure 3-8), and from 
the Gln41 to bound citrate, showing how the two mutations cooperate to bind ligands. 
The M127V mutation causes the smaller of two channels to the NfsB active site to 
open up (Figure 3-9), aiding access to the active site. The unnatural amino acids pNF 
and pAF, were both introduced in place of Phe124 and the crystal structures of both 
showed an effective rotamer change of the residue, placing the new polar group next 
to the substrate binding pocket (Figure 4-11 and Figure 4-14). The kinetics of the 
mutants have been further studied, and stopped-flow kinetics have shown that as the 
mutants have been selected for their CB1954 binding, NADH binding has suffered and 
should this trend continue then the rate determining step (currently product release), 
may become the rate of NADH oxidation (Section 3.13). 
 
The crystal structure of NfsA has also been determined bound to the inhibitors 
succinate and fumarate, the substrates quinone (and product quinol) and 
nitrofurantoin, as well as a second bound FMN (Chapter 5). These structures have 
shown for the first time the residues involved in substrate binding, and the FMN 





5-31). Steady-state kinetics of substrates and inhibitors found in the crystals have also 
been shown, showing that fumarate is a better inhibitor than succinate. 
 
6.2 Comparison of NfsA and NfsB 
6.2.1 Structural Comparison 
NfsA and NfsB exhibit little sequential homology (16.1% identity, 27.2% similarity) 
but do exhibit some structural homology. Figure 6-1 shows a structural alignment of 
the crystal structures of NfsA and NfsB dimers, whilst Figure 6-2 shows a sequence 
alignment with structural elements shown. Both enzymes have a 5-stranded 
anti-parallel β-sheet core surrounded by α-helices. The active site is located at the 
dimer interface with the re-face of the isoalloxazine ring of the FMN presented 
towards the substrate pocket. The areas shown within the black circles on Figure 6-1 
have each structural element matched up to one from the other enzyme, although by 
no means perfectly aligned. It is the outer helices where the structure of the enzymes 
differ the most, especially helices I and J in NfsA and E and F in NfsB. These 
differences may help to explain NfsA’s preference for NADPH over NADH, as it is 
the loop between helices I and J that has been shown to be involved in NADPH 
phosphate binding (Kobori et al., 2001). The sequence alignment shows that the 
majority of the conserved regions are early in the sequence where the structural 
elements also overlay well, however beyond the 100th residues the similarities in 







Figure 6-1: Comparison of the crystal structures of NfsA (right) and NfsB (left) shown with α-helices in purple and β-sheets in 
yellow. The two FMN prosthetic groups are shown as magenta spheres. The structures were aligned using THESEUS (Theobald 
and Wuttke, 2008). The black circles over each image contain the area of the protein where each structure element approximately 













Figure 6-2: Sequence alignment of NfsA and NfsB showing secondary structural elements. Alignment performed using ClustalW2 














The active sites of NfsA and NfsB are compared in Figure 6-3, showing a numbers of 
functionally conserved residues shown in purple. Most of the residues directly 
interacting with the FMN prosthetic group are conserved in function across the two 
sites, although a few non-conserved interactions are seen. These interactions are 
summarised in Table 6-1. There are three conserved loops, the first roughly from 
residues 10-15 in each enzyme, which contains polar groups that primarily interact 
with the flavin phosphate. The residues here are shifted by one amino acid between the 
proteins, but the nature of the hydrogen bonding interactions are conserved for the δ+ 
or δ- charge of the hydrogen bonding atom. The second conserved loop, is from 39-41 
in both enzymes, and is conserved for side chain function, although most of the side 
chains point away from the active site. The third loop (residues 128-131 in NfsA and 
163-166 in NfsB) interacts with the re face of the FMN. This is mostly a backbone 
interaction and so the only conserved residue is the final of these 4, which is a glycine 




Figure 6-3: A comparison of the active sites of NfsA (left) and NfsB (right). The NfsA Succinate 1 structure is compared with the 
WT-NfsB nicotinate-bound structure (pdb I.D. 1ICR 
4.0 Å of either the FMN or the succinate/nicotinate, 
conserved function between the two 






(Lovering et al., 2001)) as the ligands are a similar size. All residues within 
which are themselves shown in pink. Of the surrounding residues, those with 












Function Side chain or main 
chain interaction 
His11 Arg10 Hydrogen bonding to FMN 
phosphate 
Side 
Ser13 Ser12 Hydrogen bonding to FMN 
phosphate 
Side 
Arg15 Lys14 Hydrogen bonding to FMN 
ketone oxygen ‘O2’ 
Side 
Ser39 Ser39 Hydrophobic interactions with 
FMN 
Main 
Ser40 Ser40 Hydrophobic interactions with 
FMN 
Main 
Ser41 Thr41 Hydrophobic interactions with 
FMN and hydrogen bonding to 
substrate 
Side and Main 
Gln67 Asn71 Hydrogen bonding to FMN 
ketone ‘O4’ and nitrogen ‘N3’ 
Side 
128-131 163-166 Hydrogen bonding and 
hydrophobic interactions to 
FMN isoalloxazine ring system 
Main 
Arg169 Arg207 Hydrogen bonding to FMN 
phosphate 
Side 
Table 6-1: Functionally conserved interactions in the active sites of NfsA and NfsB. 
 
 
6.2.2 Comparison for use in Gene Therapy 
The best indication for the potential of each enzyme for use in GDEPT with CB1954 
or other prodrugs will be the ability of the combination of prodrug and enzyme to 
shrink tumours and kill tumour cells. However, understanding the interactions in the 
active site of the enzymes can allow rational design of future drugs and drive further 





vivo (see Section 1.5.3.2). This difference between the in vivo and in vitro effect could 
be explained either by increased inhibition by small molecules in the cell or by relative 
levels of cofactors available. More cofactor molecules will be available to NfsB since 
it can utilize either NADH or NADPH. It has been estimated that the cellular 
concentration of NAD+ and NADH is ~10-fold higher than the concentration of 
NADP+ and NADPH (Reiss et al., 1984), with cytosol concentrations (of NAD+ and 
NADH) estimated at around 0.3 mM in animals (Yamada et al., 2006, Yang et al., 
2007) and 1.0 – 2.0 mM in yeast (Belenky et al., 2007). The two enzymes are 
inhibited by different molecules, for example FMN inhibits NfsA but not NfsB, whilst 
dicoumarol inhibits NfsB but not NfsA (Zenno et al., 1996a). This study has shown 
that NfsA is inhibited by succinate and fumarate; both molecules are members of the 
Citric Acid Cycle and so will be present in most cells. Experiments not detailed here 
showed that neither inhibit NfsB. Fumarate levels in some human cells have been 
shown to be 20-40 µM (Koivunen et al., 2007), and levels of succinate would 
presumably be similar. So the Ki’s of succinate and fumarate and 100- and 10-fold 
higher than the estimated concentrations, implying succinate is unlikely to cause 
significant inhibition in vivo but fumarate will likely cause some low levels.  
 
6.3 Rationalisation of Improvements Seen with NfsB Mutants 
All of the NfsB mutants in this study reduce CB1954 with higher specificity constants 
than WT, and crystal structures can give an insight into how these improvements 
work. The effect of the T41L and N71S mutations have been discussed elsewhere for 
the crystal structures of the single mutants (Race et al., 2007), and no additional 





F124 has also been suggested to be primarily a steric effect, and mutants showed 
either multiple conformations of side chains or polar side chains moving away from 
the active site and into a polar pocket. The combination of T41Q and F124T provided 
more improved kinetics than expected from the combination of single mutations 
(Guise et al., 2007, Jarrom et al., 2009). The structures of the T41Q/N71S/F124T 
triple mutant and the T41Q/N71S/F124T/M127V quadruple mutant present here 
suggest a reason for the observed cooperativity. The two side chains interact with each 
other in the triple and quadruple mutants, through a hydrogen-bond between the 
glutamine NE2 and the threonine OG1 (Figure 3-11). These interactions may be 
important in the binding of larger substrates as can be seen when the inhibitor citrate is 
bound in the active site, as Glu 41 hydrogen bonds to the citrate as well as Thr 124. 
This may explain the synergy of the two mutations, through the increased interactions 
with substrates stabilised through the interaction between the side chains. The T41Q 
mutant was detrimental on its own, and this may be because without the F124T 
mutation the glutamine side chain may not be in the same position and may interfere 
with the action of the enzyme.  
 
There are two channels leading into the active site, both shown in Figure 3-9 a). The 
smaller of the two is too small for most substrates but may be a path for solvent or 
protons. The M127V mutation opens up this smaller channel and effectively merges 
the two together (Figure 3-9 b)). In part it does this by replacing M127 with a smaller 
residue, but there are other changes induced including movement in the position of the 
ASN67 side chain. This would provide improved access for substrates and solvent to 





similar method to the T41Q/N71S/F124T triple mutant (described in Section 
1.6.2.3.1), giving a similar improvement over WT in terms of IC50 for CB1954 
(unpublished work by Simon Vass). However subsequent studies by undergraduate 
project student Alex Gavin (unpublished), suggest that the quadruple mutant binds 
CB1954 less tightly in vitro than the triple, but binds menadione more strongly than 
any previously observed mutant. So this opening up of the active site may be more 
beneficial for the larger menadione.  
 
6.4 Clues to cofactor and substrate binding in NfsA 
In Section 5.13.1 FMN was identified as a pseudo-substrate of NfsA, given a single 
amino acid substitution (E99G) converts NfsA to a flavin reductase with similar 
activity to Frp, the flavin reductase from Vibrio harveyi (Zenno et al., 1998). Similarly 
NfsB can be converted to a flavin reductase with a mutation of Phe 124 to 10 other 
amino acids (Zenno et al., 1996b), and its activity is similar to FRase I, the flavin 
reductase from Vibrio fischeri. Noticeably only one of these mutations (F124H) 
improved activity of NfsB with either NFZ or CB1954 (Grove et al., 2003). Frp and 
NfsA share much sequence homology, as do FRase I and NfsB. The NfsA FMN 
structure may give clues to NADPH binding and the specificity of NfsA for the 
cofactor as it shows how NfsA can form a phosphate binding pocket (see Section 
5.13.4). If FMN could be bound to NfsB it is possible that conclusions could be drawn 
about the presence or lack of a phosphate-binding pocket, however, if as speculated 
here, it is the phosphate binding pocket of NfsA that leads to the specificity, then it is 
likely that getting a structure of NfsB bound to FMN would prove difficult as it would 






6.5 Clues to mechanism of reaction 
Section 1.6.1.1 details the possible mechanisms of oxidation and reduction in the 
FMN-bound nitroreductases. The reduction of the flavin by NAD(P)H and the 
reduction of quinones is likely to be by hydride transfer (simultaneous transfer of 
hydrogen and electrons from the FMN) as both can only be involved in two electron 
reductions. However a recent study has suggested that the reduction of CB1954 (and 
presumably other nitroaromatics) by NfsB happens by electron transfer from the flavin 
followed by proton transfer from solution (Christofferson and Wilkie, 2009) 
(discussed in Section 1.6.1.1). There was further evidence for this mechanism as the 
crystal structure of NfsB bound to NFZ (a nitroaromatic substrate) showed NFZ bound 
with the nitro group away from the reactive N5 nitrogen of the FMN (Race et al., 
2005) (Figure 1-22). If the mechanism were hydride transfer then NFZ in this structure 
would not be in an active conformation, however for electron transfer (transfer of two 
electrons from the flavin and one proton from solution) a fully conjugated substrate 
(such as NFZ and CB1954) would not require the nitro group to be above the N5 
nitrogen. The NfsA Nitrofurantoin structure presented in Section 5.10 has the NFN 
bound with the nitro group away from the reactive centre of the flavin ring system. It 
is likely the chemistry of the active site of NfsA and NfsB have the same mechanism, 
so this adds to the evidence that the reduction of nitroaromatics by the E. coli 






There are other potential explanations for the nitro groups being bound away from the 
active site in the two crystal structures. Since the enzymes in the crystals are oxidised 
and the nitroaromatic substrates interact with the reduced enzyme complex, the 
binding is not necessarily representative of an active complex. It is possible that the 
change in the redox state of the FMN would lead to the substrates binding in a 
different orientation to that observed with the oxidised enzyme (as proposed 
previously Race et al. (Race et al., 2005)). Another possibility is that the major 
binding orientation of the substrate in the enzyme is not the reactive conformation, 
which only occurs rarely. This has been proposed to be the case with pentaerythritol 
tetranitrate reductase based upon similar results (Khan et al., 2005). However the 
combination of the two crystal structures and the biophysical calculations 
(Christofferson and Wilkie, 2009) suggests strongly that the reason for the unexpected 
orientation is that the mechanism is electron transfer. 
 
6.6 Implications of Electron Transfer on New Prodrug Design 
If the mechanism of reduction is electron transfer this would affect the rational design 
of further prodrugs based upon the crystal structures of the enzymes. Firstly the 
prodrug would not have to be orientated with the group to be reduced above the FMN 
N5 nitrogen. Secondly the drug would not have to be as close to the flavin ring 
system, although the closer the drug the faster the rate of electron transfer (see Section 
1.6.1.1). This would increase the range of possibilities for prodrug design; the drugs 
could be designed to interact with any part of the active site, and in-particular for 






6.7 Residues in NfsA to Target for Mutagenesis 
The determination of the ligand-bound crystal structure of NfsB led to the 
identification of 9 residues to mutate and has since led to the discovery of mutants 
showing much improved activity with CB1954 (see Section 1.5.3.1). The 
determination of ligand-bound structures of NfsA (Chapter 5) would allow a similar 
targeting of residues for mutagenesis. The comparison of the active sites of NfsA and 
NfsB (Section 6.2.1), would indicate that mutations of Gly130 and Gly131 in NfsA 
would likely not be successful as mutations of the homologous Glu165 and Gly166 in 
NfsB were not (Grove et al., 2003). Three areas are identified here, including ten 
residues to target for mutational studies (Figure 6-4). These fall into three areas. 
Firstly, the series of serines from 39-41, which include residues homologous to Ser40 
and Thr41 in NfsB that have been mutated in improved mutants of NfsB (Grove et al., 
2003). Secondly, the residues interacting with the diketone ring of the FMN (Arg15, 
Gln 67 and His69), which include a residue (Gln67) homologous to the Asn71 that is 
mutated in the NfsB mutants presented in Chapter 3, which has been shown to alter 
the redox potential of the FMN (unpublished work by Dr Ross Anderson, University 
of Bristol, UK). Finally, the key Arg 225 (Section 5.13.7) and surrounding residues 
(Glu99, Arg133 and Aln134), as the effect of mutating Glu99 has already been shown 
to change substrate specificity in NfsA (Section 5.13.3 (Zenno et al., 1998)). Arg225 
may prove to be too important to mutate and is one of three of the ten residues 
suggested to bind NADPH (along with Ser41 and Gln67, which have successful 
homologous NfsB mutants). If looking at larger prodrugs then the flexible loop (200 - 




Figure 6-4: Potential residues in NfsA to be targeted for 
improve specificity for CB1954. The NfsA Succinate 1 structure is shown





mutagenesis aiming to 









Appendix: Solving a Crystal Structure 
 
In protein X-ray crystallography a protein crystal is placed in an X-ray beam, and the 
diffracted X-rays are analysed on an area detector. The X-rays diffract of the electron 
clouds of the protein atoms within the crystal. This is possible as X-rays have a 
wavelength of the same order of magnitude of the gaps between atoms (~0.5 – 1.5 Å). 
The diffraction patterns formed are made up of reflections of differing intensities. 
When a series of diffraction patterns are collected whilst rotating the crystal, the data 
is processed, and each of the reflections is indexed and integrated to give a list of 
reflections and their intensities. Indexing is the process by which the space group is 
identified. The space group defines the arrangement of protein molecules in the unit 
cell. Symmetry operations describe the relationships between the molecules, in protein 
molecules only rotation-axis and screw-axis are possible, and as mirror symmetry or 
inversion centres are not possible due to the chirality of amino acids found in the 
body. Of the two possible stereoisomers only L-amino acids are found in nature. The 
intensities are merged to create a single file, and scaled so that reflections from 






In order to convert the scaled reflections into an electron density map we need to 
calculate the structure factor, F(h,k,l) for the structure. The structure factor is defined by 
the equation below: 
R(S,1,U) 	 V W(X) exp[2\ · ^(ℎ<(X) +	`(X) +	Ba(X)bGIcd7  
The structure factor is a complex number comprising a real and imaginary component 
(expressed in terms of i), where f(j) is the scattering factor of atom j, which depends on 
the atom type and the diffraction angle of the reflection (h,k,l). The x, y and z represent 
the fractional coordinates of each atom in the suspension, and h, k, and l the indices of 
the corresponding reflection. What we have from the scaled reflections and intensity 
for each reflection, and this is directly proportional to the square of the structure factor 
amplitude, |F(h,k,l)|, as seen below: 
eS1U 	 fR(S,1,U)f8 · gh ·  
Where LP is a combined geology and polarisation factor, dependent upon the 
experimental setup, and A is an absorption correction factor. From this we can see that 
the structure factor cannot be directly calculated from the intensities, only the 
amplitude of it can. This gives rise to the phase problem. The structure factors are 
calculated by performing a Fourier Transform, which gives the equation below 
comprising a magnitude (|F(h,k,l)|) and a phase (φ(h,k,l)): 
R(S,1,U) 	 fR(S,1,U)fij(k,l,m) 
There are several ways of solving the phase problem. Molecular replacement was used 





to find the phase. Multiple/Single Wavelength Anomalous Diffraction (MAD/SAD) 
involves collecting data at wavelengths around the absorption edge of an atom, and 
phasing off the atoms signal to discover their location and give the initial phases. 
Finally heavy atoms can be introduced to allow a similar experiment to be performed, 
using the differences in the observed scattering factors to discover the position of the 
heavy atoms. 
 
Once we have the structure factor the electron density can be determined through the 
following equation: 
n(o,p,q) 	 1rVVVR(S,1,U)exp−2\ · ^(ℎ< + ` + Ba)U1S  
With the electron density a model structure can be determined. The fit of the model to 
the density is measured by the crystallographic R-factor: 
s 	∑ ||R=>?| − |RU||∑|R=>?|  
Where Fobs is the observed structure factor, and Fcal is the calculated or expected 
structure factor. Another R-factor, called Rfree, is calculated from 5% of the data left 
out of the structure calculations to provide an unbiased estimate of the fit of the model 
to the data. 
 
Model building is performed by comparing the model to the electron density. The 





which highlights the differences between the model and the density producing positive 
(unmodelled) density and negative density (no density to support the model). This 
difference map is a Fo-Fc map. 
 
Some parts of the structure are more flexible than others. The degree of movement of 
each atom can be judged by looking at the B-factor (also known as the Temperature 
factor or Debye–Waller factor): 
v  8\8〈y8〉 
Where 〈y8〉 is the mean squared displacement. Each atom is given a value with units 
in Å2, with higher values indicating more mobile parts of the structure and lower 
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